{
    "questions": [
        {
            "body": "Is TREM2 associated with Alzheimer's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23855982",
                "http://www.ncbi.nlm.nih.gov/pubmed/23391427",
                "http://www.ncbi.nlm.nih.gov/pubmed/24041969",
                "http://www.ncbi.nlm.nih.gov/pubmed/23582655",
                "http://www.ncbi.nlm.nih.gov/pubmed/23562540",
                "http://www.ncbi.nlm.nih.gov/pubmed/23150908",
                "http://www.ncbi.nlm.nih.gov/pubmed/17088018",
                "http://www.ncbi.nlm.nih.gov/pubmed/24119542",
                "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
                "http://www.ncbi.nlm.nih.gov/pubmed/23407992",
                "http://www.ncbi.nlm.nih.gov/pubmed/23380991",
                "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
                "http://www.ncbi.nlm.nih.gov/pubmed/23692967",
                "http://www.ncbi.nlm.nih.gov/pubmed/24002183"
            ],
            "ideal_answer": [
                "A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/TREM2_HUMAN",
                "http://www.uniprot.org/uniprot/TREM2_MOUSE",
                "http://www.disease-ontology.org/api/metadata/DOID:10652",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544"
            ],
            "type": "yesno",
            "id": "531a31a1b166e2b806000035",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17088018",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1210,
                    "text": " These data demonstrate that TREM2 coding region is highly conserved, implying a crucial role of this receptor. Further studies, including a functional analysis, are certainly required to clarify the role of TREM2 in neurodegenerative processes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17088018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 278,
                    "text": "Moreover, a rare TREM2 exon 2 variant (p.R47H) was reported to increase the risk of Alzheimer's disease (AD) with an odds ratio as strong as that for APOE\u03b54",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24119542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 601,
                    "text": "We observed an enrichment of rare variants across TREM2 in both AD and FTD patients compared to controls, most notably in the extracellular IgV-set domain",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24119542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 764,
                    "offsetInEndSection": 966,
                    "text": "None of the rare variants individually reached significant association, but the frequency of p.R47H was increased ~ 3-fold in both AD and FTD patients compared to controls, in line with previous reports",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24119542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1090,
                    "offsetInEndSection": 1313,
                    "text": "Our data corroborate and extend previous findings to include an increased frequency of rare heterozygous TREM2 variations in AD and FTD, and show that TREM2 variants may play a role in neurodegenerative diseases in general.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24119542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2,
                    "offsetInEndSection": 170,
                    "text": "non-synonymous genetic rare variant, rs75932628-T (p.R47H), in the TREM2 gene has recently been reported to be a strong genetic risk factor for Alzheimer's disease (AD)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24041969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 942,
                    "offsetInEndSection": 1076,
                    "text": "These data strongly support the important role of p.R47H in AD risk, and suggest that this rare genetic variant is not related to FTD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24041969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 279,
                    "text": " Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24002183",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 672,
                    "text": "Our results indicate that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24002183",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 7,
                    "offsetInEndSection": 157,
                    "text": "studies have identified the rs75932628 (R47H) variant in TREM2 as an Alzheimer's disease risk factor with estimated odds ratio ranging from 2.9 to 5.1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23855982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 850,
                    "text": "This study replicates the association between R47H and Alzheimer's disease risk in a large, population-based sample, and estimates the population frequency and attributable risk of this rare variant",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23855982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 858,
                    "offsetInEndSection": 965,
                    "text": "Moreover, mutation scanning of the five exons of TREM2 failed to detect the presence of novel polymorphisms",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17088018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 798,
                    "offsetInEndSection": 1048,
                    "text": "A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimer's disease in Iceland",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150908",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1362,
                    "offsetInEndSection": 1517,
                    "text": "We also found that carriers of rs75932628-T between the ages of 80 and 100 years without Alzheimer's disease had poorer cognitive function than noncarriers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150908",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1542,
                    "offsetInEndSection": 1835,
                    "text": "Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer's disease. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer's disease through impaired containment of inflammatory processes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150908",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 197,
                    "text": "rs75932628-T variant of the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) has recently been identified as a rare risk factor for late-onset Alzheimer's disease (AD)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380991",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 690,
                    "text": "These results confirm the association between this variant and AD and underline its involvement in early-onset cases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23380991",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 125,
                    "text": "recent studies have reported the association of rs75932628-T in the TREM2 gene with the risk for Alzheimer's disease (AD)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391427",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 269,
                    "text": "Rs75932628-T is a rare nonsynonymous variant (p.R47H) that confers a high risk of AD with an effect size similar to that of the APOE \u025b4 allele",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391427",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 896,
                    "offsetInEndSection": 1043,
                    "text": "Here, we report the first positive replication study in a Spanish population and confirm that TREM2 rs75932628-T is associated with the risk for AD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391427",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 7,
                    "offsetInEndSection": 285,
                    "text": "works have demonstrated a rare functional variant (R47H) in triggering receptor expressed on myeloid cells (TREM) 2 gene, encoding TREM2 protein, increase susceptibility to late-onset Alzheimer's disease (AD), with an odds ratio similar to that of the apolipoprotein E \u03b54 allele",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 636,
                    "text": "The reduced function of TREM2 was speculated to be the main cause in the pathogenic effects of this risk variant, and TREM2 is highly expressed in white matter, as well as in the hippocampus and neocortex, which is partly consistent with the pathological features reported in AD brain, indicating the possible involvement of TREM2 in AD pathogenesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 858,
                    "text": "Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 860,
                    "offsetInEndSection": 980,
                    "text": "TREM2 also participates in the regulation of phagocytic pathways that are responsible for the removal of neuronal debris",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1160,
                    "offsetInEndSection": 1295,
                    "text": "Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23407992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 495,
                    "offsetInEndSection": 927,
                    "text": "Under the hypothesis that low-prevalence variants showing moderate-to-high effect size may be associated with risk for sAD, two independent research groups have demonstrated that a rare variant (rs75932628, encoding a substitution of arginine by histidine at residue 47 (R47H), in the TREM2 gene, which encodes the triggering receptor expressed on myeloid cells 2) is significantly associated with an increased susceptibility to sAD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 604,
                    "text": "Recently, a novel variant in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) has been identified that has refocused the spotlight back onto inflammation as a major contributing factor in AD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 748,
                    "text": "TREM gene cluster, a region recently reported to harbor rare variants that increase AD risk",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562540",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 7,
                    "offsetInEndSection": 131,
                    "text": "evidence suggests that rare genetic variants within the TREM2 gene are associated with increased risk of Alzheimer's disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582655",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1343,
                    "text": "These data suggest that a mutational burden in TREM2 may serve as a risk factor for neurodegenerative disease in general, and that potentially this class of TREM2 variant carriers with dementia should be considered as having a molecularly distinct form of neurodegenerative disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582655",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1502,
                    "offsetInEndSection": 1666,
                    "text": "The association of TREM2 variants with AD brings innate immune signaling into the light, affirming innate immunity's role as a significant factor in AD pathogenesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692967",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 872,
                    "offsetInEndSection": 1113,
                    "text": "The purpose of this paper is to discuss these recent developments including the potential role that TREM2 normally plays and how loss of function may contribute to AD pathogenesis by enhancing oxidative stress and inflammation within the CNS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533697",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1861,
                    "offsetInEndSection": 2125,
                    "text": "Even though we are more at the beginning than at the end of sAD genetics, there is some reason for optimism given the recent identification of novel risk or protective variants (such as rare TREM2 and APP mutations) showing strong statistical associations with sAD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23510020",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the enzyme ERAP2 associated with the disease birdshot chorioretinopathy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24957906",
                "http://www.ncbi.nlm.nih.gov/pubmed/29769354"
            ],
            "ideal_answer": [
                "Yes,\nBSCR is also associated with endoplasmic reticulum aminopeptidase 2 (ERAP2), an enzyme involved in processing HLA class I ligands."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c76be617c78d694710000a5",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "Allele-specific Alterations in the Peptidome Underlie the Joint Association of HLA-A*29:02 and Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) with Birdshot Chorioretinopathy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29769354",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 311,
                    "text": "BSCR is also associated with endoplasmic reticulum aminopeptidase 2 (ERAP2), an enzyme involved in processing HLA class I ligands, thus implicating the A*29:02 peptidome in this disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29769354",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24957906",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does amiodarone affect thyroid hormone receptors in the myocardium?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10445678",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781936",
                "http://www.ncbi.nlm.nih.gov/pubmed/7598731",
                "http://www.ncbi.nlm.nih.gov/pubmed/17535870"
            ],
            "ideal_answer": [
                "Yes"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/THA_LITCT",
                "http://www.uniprot.org/uniprot/THB_SHEEP",
                "http://www.uniprot.org/uniprot/THA_MOUSE",
                "http://www.uniprot.org/uniprot/THAA_PAROL",
                "http://www.uniprot.org/uniprot/THA_PYGAD",
                "http://www.uniprot.org/uniprot/THA_CHICK",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.uniprot.org/uniprot/THA_APTPA",
                "http://www.uniprot.org/uniprot/THB_CAIMO",
                "http://www.uniprot.org/uniprot/THA_CAIMO",
                "http://www.uniprot.org/uniprot/THA_PIG",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988",
                "http://www.uniprot.org/uniprot/THBA_XENLA",
                "http://www.uniprot.org/uniprot/THB_PAROL",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000638",
                "http://www.uniprot.org/uniprot/THB_DANRE",
                "http://www.uniprot.org/uniprot/THB_RAT",
                "http://www.biosemantics.org/jochem#4274241",
                "http://www.uniprot.org/uniprot/THAA_DANRE",
                "http://www.uniprot.org/uniprot/THA_ELECQ",
                "http://www.uniprot.org/uniprot/THAA_XENLA",
                "http://www.uniprot.org/uniprot/THA_HIPHI",
                "http://www.uniprot.org/uniprot/THA_SPAAU",
                "http://www.uniprot.org/uniprot/THA_NECMA",
                "http://www.uniprot.org/uniprot/THB_HUMAN",
                "http://www.uniprot.org/uniprot/THA_HUMAN",
                "http://www.uniprot.org/uniprot/THB_LITCT",
                "http://www.uniprot.org/uniprot/THA_SHEEP",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042",
                "http://www.uniprot.org/uniprot/THB_CHICK",
                "http://www.uniprot.org/uniprot/THA_RAT",
                "http://www.uniprot.org/uniprot/THA_ONCMY",
                "http://www.uniprot.org/uniprot/THA_SALSA",
                "http://www.uniprot.org/uniprot/THB_MOUSE"
            ],
            "type": "yesno",
            "id": "516d5baa298dcd4e51000078",
            "snippets": [
                {
                    "offsetInBeginSection": 732,
                    "offsetInEndSection": 845,
                    "text": "AM and Dron affected TR expression in the RA similarly by decreasing TRalpha 1 and beta 1 expression by about 50%",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535870",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 847,
                    "offsetInEndSection": 933,
                    "text": "In the LVW, AM and Dron decreased TRbeta 1 and, interestingly, AM increased TRalpha 1.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535870",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 935,
                    "offsetInEndSection": 975,
                    "text": "n the apex, AM also increased TRalpha 2.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535870",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1324,
                    "text": "Both in treated and untreated mice, TRalpha2 mRNA had the highest density in mouse heart, whereas TRbeta2 mRNA had the lowest density. Amiodarone dose-dependently downregulated the levels of TRalpha1 and beta1 mRNA in comparison to the control.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10445678",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1537,
                    "offsetInEndSection": 1648,
                    "text": "amiodarone subtype selectively downregulates the TR mRNA levels in mouse myocardium in a dose-dependent manner.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10445678",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1613,
                    "offsetInEndSection": 1691,
                    "text": "Western blot analysis revealed no change in the expression of the ThR protein.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781936",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 830,
                    "offsetInEndSection": 1094,
                    "text": "Amiodarone and T3, respectively, downregulated T3R alpha 1, T3R beta 1, T3R beta 2 (p < 0.05), but did not affect the levels of T3R alpha 2. Amiodarone and T3, added together, upregulated T3R alpha 2 and T3R beta 1 (p < 0.05) as compared to amiodarone or T3 alone.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7598731",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is curcumin a phytochemical?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25272063",
                "http://www.ncbi.nlm.nih.gov/pubmed/25640947",
                "http://www.ncbi.nlm.nih.gov/pubmed/26155681",
                "http://www.ncbi.nlm.nih.gov/pubmed/25543853",
                "http://www.ncbi.nlm.nih.gov/pubmed/25149981",
                "http://www.ncbi.nlm.nih.gov/pubmed/24815764",
                "http://www.ncbi.nlm.nih.gov/pubmed/25542083",
                "http://www.ncbi.nlm.nih.gov/pubmed/25964558",
                "http://www.ncbi.nlm.nih.gov/pubmed/24293118",
                "http://www.ncbi.nlm.nih.gov/pubmed/25661742",
                "http://www.ncbi.nlm.nih.gov/pubmed/24669820",
                "http://www.ncbi.nlm.nih.gov/pubmed/25541178",
                "http://www.ncbi.nlm.nih.gov/pubmed/24482305"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A2792113",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A2792113",
                    "o": "curcumin III"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1259941",
                    "o": "http://linkedlifedata.com/resource/umls/label/A2792113"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A2792113",
                    "o": "C475935"
                },
                {
                    "p": "http://linkedlifedata.com/resource/pubmed/registryNumber",
                    "s": "http://linkedlifedata.com/resource/pubmed/chemical/Curcumin",
                    "o": "458-37-7"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/pubmed/chemical/Curcumin",
                    "o": "Curcumin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16717035",
                    "o": "846163"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16717035",
                    "o": "Curcumin Oral Capsule"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2683192",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16717035"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2683192",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16717035"
                }
            ],
            "ideal_answer": [
                "Yes, curcumin is a phytochemical derived from rhizome of turmeric Curcuma longa."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003474",
                "http://www.biosemantics.org/jochem#4272467",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064209"
            ],
            "type": "yesno",
            "id": "56b0eb3b0a360a5e45000019",
            "snippets": [
                {
                    "offsetInBeginSection": 366,
                    "offsetInEndSection": 507,
                    "text": "we analyzed turmeric from different agroclimatic regions for influence of various factors on its growth and yield of important phytochemicals",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26155681",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "The phytochemical, curcumin, has been reported to play many beneficial roles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25541178",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 470,
                    "text": "Curcumin (CUR), the major component in Curcuma longa, has been shown as a potent chemopreventive phytochemical that modulates various signaling pathways. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640947",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 277,
                    "text": "Curcumin (CUR) is a phytochemical that inhibits the xenobiotic ABC efflux transporters implicated in cancer multidrug resistance (MDR), such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 and 5 (MRP1 and MRP5). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25543853",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 261,
                    "text": "In this study, we tested the efficacy of combining temozolomide with curcumin, a phytochemical known to inhibit glioblastoma growth, and investigated the mechanisms involved.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 583,
                    "text": " In the present study, we investigate whether curcumin (cur), a phytochemical compound with potent anti-inflammatory effect",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 126,
                    "text": "the Phytochemicals Curcumin ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25964558",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 388,
                    "text": "in combination with the phytochemicals curcumin and quercetin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25964558",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 116,
                    "text": "Curcumin is a phytochemical derived from rhizome of turmeric Curcuma longa, present in the curry spice. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25149981",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 352,
                    "text": "Curcumin, a naturally occurring polyphenolic phytochemical isolated from the medicinal plant Curcuma longa, has anti-inflammatory activities",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482305",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 400,
                    "text": "In the present study curcumin (CUR), a known anticancer phytochemical, ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24815764",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 8,
                    "offsetInEndSection": 82,
                    "text": " Curcumin, a natural phytochemical, exhibits potent anticancer activities.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293118",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 355,
                    "text": "hat curcumin, a phytochemical compound with potent anti-inflammatory properties ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669820",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 395,
                    "text": "curcumin, a phytochemical",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25272063",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is muscle regeneration possible in mdx mice with the use of induced mesenchymal stem cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17999592",
                "http://www.ncbi.nlm.nih.gov/pubmed/25102299"
            ],
            "ideal_answer": [
                "Purified induced mesenchymal stem cells (iMSCs) display fibroblast-like morphology, form three-dimensional spheroid structures, express characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105, and are capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplantation of iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowers oxidative damage, and restores the expression levels of normal dystrophin, leading to skeletal muscle regeneration.",
                "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "57134d511174fb1755000002",
            "snippets": [
                {
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 1147,
                    "text": "Purified iMSCs displayed fibroblast-like morphology, formed three-dimensional spheroid structures, and expressed characteristic mesenchymal stem cell surface markers such as CD29, CD33, CD73, CD90, and CD105. Moreover, iMSCs were capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1260,
                    "text": "This study demonstrates the therapeutic potential of purified iMSCs in skeletal muscle regeneration in mdx mice",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Flk-1+ adipose-derived mesenchymal stem cells differentiate into skeletal muscle satellite cells and ameliorate muscular dystrophy in mdx mice",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999592",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 784,
                    "text": "Within mdx mice, an animal model of DMD, adipose tissue-derived Flk-1(+) MSCs (AD-MSCs) homed to and differentiated into cells that repaired injured muscle tissue. This repair correlated with reconstitution of dystrophin expression on the damaged fibers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999592",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1076,
                    "offsetInEndSection": 1133,
                    "text": "Flk-1(+) AD-MSC transplants may repair muscular dystrophy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17999592",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1336,
                    "offsetInEndSection": 1531,
                    "text": "This study demonstrates the therapeutic potential of purified iMSCs in skeletal muscle regeneration in mdx mice, and suggests that iPSCs are a viable alternate source for deriving MSCs as needed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 935,
                    "offsetInEndSection": 1147,
                    "text": "Transplanting iMSC cells to tibialis anterior skeletal muscle tissue in mdx mice lowered oxidative damage as evidenced by a reduction in nitrotyrosine levels, and normal dystrophin expression levels were restored",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1343,
                    "text": "This study demonstrates the therapeutic potential of purified iMSCs in skeletal muscle regeneration in mdx mice, and suggests that iPSCs are a viable alternate source for deriving MSCs as needed",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102299",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are alterations in ultraconserved elements implicated in breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                "http://www.ncbi.nlm.nih.gov/pubmed/21331621"
            ],
            "ideal_answer": [
                "Yes. SNPs in ultraconserved elements (UCEs) might be associated with cancer risk."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069584",
                "http://www.disease-ontology.org/api/metadata/DOID:0060548",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061325",
                "http://www.disease-ontology.org/api/metadata/DOID:1612",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001943",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000072656",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050436",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058922",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001940",
                "http://www.disease-ontology.org/api/metadata/DOID:14521",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018567",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064726"
            ],
            "type": "yesno",
            "id": "587e276be96a600607000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "text": "SNPs in ultraconserved elements and familial breast cancer risk",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 822,
                    "text": " In the present study, we investigated the influence of six SNPs within UCEs on familial breast cancer risk. Two out of six SNPs showed an association with familial breast cancer risk",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1456,
                    "offsetInEndSection": 1545,
                    "text": "This is the first study indicating that SNPs in UCEs might be associated with cancer risk",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "SNPs in ultraconserved elements and familial breast cancer risk.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 244,
                    "text": "Recent studies have indicated that UCEs are not mutation cold regions and likely to be concerned with cancers, including breast cancer (BC). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331621",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "SNPs in ultraconserved elements and familial breast cancer risk.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Genetic variants in ultraconserved elements and risk of breast cancer in Chinese population.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331621",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is golimumab effective for sarcoidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29601563",
                "http://www.ncbi.nlm.nih.gov/pubmed/25034562"
            ],
            "ideal_answer": [
                "No, golimumab is not effective for treatment of sarcoidosis."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e476b99d14c9f295d000001",
            "snippets": [
                {
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 754,
                    "text": "Introduced monoclonal antibodies (infliximab, etanercept, adaluimumab, golimumab, rituximab), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with SA. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29601563",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1399,
                    "offsetInEndSection": 1520,
                    "text": "Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1399,
                    "offsetInEndSection": 1519,
                    "text": "Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25034562",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can the yeast protein Abf1 act as insulator?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12200417"
            ],
            "ideal_answer": [
                "Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity",
                "yes",
                "Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a857bfffaa1ab7d2e000030",
            "snippets": [
                {
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 187,
                    "text": "Saccharomyces cerevisiae Rap1p and Abf1p proteins are endowed with a potent insulating capacity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 424,
                    "text": "Insulating domains in Rap1p coincide with previously described transcription activation domains, whereas four adjacent subdomains spanning the whole of the Abf1p C terminus (440-731) were found to display autonomous insulating capacity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 658,
                    "text": "That both Rap1p and Abf1p silencing domains either contain or largely overlap with an insulating domain suggests that insulation conveys some undefined chromosome organization capacity that also contributes a function in silencing. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is GAGA associated with nucleosome-free regions (NFR)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15579691",
                "http://www.ncbi.nlm.nih.gov/pubmed/8474442",
                "http://www.ncbi.nlm.nih.gov/pubmed/11158316",
                "http://www.ncbi.nlm.nih.gov/pubmed/7737124"
            ],
            "ideal_answer": [
                "The GAGA factor is a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin. The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions. While chromatin remodeling upon transcription factor interaction has previously been interpreted to involve nucleosome disruption, the data suggest energy-dependent nucleosome sliding as main principle of chromatin reorganization.",
                "The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1. To study the contribution of transcription factors to the establishment of this specific chromatin configuration we assembled nucleosomes on the hsp26 promoter using a cell-free reconstitution system derived from fly embryos. This (CT)n element appears to contribute to formation of the wild-type chromatin structure of hsp26, an organized nucleosome array that leaves the HSEs in nucleosome-free, DNase I-hypersensitive (DH) sites (Q. Lu, L.L. Wallrath, B.D. Allan, R.L. Glaser, J.T. Lis, and S.C.R. Elgin, J. Mol. Biol. Both DH sites were readily reconstituted from extract components.",
                "One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0016584",
                "http://amigo.geneontology.org/amigo/term/GO:0034728",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009707",
                "http://amigo.geneontology.org/amigo/term/GO:0000786"
            ],
            "type": "yesno",
            "id": "56f3f6b12ac5ed145900001a",
            "snippets": [
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 510,
                    "text": "One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15579691",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 832,
                    "text": "The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11158316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 980,
                    "text": "The interactions of GAGA factor and heat shock factor with their binding sites in chromatin occurred in two modes. Their interaction with binding sites in the nucleosome-free regions did not require ATP. In the presence of ATP both factors interacted also with nucleosomal binding sites, causing nucleosome rearrangements and a refinement of nucleosome positions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7737124",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 982,
                    "offsetInEndSection": 1212,
                    "text": "While chromatin remodeling upon transcription factor interaction has previously been interpreted to involve nucleosome disruption, the data suggest energy-dependent nucleosome sliding as main principle of chromatin reorganization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7737124",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1795,
                    "offsetInEndSection": 1942,
                    "text": " These (CT)n repeats are associated with a nonhistone protein(s) in vivo and are bound by a purified Drosophila protein, the GAGA factor, in vitro.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 630,
                    "text": "This (CT)n element appears to contribute to formation of the wild-type chromatin structure of hsp26, an organized nucleosome array that leaves the HSEs in nucleosome-free, DNase I-hypersensitive (DH) site",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 1086,
                    "text": "The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11158316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 758,
                    "text": "One of the three nuclease hypersensitive sites in the Fab-7 boundary, HS1, contains multiple consensus-binding sequences for the GAGA factor, a protein known to be involved in the formation and/or maintenance of nucleosome-free regions of chromatin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15579691",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "The iab-7 polycomb response element maps to a nucleosome-free region of chromatin and requires both GAGA and pleiohomeotic for silencing activity.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11158316",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 833,
                    "text": "The HS3 sequence contains consensus binding sites for the GAGA factor, a protein implicated in the formation of nucleosome-free regions of chromatin, and Pleiohomeotic (Pho), a Polycomb group protein that is related to the mammalian transcription factor YY1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11158316",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the CTCF protein co-localize with cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22780989",
                "http://www.ncbi.nlm.nih.gov/pubmed/23010778",
                "http://www.ncbi.nlm.nih.gov/pubmed/19158269",
                "http://www.ncbi.nlm.nih.gov/pubmed/22550178",
                "http://www.ncbi.nlm.nih.gov/pubmed/19109133",
                "http://www.ncbi.nlm.nih.gov/pubmed/23204437",
                "http://www.ncbi.nlm.nih.gov/pubmed/18623068",
                "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19308701",
                "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                "http://www.ncbi.nlm.nih.gov/pubmed/24257606",
                "http://www.ncbi.nlm.nih.gov/pubmed/20133600",
                "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                "http://www.ncbi.nlm.nih.gov/pubmed/21106760",
                "http://www.ncbi.nlm.nih.gov/pubmed/23945083",
                "http://www.ncbi.nlm.nih.gov/pubmed/22952237",
                "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                "http://www.ncbi.nlm.nih.gov/pubmed/18550811",
                "http://www.ncbi.nlm.nih.gov/pubmed/21948239",
                "http://www.ncbi.nlm.nih.gov/pubmed/21970734",
                "http://www.ncbi.nlm.nih.gov/pubmed/22440186",
                "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                "http://www.ncbi.nlm.nih.gov/pubmed/20219941",
                "http://www.ncbi.nlm.nih.gov/pubmed/21628529",
                "http://www.ncbi.nlm.nih.gov/pubmed/23295672",
                "http://www.ncbi.nlm.nih.gov/pubmed/21606361",
                "http://www.ncbi.nlm.nih.gov/pubmed/23804403",
                "http://www.ncbi.nlm.nih.gov/pubmed/23498937"
            ],
            "ideal_answer": [
                "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin.",
                "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin  "
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/CTCF_RAT",
                "http://www.uniprot.org/uniprot/CTCFL_HUMAN"
            ],
            "type": "yesno",
            "id": "5344310baeec6fbd0700000c",
            "snippets": [
                {
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 560,
                    "text": "To investigate cohesin-non-CTCF (CNC) binding events in vivo we mapped cohesin and CTCF, as well as a collection of tissue-specific and ubiquitous transcriptional regulators using ChIP-seq in primary mouse liver.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 886,
                    "text": "In contrast to regions of the genome where cohesin and CTCF colocalize, CNC sites coincide with the binding of master regulators and enhancer-markers and are significantly associated with liver-specific expressed genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 541,
                    "text": "Here we report that cohesins colocalize with CTCF at two additional imprinted loci, the Dlk1-Dio3 and the Kcnq1/Kcnq1ot1 loci.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21628529",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 834,
                    "text": "By use of human hepatocellular carcinoma cells (HepG2), we found that liver-specific transcription factors colocalize with cohesin independently of CTCF at liver-specific targets that are distinct from those found in breast cancer cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219941",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 879,
                    "text": "Because cohesin can colocalize with CTCF, we performed chromatin immunoprecipitation for the cohesin subunit Rad21 and found lineage and stage-specific Rad21 recruitment to CTCF in all Ig loci",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19109133",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 486,
                    "text": "Here we show that zebrafish runx1 is directly bound by cohesin and CCCTC binding factor (CTCF) at the P1 and P2 promoters, and within the intron between P1 and P2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 866,
                    "text": "The intronic binding sites for cohesin and CTCF coincide with histone modifications that confer enhancer-like properties, and two of the cohesin/CTCF sites behaved as insulators in an in vivo assay",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 1023,
                    "text": "The identified cohesin and CTCF binding sites are likely to be cis-regulatory elements (CREs) for runx1 since they also recruit RNA polymerase II (RNAPII).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 387,
                    "text": "We have found that CTCF and cohesin are highly enriched at the convergent and partially overlapping transcripts for the LMP1 and LMP2A genes, but it is not yet known how CTCF and cohesin may coordinately regulate these transcripts",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257606",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 124,
                    "text": "haracterization of constitutive CTCF/cohesin loci: a possible role in establishing topological domains in mammalian genomes",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945083",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 890,
                    "text": "Our analysis revealed: 1) constitutive CTCF loci were located in constitutive open chromatin and often co-localized with constitutive cohesin loci",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 922,
                    "text": "In brain, a third of CTCF and cohesin binding sites coincide, consistent with the potential for many interactions between cohesin and CTCF but also many instances of independent action",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23804403",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 389,
                    "text": "Here, we focus on the emerging roles of CTCF and the cohesin in coordinating long-range interactions between regulatory elements",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23498937",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 1018,
                    "text": "Chromatin immunoprecipitation for CTCF and the cohesin subunits RAD21 and SMC3 reveals evolutionarily conserved binding sites within unmethylated regions \u223c5 kb downstream of the PLAGL1 differentially methylated region and within the PLAGL1 3' untranslated region (UTR)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 42,
                    "text": "TCF physically links cohesin to chromatin",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550811",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 65,
                    "text": "ohesin and CTCF: cooperating to control chromosome conformation?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18623068",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 374,
                    "text": "Recently, three groups mapped numerous cohesin-binding sites in mammalian chromosomes and found substantial overlap with the CCCTC-binding factor (CTCF)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18623068",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 644,
                    "text": "We found that each site contains a conserved CTCF consensus sequence, binds CTCF, and recruits the cohesin subunit Rad21 in vivo",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158269",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 408,
                    "text": "Recent experiments have revealed that cohesin binds to the same sites in mammalian genomes as the zinc finger transcription factor CTCF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19308701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 765,
                    "text": "Here we review what is known about the roles of cohesin and CTCF in regulating gene expression in mammalian cells, and we discuss how cohesin might mediate the insulator function of CTCF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19308701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 674,
                    "text": "Previous studies have shown that this major latency control region is occupied by the cellular chromatin boundary factor CTCF and chromosome structural maintenance proteins SMC1, SMC3, and RAD21, which comprise the cohesin complex",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1070,
                    "text": "Cohesin subunits assembled at the CTCF binding sites and bound CTCF proteins in a cell cycle-dependent manner",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1533,
                    "offsetInEndSection": 1788,
                    "text": "We propose that the CTCF-cohesin complex plays a critical role in regulating the cell cycle control of viral gene expression during latency and that failure to maintain cell cycle control of latent transcripts inhibits host cell proliferation and survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 298,
                    "text": "We used chromosome conformation capture to determine long-range interactions among CTCF/cohesin sites over 2 Mb on human chromosome 11 encompassing the beta-globin locus and flanking olfactory receptor genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20133600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1115,
                    "text": "These results support a genome-wide role for CTCF/cohesin sites through loop formation that both influences transcription and contributes to cell-type-specific chromatin organization and function",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20133600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 741,
                    "offsetInEndSection": 892,
                    "text": "Increased methylation at this promoter triggered the dissociation of the insulator protein CTCF as well as the accompanying cohesin from the BDNF locus",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106760",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 152,
                    "text": "icotinamide adenine dinucleotide (NAD)-regulated DNA methylation alters CCCTC-binding factor (CTCF)/cohesin binding and transcription at the BDNF locus",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106760",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 234,
                    "text": "ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 411,
                    "text": "We show here that the interaction of CTCF with the cohesin complex involves direct contacts between the cohesin subunit SA2 and specific regions of the C-terminal tail of CTCF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 743,
                    "offsetInEndSection": 885,
                    "text": "Taken together, our results demonstrate that specific sites on the C terminus of CTCF are essential for cohesin binding and insulator function",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 887,
                    "offsetInEndSection": 1004,
                    "text": "The only direct interaction between CTCF and cohesin involves contact with SA2, which is external to the cohesin ring",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 626,
                    "offsetInEndSection": 788,
                    "text": "These numerous CTCF/cohesin sites potentially form the bases of the multiloop rosette structures at the Igh locus that compact during Ig heavy chain rearrangement",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 399,
                    "text": "We have previously shown that the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) major latency transcripts encoding LANA, vCyclin, vFLIP, v-miRNAs, and Kaposin are regulated, in part, by a chromatin organizing element that binds CTCF and cohesins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 757,
                    "offsetInEndSection": 924,
                    "text": "Mutation of the CTCF-cohesin binding site reduced or eliminated the chromatin conformation linkages, and deregulated viral transcription and genome copy number control",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1483,
                    "text": "Our findings indicate that KSHV genomes are organized into chromatin loops mediated by CTCF and cohesin interactions, and that these inter-chromosomal linkages coordinate latent and lytic gene control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 491,
                    "text": "We show here that GA disrupts an RNA polymerase II (RNAPII) complex that accumulates at the CTCF-cohesin binding site within the first intron of the latency transcript.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 492,
                    "offsetInEndSection": 638,
                    "text": "GA altered the enrichment of the RNAPII pausing complex, along with pausing factors SPT5 and NELF-A, at the intragenic CTCF-cohesin binding sites.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 960,
                    "offsetInEndSection": 1116,
                    "text": "GA treatment also inhibited the transcription of some cellular genes, like c-myc, which contain a similar CTCF-cohesin binding site within the first intron.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1223,
                    "offsetInEndSection": 1499,
                    "text": "These findings suggest that RNAPII pauses at intragenic CTCF-cohesin binding sites and that abrogation of this pausing by GA leads to loss of proper mRNA production and defects in sister chromatid cohesion, a process important for both viral and cellular chromosome stability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 120,
                    "text": "TCF and cohesin cooperatively mediate the cell-type specific interchromatin interaction between Bcl11b and Arhgap6 loci",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21948239",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 467,
                    "offsetInEndSection": 648,
                    "text": "Additional experiments verified that the interchromatin interaction between the Bcl11b and Arhgap6 loci was cell-type specific, which was cooperatively mediated by CTCF and cohesin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21948239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 118,
                    "text": "enome-wide studies of CCCTC-binding factor (CTCF) and cohesin provide insight into chromatin structure and regulation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952237",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 544,
                    "text": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952237",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 375,
                    "text": "Here, we show by ChIP-Seq that most human subtelomeres contain a CTCF- and cohesin-binding site within \u223c1-2\u2009kb of the TTAGGG repeat tract and adjacent to a CpG-islands implicated in TERRA transcription control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 974,
                    "offsetInEndSection": 1155,
                    "text": "These findings indicate that CTCF and cohesin are integral components of most human subtelomeres, and important for the regulation of TERRA transcription and telomere end protection",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 731,
                    "text": "In addition, we show that this DNA looping requires specific binding of the CTCF/cohesin complex to two symmetrically aligned binding sites in both the transcriptionally active promoters and in one of the enhancers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204437",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is progesterone effective for treatment of patients with traumatic brain injury based on clinical trial data?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17327733",
                "http://www.ncbi.nlm.nih.gov/pubmed/19318112",
                "http://www.ncbi.nlm.nih.gov/pubmed/23326789",
                "http://www.ncbi.nlm.nih.gov/pubmed/17418038",
                "http://www.ncbi.nlm.nih.gov/pubmed/18447940",
                "http://www.ncbi.nlm.nih.gov/pubmed/19401954",
                "http://www.ncbi.nlm.nih.gov/pubmed/22033509",
                "http://www.ncbi.nlm.nih.gov/pubmed/24241345",
                "http://www.ncbi.nlm.nih.gov/pubmed/19660659",
                "http://www.ncbi.nlm.nih.gov/pubmed/17011666",
                "http://www.ncbi.nlm.nih.gov/pubmed/22570859",
                "http://www.ncbi.nlm.nih.gov/pubmed/25493974",
                "http://www.ncbi.nlm.nih.gov/pubmed/21249708",
                "http://www.ncbi.nlm.nih.gov/pubmed/25493978",
                "http://www.ncbi.nlm.nih.gov/pubmed/23076947",
                "http://www.ncbi.nlm.nih.gov/pubmed/18522765",
                "http://www.ncbi.nlm.nih.gov/pubmed/17933428",
                "http://www.ncbi.nlm.nih.gov/pubmed/22626570",
                "http://www.ncbi.nlm.nih.gov/pubmed/22668124",
                "http://www.ncbi.nlm.nih.gov/pubmed/24900479",
                "http://www.ncbi.nlm.nih.gov/pubmed/20486864",
                "http://www.ncbi.nlm.nih.gov/pubmed/23871679",
                "http://www.ncbi.nlm.nih.gov/pubmed/22300914",
                "http://www.ncbi.nlm.nih.gov/pubmed/17588708",
                "http://www.ncbi.nlm.nih.gov/pubmed/24205899",
                "http://www.ncbi.nlm.nih.gov/pubmed/19394357",
                "http://www.ncbi.nlm.nih.gov/pubmed/21497181"
            ],
            "ideal_answer": [
                "No. Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. However, a recent large clinical trial showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.biosemantics.org/jochem#4271493"
            ],
            "type": "yesno",
            "id": "54cf48acf693c3b16b00000b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "BACKGROUND: Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1583,
                    "text": "The proportion of patients with a favorable outcome on the Glasgow Outcome Scale (good recovery or moderate disability) was 50.4% with progesterone, as compared with 50.5% with placebo. Mortality was similar in the two groups. No relevant safety differences were noted between progesterone and placebo. CONCLUSIONS: Primary and secondary efficacy analyses showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "BACKGROUND: Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Progesterone has been shown to improve neurologic outcome in multiple experimental models and two early-phase trials involving patients with TBI. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1490,
                    "offsetInEndSection": 1869,
                    "text": "There was no significant difference between the progesterone group and the placebo group in the proportion of patients with a favorable outcome (relative benefit of progesterone, 0.95; 95% confidence interval [CI], 0.85 to 1.06; P=0.35). Phlebitis or thrombophlebitis was more frequent in the progesterone group than in the placebo group (relative risk, 3.03; CI, 1.96 to 4.66). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1950,
                    "offsetInEndSection": 2094,
                    "text": "CONCLUSIONS: This clinical trial did not show a benefit of progesterone over placebo in the improvement of outcomes in patients with acute TBI. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 693,
                    "text": "Numerous studies, however, show that progesterone has substantial pleiotropic properties as a neuroprotective agent in both animal models and humans.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24241345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 1190,
                    "text": "RESULTS: There was a better recovery rate and GOS score for the patients who were given progesterone than for those in the control group in a 3-months follow-up period (50% vs. 21%); subgroup analysis showed a significant difference in the percentage of favorable outcome between the two groups with GCS of 5-8 (p=0.03). CONCLUSION: The use of progesterone may significantly improve neurologic outcome of patients suffering severe TBI up to 3 months after injury, especially those with 5\u2264GCS\u22648, providing a potential benefit to the treatment of acute severe TBI patients. Considering this drug had no significant side effects, so progesterone could be used in patients with severe TBI as a neuro-protective drug.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871679",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1127,
                    "offsetInEndSection": 1283,
                    "text": "While progesterone and ciclosporin have shown promise in phase II studies, success in larger phase III, randomized, multicentre, clinical trials is pending.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22668124",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1458,
                    "offsetInEndSection": 1793,
                    "text": " All three studies reported the effects of progesterone on mortality. The pooled risk ratio (RR) for mortality at end of follow-up was 0.61, 95% confidence interval (CI) 0.40 to 0.93. Three studies measured disability and found the RR of death or severe disability in patients treated with progesterone to be 0.77, 95% CI 0.62 to 0.96.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23076947",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2161,
                    "offsetInEndSection": 2418,
                    "text": "AUTHORS' CONCLUSIONS: Current clinical evidence from three small RCTs indicates progesterone may improve the neurologic outcome of patients suffering TBI. This evidence is still insufficient and further multicentre randomised controlled trials are required.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23076947",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1438,
                    "offsetInEndSection": 1976,
                    "text": "GOS was classified to 2 main categories of favorable and unfavorable recovery, of which, favorable recovery in placebo, progesterone, and progesterone-vitamin D was 25%, 45%, and 60%, respectively which showed a statistical significant difference among the groups (P-value = 0.03). CONCLUSION: The results showed that recovery rate in patients with severe brain trauma in the group receiving progesterone and vitamin D together was significantly higher than that of progesterone group, which was in turn higher than that of placebo group.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326789",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1287,
                    "offsetInEndSection": 1575,
                    "text": " The pooled relative risk (RR) for mortality at end of follow-up is 0.61, 95% confidence interval (CI) 0.40 to 0.93. Three studies measured disability and found the RR of death or severe disability in patients treated with progesterone was 0.77, 95% confidence interval (CI) 0.62 to 0.96.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249708",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1774,
                    "offsetInEndSection": 2031,
                    "text": "AUTHORS' CONCLUSIONS: Current clinical evidence from three small RCTs indicates progesterone may improve the neurologic outcome of patients suffering TBI. This evidence is still insufficient and further multicentre randomised controlled trials are required.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249708",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 633,
                    "text": "Clinical trials have shown that short-and long-term progesterone treatment induces a significant improvement in the level of disability among patients with brain injury. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": -1,
                    "offsetInEndSection": 142,
                    "text": "Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 998,
                    "text": "CONCLUSION: Our data suggest that acute severe TBI patients with administration of progesterone hold improved neurologic outcomes for up to 6 months. These results provide information important for further large and multicenter clinical trials on progesterone as a promising neuroprotective drug. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1496,
                    "offsetInEndSection": 1814,
                    "text": "The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01). The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2139,
                    "offsetInEndSection": 2436,
                    "text": "CONCLUSION: Our data suggest that acute severe TBI patients with administration of progesterone hold improved neurologic outcomes for up to 6 months. These results provide information important for further large and multicenter clinical trials on progesterone as a promising neuroprotective drug. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 376,
                    "offsetInEndSection": 632,
                    "text": "These data, combined with the results of the previously published ProTECT trial, show progesterone to be safe and potentially efficacious in the treatment of TBI. Larger phase III trials will be necessary to verify results prior to clinical implementation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18522765",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1388,
                    "offsetInEndSection": 1649,
                    "text": "CONCLUSION: It indicated that successive early application of PG will benefit the patients with acute severe head injury by improving the recovery and reducing the disability, which may be related to its alleviating inflammatory and lipid peroxidation response.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17418038",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1508,
                    "text": "Adverse and serious adverse event rates were similar in both groups, except that patients randomized to progesterone had a lower 30-day mortality rate than controls (rate ratio 0.43; 95% confidence interval 0.18 to 0.99). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17011666",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1690,
                    "offsetInEndSection": 1963,
                    "text": "However, moderate traumatic brain injury survivors who received progesterone were more likely to have a moderate to good outcome than those randomized to placebo. CONCLUSION: In this small study, progesterone caused no discernible harm and showed possible signs of benefit.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17011666",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "After more than 30 years of research and 30 failed clinical trials with as many different treatments, progesterone is the first agent to demonstrate robust clinical efficacy as a treatment for traumatic brain injuries.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "After more than 30 years of research and 30 failed clinical trials with as many different treatments, progesterone is the first agent to demonstrate robust clinical efficacy as a treatment for traumatic brain injuries",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 763,
                    "text": "A US National Institutes of Health-sponsored, nationwide Phase III clinical trial is now evaluating progesterone for moderate-to-severe TBI in 1200 patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22033509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 921,
                    "text": "An industry-sponsored Phase III international trial is also under way, and planning for a trial using progesterone to treat pediatric brain injury has begun",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22033509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 316,
                    "text": "More than two decades of pre-clinical research and two recent clinical trials have shown that progesterone (PROG) and its metabolites exert beneficial effects after traumatic brain injury (TBI) through a number of metabolic and physiological pathways that can reduce damage in many different tissues and organ systems",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19394357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "text": "After more than 30 years of research and 30 failed clinical trials with as many different treatments, progesterone is the first agent to demonstrate robust clinical efficacy as a treatment for traumatic brain injuries",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 1248,
                    "text": "RESULTS: Analysis of these reviews yielded meanfuling observations: (1) The effectiveness of most ordinary treatments in TBI is inconclusive except that corticosteroids are likely to be ineffective or harmful, and tranexamic acid, nimodipine and progesterone show a promising effect in bleeding trauma, traumatic subarachnoid hemorrhage, TBI or severe TBI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 387,
                    "text": "Laboratory data strongly show that progesterone treatment after TBI reduces edema, improves outcomes, and restores blood-brain barrier function. Clinical studies to date agree with these data, and there are ongoing human trials for progesterone treatment after TBI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19401954",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Citrobacter rodentium pathogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28085133",
                "http://www.ncbi.nlm.nih.gov/pubmed/27624779",
                "http://www.ncbi.nlm.nih.gov/pubmed/27821583",
                "http://www.ncbi.nlm.nih.gov/pubmed/27633986"
            ],
            "ideal_answer": [
                "Yes, the mouse pathogen Citrobacter rodentium, colonize the gut mucosa via attaching and effacing lesion formation and cause diarrheal diseases."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5aa4faaed6d6b54f7900000b",
            "snippets": [
                {
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 855,
                    "text": "One day after colonization, mice were infected with the colonic pathogen, Citrobacter rodentium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27633986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "The human pathogen enteropathogenic Escherichia coli (EPEC), as well as the mouse pathogen Citrobacter rodentium, colonize the gut mucosa via attaching and effacing lesion formation and cause diarrheal diseases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27624779",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1578,
                    "offsetInEndSection": 1624,
                    "text": "EPEC-like mouse pathogen Citrobacter rodentium",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085133",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 581,
                    "text": "Here, we develop a model that provides that link for the investigation of Citrobacter rodentium infection, a mouse model for enteropathogenic Escherichia coli (EPEC). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821583",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is tubulin acetylation involved in cell motility?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22193721",
                "http://www.ncbi.nlm.nih.gov/pubmed/20308065",
                "http://www.ncbi.nlm.nih.gov/pubmed/20940043",
                "http://www.ncbi.nlm.nih.gov/pubmed/12024216",
                "http://www.ncbi.nlm.nih.gov/pubmed/22589388",
                "http://www.ncbi.nlm.nih.gov/pubmed/23019416",
                "http://www.ncbi.nlm.nih.gov/pubmed/12677000"
            ],
            "ideal_answer": [
                "Yes, induction of alpha-tubulin acetylation correlates with inhibition of cell motility, while it is involved in additional cellular processes, e.g. cell cycle progression, differentiation, intracellular trafficking, and signalling. Dynamic microtubule (MT) acetylation/deacetylation mediating cell motility and adhesion is controlled by enzymes such as HDAC6, a major cytoplasmic \u03b1-tubulin deacetylase. While its overexpression and activation is capable to enhance cell motility, HDAC6 activity can also be negatively regulated by a number of cellular inhibitors, thus decreasing the ability of cells for migration."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0048870",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054443",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007021",
                "http://www.uniprot.org/uniprot/TBA_GIBZE",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002465",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:2000145",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014404",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0019799",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050257",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090043",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045298",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000107",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071929"
            ],
            "type": "yesno",
            "id": "5317606eb166e2b80600000d",
            "snippets": [
                {
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 710,
                    "text": "In this study, we found that paclitaxel induced tubulin acetylation in endothelial and tumor cells, at concentrations that affected cell motility but not proliferation (10(-8) to 10(-9) M, for 4 hours). Induction of tubulin acetylation correlated with inhibition of motility but not proliferation based on a comparison of highly and poorly cytotoxic taxanes (paclitaxel and IDN5390) and tumor cell lines sensitive and resistant to paclitaxel (1A9 and 1A9 PTX22).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019416",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 845,
                    "offsetInEndSection": 1226,
                    "text": "we found that overexpression of the tubulin deacetylase SIRT2 increased cell motility and reduced cell response to the anti-motility activity of paclitaxel. Conversely, the SIRT2 inhibitor splitomicin reduced cell motility and potentiated the anti-motility activity of paclitaxel. The inhibitory effect was further potentiated by the addition of the HDAC6 inhibitor trichostatin A.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019416",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "Cell motility and adhesion involves dynamic microtubule (MT) acetylation/deacetylation, a process regulated by enzymes as HDAC6, a major cytoplasmic \u03b1-tubulin deacetylase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22193721",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 709,
                    "text": "GRK2 and HDAC6 colocalize in the lamellipodia of migrating cells, leading to local tubulin deacetylation and enhanced motility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22193721",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 798,
                    "offsetInEndSection": 1014,
                    "text": "This review highlights the emerging roles of tubulin acetylation in multiple cellular functions, ranging from cell motility, cell cycle progression or cell differentiation to intracellular trafficking and signalling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20940043",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 1017,
                    "text": "Our results indicate that TPPP/p25 binds to HDAC6 (histone deacetylase 6), an enzyme responsible for tubulin deacetylation. Moreover, we demonstrated that the direct interaction of these two proteins resulted in the inhibition of the deacetylase activity of HDAC6.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20308065",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1490,
                    "offsetInEndSection": 1745,
                    "text": "Finally, we demonstrated that, similarly to other HDAC6 inhibitors, TPPP/p25 influences the microtubule dynamics by decreasing the growth velocity of the microtubule plus ends and also affects cell motility as demonstrated by time lapse video experiments.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20308065",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 389,
                    "offsetInEndSection": 462,
                    "text": "\"tubacin,\" which inhibits alpha-tubulin deacetylation in mammalian cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12677000",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 677,
                    "text": "We provide evidence that class II histone deacetylase 6 (HDAC6) is the intracellular target of tubacin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12677000",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 901,
                    "text": "Tubacin treatment did not affect the stability of microtubules but did decrease cell motility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12677000",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1376,
                    "text": "They also suggest that small molecules that selectively inhibit HDAC6-mediated alpha-tubulin deacetylation, a first example of which is tubacin, might have therapeutic applications as antimetastatic and antiangiogenic agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12677000",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1164,
                    "text": "Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12024216",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 970,
                    "offsetInEndSection": 1334,
                    "text": "HDAC6 is a major cytoplasmic a-tubulin deacetylase that is involved in cell motility and adhesion. GRK2 dynamically and directly associates with and phosphorylates HDAC6 to stimulate its a-tubulin deacetylase activity at specific cellular localizations, such as the leading edge of migrating cells, thus promoting local tubulin deacetylation and enhanced motility.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589388",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are AAV vectors considered for the treatment of retinal dystrophies?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26609316"
            ],
            "ideal_answer": [
                "Yes, AAV vectors are considered for the treatment of retinal dystrophies."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a74acd80384be9551000006",
            "snippets": [
                {
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 529,
                    "text": " These novel gene vectors aim to more safely and efficiently transduce retinal cells, expand the gene packaging capacity of AAV, and utilize new strategies to correct the varying mechanisms of dysfunction found with inherited retinal dystrophies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609316",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there increased recombination rate in human regulatory domains?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29058599"
            ],
            "ideal_answer": [
                "No. There is evidence of significantly reduced recombination rate compared to matched control regions at human regulatory domains."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0006310",
                "https://meshb.nlm.nih.gov/record/ui?ui=D050436",
                "https://meshb.nlm.nih.gov/record/ui?ui=D011995"
            ],
            "type": "yesno",
            "id": "5a774ce1faa1ab7d2e000006",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Evidence of reduced recombination rate in human regulatory domains.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 1664,
                    "text": "We study the relationship between recombination rate and gene regulatory domains, defined by a gene and its linked control elements. We define these links using expression quantitative trait loci (eQTLs), methylation quantitative trait loci (meQTLs), chromatin conformation from publicly available datasets\u00a0(Hi-C and ChIA-PET), and correlated activity links that we infer across cell types. Each link type shows a \"recombination rate\u00a0valley\" of significantly reduced recombination rate compared to matched control regions. This recombination rate\u00a0valley is most pronounced for gene regulatory domains of early embryonic development genes, housekeeping genes, and constitutive regulatory elements, which are known to show increased evolutionary constraint across species. Recombination rate\u00a0valleys show increased DNA methylation, reduced doublestranded break initiation, and increased repair efficiency, specifically in the lineage leading to the germ line. Moreover, by using only the overlap of functional links and DNA methylation in germ cells, we are able to predict the recombination rate with high accuracy.CONCLUSIONS: Our results suggest the existence of a recombination rate valley at regulatory domains and provide a potential molecular mechanism to interpret the interplay between genetic and epigenetic variations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the protein pelota a ribosomal rescue factor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20876129",
                "http://www.ncbi.nlm.nih.gov/pubmed/25061210",
                "http://www.ncbi.nlm.nih.gov/pubmed/27493551"
            ],
            "ideal_answer": [
                "Yes, in eukaryotes, Pelota (Dom34 in yeast) and Hbs1 are responsible for solving general problems of ribosomal stall in translation."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ad35933133db5eb78000001",
            "snippets": [
                {
                    "offsetInBeginSection": 347,
                    "offsetInEndSection": 411,
                    "text": "a novel binding partner of the ribosome recycling protein Pelota",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25061210",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 399,
                    "text": "n eukaryotes, Pelota (Dom34 in yeast) and Hbs1 are responsible for solving general problems of ribosomal stall in translation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 183,
                    "offsetInEndSection": 334,
                    "text": "In eukaryotes, the protein complex of Pelota (yeast Dom34) and Hbs1 translational GTPase recognizes the stalled ribosome containing the defective mRNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20876129",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the association of PARP1 and CTCF follow a circadian rhythm?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26321255"
            ],
            "ideal_answer": [
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription. PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.",
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity. Here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains. ",
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.",
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains . Parp1- and ctcf-regulated contacts between circadian loci to the lamina, followed by the acquisition of repressive h3k9me2 marks and transcriptional attenuation here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains . PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity. ",
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs). PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity. ",
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. Uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains . PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity. ",
                "yes",
                "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D002940",
                "http://amigo.geneontology.org/amigo/term/GO:0007623",
                "http://www.uniprot.org/uniprot/CTCF_MOUSE",
                "http://www.uniprot.org/uniprot/CTCF_CHICK",
                "https://meshb.nlm.nih.gov/record/ui?ui=D000067856",
                "https://meshb.nlm.nih.gov/record/ui?ui=D011065",
                "https://meshb.nlm.nih.gov/record/ui?ui=D011064",
                "https://meshb.nlm.nih.gov/record/ui?ui=D000071137",
                "https://meshb.nlm.nih.gov/record/ui?ui=D039103",
                "http://amigo.geneontology.org/amigo/term/GO:0072572",
                "https://meshb.nlm.nih.gov/record/ui?ui=D039102",
                "https://meshb.nlm.nih.gov/record/ui?ui=D000075223",
                "http://amigo.geneontology.org/amigo/term/GO:0042753",
                "http://amigo.geneontology.org/amigo/term/GO:0042754",
                "http://amigo.geneontology.org/amigo/term/GO:0048512",
                "http://www.uniprot.org/uniprot/CTCF_RAT",
                "https://meshb.nlm.nih.gov/record/ui?ui=D000075225",
                "http://www.uniprot.org/uniprot/CTCF_HUMAN",
                "http://amigo.geneontology.org/amigo/term/GO:0009649",
                "https://meshb.nlm.nih.gov/record/ui?ui=D020178",
                "https://meshb.nlm.nih.gov/record/ui?ui=D056925"
            ],
            "type": "yesno",
            "id": "5a86e66dfaa1ab7d2e000035",
            "snippets": [
                {
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 306,
                    "text": "here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 759,
                    "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 959,
                    "offsetInEndSection": 1127,
                    "text": "PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 1127,
                    "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation. Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription. PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1112,
                    "text": "transcriptionally active and inactive chromatin domains tend to segregate into separate sub nuclear compartments to maintain stable expression patterns however here we uncovered an inter chromosomal network connecting active loci enriched in circadian genes to repressed lamina associated domains lads the interactome is regulated by parp1 and its co factor ctcf they not only mediate chromatin fiber interactions but also promote the recruitment of circadian genes to the lamina synchronization of the circadian rhythm by serum shock induces oscillations in parp1 ctcf interactions which is accompanied by oscillating recruitment of circadian loci to the lamina followed by the acquisition of repressive h3k9me2 marks and transcriptional attenuation furthermore depletion of h3k9me2 3 inhibition of parp activity by olaparib or downregulation of parp1 or ctcf expression counteracts both recruitment to the envelope and circadian transcription parp1 and ctcf regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 760,
                    "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21266479",
                "http://www.ncbi.nlm.nih.gov/pubmed/19410542",
                "http://www.ncbi.nlm.nih.gov/pubmed/25813039",
                "http://www.ncbi.nlm.nih.gov/pubmed/22122340",
                "http://www.ncbi.nlm.nih.gov/pubmed/18268003"
            ],
            "ideal_answer": [
                "H2A.Z probably helps RSC in keeping the gene nucleosome-free.",
                "H2A.Z probably helps RSC in keeping the gene nucleosome-fre",
                "Yes, the chromatin remodeling complex, RSC, uses H2A. Z nucleosomes to remodel chromatin.",
                "yes, Accordingly, the absence of SWR-C or histone H2A.Z results in compromised chromatin remodeling and impaired gene expression in the absence of RSC and H3K4 methylation.",
                "H2A.Z probably helps RSC in keeping the gene nucleosome-fre Accordingly, the absence of SWR-C or histone H2A.Z results in compromised chromatin remodeling and impaired gene expression in the absence of RSC and H3K4 methylation."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d385f717bc3fee31f00001a",
            "snippets": [
                {
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 927,
                    "text": "In contrast, the upstream nucleosome which covers the TATA box under repressed conditions is shifted approximately 50 bp further upstream by the ATP-dependent chromatin remodeler RSC upon activation. It is marked with the histone variant H2A.Z and H4K16 acetylation in active state",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18268003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 576,
                    "text": "In RSC-depleted cells, NFRs shrink such that the average positions of flanking nucleosomes move toward predicted sites.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19410542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 819,
                    "text": "In contrast, H2A.Z deposition is dispensable for nucleosome positioning. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19410542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 723,
                    "text": "Emerging lines of evidence indicate that histone variants (H2AX and H2A.Z), histone post-translational modifications (acetylation, phosphorylation, methylation and ubiquitination) and chromatin-remodeling complexes (INO80, SWR1, SWI/SNF, RSC and NuRD) are important and direct players in the DNA double-strand break (DSB) response as well.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122340",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 865,
                    "text": "H2A.Z probably helps RSC in keeping the gene nucleosome-fre",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21266479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 925,
                    "offsetInEndSection": 1092,
                    "text": "Accordingly, the absence of SWR-C or histone H2A.Z results in compromised chromatin remodeling and impaired gene expression in the absence of RSC and H3K4 methylation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25813039",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Have mutations in the ZEB2 gene been found in any human syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17958891",
                "http://www.ncbi.nlm.nih.gov/pubmed/19842203",
                "http://www.ncbi.nlm.nih.gov/pubmed/17203459",
                "http://www.ncbi.nlm.nih.gov/pubmed/23523603",
                "http://www.ncbi.nlm.nih.gov/pubmed/23243526",
                "http://www.ncbi.nlm.nih.gov/pubmed/24029077",
                "http://www.ncbi.nlm.nih.gov/pubmed/16150342",
                "http://www.ncbi.nlm.nih.gov/pubmed/18445050",
                "http://www.ncbi.nlm.nih.gov/pubmed/23427518",
                "http://www.ncbi.nlm.nih.gov/pubmed/23322667",
                "http://www.ncbi.nlm.nih.gov/pubmed/16053902",
                "http://www.ncbi.nlm.nih.gov/pubmed/22486326",
                "http://www.ncbi.nlm.nih.gov/pubmed/19215041",
                "http://www.ncbi.nlm.nih.gov/pubmed/16688751",
                "http://www.ncbi.nlm.nih.gov/pubmed/23001561",
                "http://www.ncbi.nlm.nih.gov/pubmed/22246645",
                "http://www.ncbi.nlm.nih.gov/pubmed/20428734",
                "http://www.ncbi.nlm.nih.gov/pubmed/23152852",
                "http://www.ncbi.nlm.nih.gov/pubmed/24282181",
                "http://www.ncbi.nlm.nih.gov/pubmed/17932455",
                "http://www.ncbi.nlm.nih.gov/pubmed/20093881",
                "http://www.ncbi.nlm.nih.gov/pubmed/18259761",
                "http://www.ncbi.nlm.nih.gov/pubmed/15006694",
                "http://www.ncbi.nlm.nih.gov/pubmed/14681759",
                "http://www.ncbi.nlm.nih.gov/pubmed/15908750",
                "http://www.ncbi.nlm.nih.gov/pubmed/21893004",
                "http://www.ncbi.nlm.nih.gov/pubmed/23312518",
                "http://www.ncbi.nlm.nih.gov/pubmed/18230842",
                "http://www.ncbi.nlm.nih.gov/pubmed/12746390",
                "http://www.ncbi.nlm.nih.gov/pubmed/23466526",
                "http://www.ncbi.nlm.nih.gov/pubmed/20125191",
                "http://www.ncbi.nlm.nih.gov/pubmed/16088920",
                "http://www.ncbi.nlm.nih.gov/pubmed/17223398",
                "http://www.ncbi.nlm.nih.gov/pubmed/20145308",
                "http://www.ncbi.nlm.nih.gov/pubmed/16532472",
                "http://www.ncbi.nlm.nih.gov/pubmed/19236961"
            ],
            "ideal_answer": [
                "Yes, the Mowat-Wilson syndrome"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/ZEB2_HUMAN",
                "http://www.uniprot.org/uniprot/ZEB2_MOUSE"
            ],
            "type": "yesno",
            "id": "53552ed7f1005d6b58000001",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 156,
                    "text": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24282181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 17,
                    "offsetInEndSection": 233,
                    "text": "Mowat-Wilson syndrome (MWS; OMIM#235730) have characteristic facial features, a variety of congenital anomalies such as Hirschsprung disease, and intellectual disabilities caused by mutation or deletion of ZEB2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029077",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 111,
                    "text": "owat-Wilson syndrome (MWS) is a genetic disease caused by heterozygous mutations or deletions of the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 354,
                    "text": "MWS is caused by de novo heterozygous mutations in the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 274,
                    "text": "The cause of MWS is a de novo mutation in the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 111,
                    "text": "owat-Wilson syndrome (MWS) is a genetic disease caused by heterozygous mutations or deletions of the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322667",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 691,
                    "text": "MWS have a heterozygous loss-of-function mutation in the zinc finger E-box protein 2 (ZEB2) gene, also called SIP1 (Smad-interacting protein 1) and ZFHX1B,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23243526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 974,
                    "text": " human Mowat-Wilson syndrome, we suggest that deletion of ZEB2, is responsible for most of the effects of the mutation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152852",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 215,
                    "text": "Mutations at the hZeb2 locus cause Mowat-Wilson syndrome (MWS)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001561",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 32,
                    "offsetInEndSection": 76,
                    "text": "Mowat-Wilson syndrome and a mutation in ZEB2",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22486326",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 93,
                    "text": "owat-Wilson syndrome (MWS) is caused by a heterozygous mutation or deletion of the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246645",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 397,
                    "text": "The syndrome is caused by mutations or deletions of the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21893004",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 85,
                    "text": "owat-Wilson syndrome (MWS) is an autosomal dominant intellectual disability syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21893004",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 710,
                    "text": "single-copy ZEB2 gene deletion at 2q22.3 consistent with Mowat-Wilson syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20093881",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 305,
                    "text": "Mowat-Wilson syndrome, confirmed by molecular analysis as a heterozygous deletion of the ZEB2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145308",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1006,
                    "offsetInEndSection": 1084,
                    "text": "deletion encompassing ZEB2, the gene responsible for the Mowat-Wilson syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20125191",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1082,
                    "text": " Six patients had deletions in the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 58,
                    "text": "ZEB2 gene analysis for Mowat-Wilson syndrome",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1144,
                    "offsetInEndSection": 1257,
                    "text": "Mowat-Wilson syndrome (MWS) like appearance was noted. The disease is caused by mutation or deletion of ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19236961",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 127,
                    "text": "owat-Wilson syndrome (MWS; OMIM #235730) is a genetic condition caused by heterozygous mutations or deletions of the ZEB2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19215041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 185,
                    "text": "owat-Wilson syndrome (MWS) is an autosomal dominant developmental disorder with mental retardation and variable multiple congenital abnormalities due to mutations of the ZEB2 (ZFHX1B) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18445050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 931,
                    "offsetInEndSection": 1071,
                    "text": "MWS is caused by heterozygous mutations or deletions in the Zinc finger E-box-binding homeobox 2 gene, ZEB2, previously called ZFHX1B (SIP1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17958891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 153,
                    "text": "owat-Wilson syndrome (MWS) is a multiple congenital anomaly-mental retardation complex caused by mutations in the Zinc Finger Homeobox 1 B gene (ZFHX1B)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932455",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 704,
                    "offsetInEndSection": 778,
                    "text": "the ZFHX1B gene, which is known to be involved in the Mowat-Wilson syndrom",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223398",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 357,
                    "offsetInEndSection": 435,
                    "text": "de novo heterozygous mutations or deletions of the ZFHX1B gene located at 2q22",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17203459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 113,
                    "text": "owat-Wilson syndrome (MWS) is a recently delineated mental retardation (MR)-multiple congenital anomaly syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17203459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 55,
                    "text": "FHX1B mutations in patients with Mowat-Wilson syndrome",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17203459",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 390,
                    "text": "Mutations leading to haploinsufficiency of the ZFHX1B gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16688751",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 98,
                    "text": "mutation in the ZFHX1B gene associated with an atypical Mowat-Wilson syndrome phenotype",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16688751",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 69,
                    "text": "ZFHX1B mutation associated with a mild Mowat-Wilson syndrome",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532472",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 20,
                    "offsetInEndSection": 197,
                    "text": "Patients with zinc finger homeo box 1B (ZFHX1B) mutations or deletions develop multiple congenital anomalies including Hirschsprung disease, known as Mowat-Wilson syndrome (MWS)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16150342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 441,
                    "text": "Heterozygous mutations or deletions involving the gene ZFHX1B (previously SIP1) [OMIM 605802] have recently been found to cause MWS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16088920",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 567,
                    "offsetInEndSection": 680,
                    "text": " ZFHX1B deletions, splice site or truncating mutations were detected in all 28 patients classified as typical MWS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16053902",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 27,
                    "offsetInEndSection": 117,
                    "text": "Mowat-Wilson syndrome with deletion/mutation in the zinc finger homeo box 1B gene (ZFHX1B)",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15908750",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 437,
                    "offsetInEndSection": 499,
                    "text": " mutations in the zinc finger homeo box 1B gene, ZFHX1B (SIP1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15908750",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 38,
                    "offsetInEndSection": 172,
                    "text": "ZFHX1B gene transcripts during mouse and human development supports the various clinical manifestations of the \"Mowat-Wilson\" syndrome",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15006694",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 287,
                    "text": " ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15006694",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 118,
                    "text": "mutation of the zinc finger homeo box 1 B gene in syndromic corpus callosum agenesis (Mowat-Wilson syndrome",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681759",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 572,
                    "text": "syndrome is the result of heterozygous deletions or truncating mutations of the ZFHX1B (SIP1) gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12746390",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 737,
                    "text": "humans with Zfhx1b mutations (Mowat-Wilson syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23312518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 665,
                    "text": "syndrome occurs as a result of heterozygous mutations or deletions in the zinc finger E-box-binding homeobox 2 gene, ZEB2, previously called ZFHX1B (SIP1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428734",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 72,
                    "text": "owat-Wilson syndrome (MWS) is a recently delineated mental retardation;",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428734",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 126,
                    "text": "Mowat-Wilson syndrome is a congenital syndrome caused by a defect of the transcriptional repressor ZFHX1B (SIP1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18259761",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 537,
                    "text": "Mowat-Wilson syndrome patients, and all siblings had the same E87X nonsense mutation in ZFHX1B",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18230842",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any involvement of the long non-coding RNA Gomafu in schizophrenia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                "http://www.ncbi.nlm.nih.gov/pubmed/25145264"
            ],
            "ideal_answer": [
                "Yes. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085",
                "http://www.disease-ontology.org/api/metadata/DOID:5419",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019967",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012561",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012559"
            ],
            "type": "yesno",
            "id": "588fbedced9bbee70d000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 1154,
                    "text": "Here, we profile these transcriptomic responses and show that long non-coding RNAs (lncRNAs) are dynamically regulated by neuronal activation, including acute downregulation of the lncRNA Gomafu, previously implicated in brain and retinal development. Moreover, we demonstrate that Gomafu binds directly to the splicing factors QKI and SRSF1 (serine/arginine-rich splicing factor 1) and dysregulation of Gomafu leads to alternative splicing patterns that resemble those observed in SZ for the archetypal SZ-associated genes DISC1 and ERBB4. Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. These results functionally link activity-regulated lncRNAs and alternative splicing in neuronal function and suggest that their dysregulation may contribute to neurological disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "Gomafu/MIAT/Rncr2 is a long noncoding RNA that has been proposed to control retinal cell specification, stem cell differentiation and alternative splicing of schizophrenia-related genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 560,
                    "offsetInEndSection": 849,
                    "text": "Moreover, we demonstrate that Gomafu binds directly to the splicing factors QKI and SRSF1 (serine/arginine-rich splicing factor 1) and dysregulation of Gomafu leads to alternative splicing patterns that resemble those observed in SZ for the archetypal SZ-associated genes DISC1 and ERBB4. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 849,
                    "offsetInEndSection": 971,
                    "text": "Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does deletion of cohesin change gene expression?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25677180"
            ],
            "ideal_answer": [
                " The conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, H3K27ac, H4K4me1, and enhancer transcription, but weakened interactions between enhancers. Interestingly, ~ 50% of deregulated genes reside in the vicinity of enhancer elements, suggesting that cohesin regulates gene expression through spatial clustering of enhancer elements.",
                "Yes. Deletion of cohesin inhibits gene expression at multiple points within the genome and in different genomic regions.",
                "The conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, H3K27ac, H4K4me1, and enhancer transcription, but weakened interactions between enhancers. 50% of deregulated genes reside in the vicinity of enhancer elements, suggesting that cohesin regulates gene expression through spatial clustering of enhancer elements.",
                "We propose a model for cohesin-dependent gene regulation in which spatial clustering of enhancer elements acts as a unified mechanism for both enhancer-promoter \"connections\" and \"insulation.\". The conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, H3K27ac, H4K4me1, and enhancer transcription, but weakened interactions between enhancers. Interestingly, ~ 50% of deregulated genes reside in the vicinity of enhancer elements, suggesting that cohesin regulates gene expression through spatial clustering of enhancer elements.",
                "Interestingly, ~ 50% of deregulated genes reside in the vicinity of enhancer elements, suggesting that cohesin regulates gene expression through spatial clustering of enhancer elements. We propose a model for cohesin-dependent gene regulation in which spatial clustering of enhancer elements acts as a unified mechanism for both enhancer-promoter \"connections\" and \"insulation.\"",
                "Yes.  Numerous studies have demonstrated that deletion of cohesin reduces gene expression at multiple points within the genome."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d35b9ecb3a6380763000004",
            "snippets": [
                {
                    "offsetInBeginSection": 932,
                    "offsetInEndSection": 1115,
                    "text": " The conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, H3K27ac, H4K4me1, and enhancer transcription, but weakened interactions between enhancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25677180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1301,
                    "text": "Interestingly, \u223c 50% of deregulated genes reside in the vicinity of enhancer elements, suggesting that cohesin regulates gene expression through spatial clustering of enhancer elements.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25677180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1302,
                    "offsetInEndSection": 1494,
                    "text": "We propose a model for cohesin-dependent gene regulation in which spatial clustering of enhancer elements acts as a unified mechanism for both enhancer-promoter \"connections\" and \"insulation.\"",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25677180",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an increased risk for meningiomas in childhood leukemia survivors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23459379",
                "http://www.ncbi.nlm.nih.gov/pubmed/30880270",
                "http://www.ncbi.nlm.nih.gov/pubmed/16193392",
                "http://www.ncbi.nlm.nih.gov/pubmed/17190987",
                "http://www.ncbi.nlm.nih.gov/pubmed/17243137",
                "http://www.ncbi.nlm.nih.gov/pubmed/23690411",
                "http://www.ncbi.nlm.nih.gov/pubmed/24767145",
                "http://www.ncbi.nlm.nih.gov/pubmed/19179425",
                "http://www.ncbi.nlm.nih.gov/pubmed/20634481",
                "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
                "http://www.ncbi.nlm.nih.gov/pubmed/28775249",
                "http://www.ncbi.nlm.nih.gov/pubmed/21671360",
                "http://www.ncbi.nlm.nih.gov/pubmed/22522336"
            ],
            "ideal_answer": [
                "Yes, the risk of meningiomas is higher in children treated with cranial irradiation for leukemia."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e324167fbd6abf43b00005a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "Cranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. Unfortunately, long-term survivors are faced with consequences of secondary neoplasia, including radiation-induced meningiomas (RIMs). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28775249",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 416,
                    "text": "Combined chemotherapy and prophylactic cranial irradiation has improved the prognosis of children with acute leukemia. However cranial irradiation carries a latent risk of the induction of secondary intracranial tumors. We encountered a patient who developed multiple intracranial radiation-induced meningiomas (RIMs) 25\u00a0years after prophylactic cranial irradiation for the treatment of acute leukemia in childhood. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24767145",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Focal cranial hyperostosis from meningioma: a complication from previous radiation treatment for childhood T-cell acute lymphoblastic leukemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23459379",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 756,
                    "text": "Presented is a case of a 20 year man with a history of T-cell lymphoblastic leukemia diagnosed at age 22 months, treated with chemotherapy and cranial irradiation. He had developed increasing prominence of the top of his head over several months. Plain radiograph showed frontal calvarium thickening with focal \"hair-on-end\" periosteal reaction. Magnetic resonance imaging revealed an enhancing dural-based mass with transcalvarial extension, confirmed after resection to be meningioma (World Health Organization Grade I). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23459379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 583,
                    "text": "RESULTS: Acute myeloid leukemia (AML; n = 186), myelodysplastic syndrome (MDS; n = 69), and nonmeningioma brain tumor (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1% \u00b1 2.9%, 31.1% \u00b1 6.2%, and 18.3% \u00b1 3.8%, respectively). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23690411",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "text": "Radiation-induced World Health Organization grade II meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood. Three case reports.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 294,
                    "text": "Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 1075,
                    "text": "RESULTS: Fifty-nine MRI abnormalities (32 cavernomas, nine focal areas of gliosis, seven dystrophic mineralizations, five cerebral atrophies, four pituitary atrophies, one diffuse radiation leukoencephalopathy, and one meningioma) were found in 43 patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Intraventricular meningioma after cranial irradiation for childhood leukemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 701,
                    "text": "Radiation-induced meningiomas may also have predilection to recur. The authors describe a case of an intraventricular meningioma occurring 23 years after cranial irradiation for childhood acute lymphoblastic leukemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20207611",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1015,
                    "offsetInEndSection": 1378,
                    "text": "Cumulative incidence at 30 years after the childhood cancer diagnosis was 20.5% (95% confidence interval [CI] = 19.1% to 21.8%) for all subsequent neoplasms, 7.9% (95% CI = 7.2% to 8.5%) for second malignant neoplasms (excluding nonmelanoma skin cancer), 9.1% (95% CI = 8.1% to 10.1%) for nonmelanoma skin cancer, and 3.1% (95% CI = 2.5% to 3.8%) for meningioma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634481",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Radiation-induced meningiomas: a shadow in the success story of childhood leukemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19179425",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1418,
                    "offsetInEndSection": 1576,
                    "text": "Although the cohort is small, it seems probable that the increasing incidence of meningioma will shadow the future of cranially irradiated leukemia survivors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19179425",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1325,
                    "text": "Age at the time of irradiation, gender, or cumulative doses of chemotherapeutic agents showed no significant association with the development of meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19179425",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Meningioma Screening With MRI in Childhood Leukemia Survivors Treated With Cranial Radiation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30880270",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17243137",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "Radiation-induced World Health Organization grade II meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17190987",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "text": "Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia ( ALL) , but have resulted in an increased risk of late central nervous system tumors , most commonly meningioma , particularly in patients who have received cranial irradiation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 723,
                    "text": "Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs , such as the lens and pituitary gland , and for the later development of a radiation-induced meningioma",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16193392",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Radiation-induced meningiomas: a shadow in the success story of childhood leukemia",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19179425",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 617,
                    "text": "We treated 3 young patients with World Health Organization grade II meningiomas who had previously received cranial irradiation for the treatment of childhood ALL: a cerebellopontine angle tumor in a 19-year-old woman , a petroclival tumor in a 28-year-old man , and a frontal parasagittal tumor in a 19-year-old woman",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 612,
                    "text": "We treated 3 young patients with World Health Organization grade II meningiomas who had previously received cranial irradiation for the treatment of childhood ALL: a cerebellopontine angle tumor in a 19-year-old woman, a petroclival tumor in a 28-year-old man, and a frontal parasagittal tumor in a 19-year-old woman.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 294,
                    "text": "Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 293,
                    "text": "Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522336",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1037,
                    "offsetInEndSection": 1179,
                    "text": "Long-term survivors who received radiotherapy for ALL in childhood are at risk for late complications, including radiation-induced meningioma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17190987",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27940037",
                "http://www.ncbi.nlm.nih.gov/pubmed/19479986",
                "http://www.ncbi.nlm.nih.gov/pubmed/23776204",
                "http://www.ncbi.nlm.nih.gov/pubmed/16282984",
                "http://www.ncbi.nlm.nih.gov/pubmed/22400011",
                "http://www.ncbi.nlm.nih.gov/pubmed/9020972",
                "http://www.ncbi.nlm.nih.gov/pubmed/23989958",
                "http://www.ncbi.nlm.nih.gov/pubmed/1684936",
                "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                "http://www.ncbi.nlm.nih.gov/pubmed/9223284",
                "http://www.ncbi.nlm.nih.gov/pubmed/9733864",
                "http://www.ncbi.nlm.nih.gov/pubmed/26730730",
                "http://www.ncbi.nlm.nih.gov/pubmed/19576221",
                "http://www.ncbi.nlm.nih.gov/pubmed/18177749",
                "http://www.ncbi.nlm.nih.gov/pubmed/28537233",
                "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                "http://www.ncbi.nlm.nih.gov/pubmed/9611233",
                "http://www.ncbi.nlm.nih.gov/pubmed/3037325",
                "http://www.ncbi.nlm.nih.gov/pubmed/2579655",
                "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                "http://www.ncbi.nlm.nih.gov/pubmed/17267594",
                "http://www.ncbi.nlm.nih.gov/pubmed/8440247",
                "http://www.ncbi.nlm.nih.gov/pubmed/16738135",
                "http://www.ncbi.nlm.nih.gov/pubmed/12601000"
            ],
            "ideal_answer": [
                "No, polyadenylation is a process that stabilizes mRNA by adding up to 200 adenosine residues to the 3' end of the trabscript"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0043631",
                "https://meshb.nlm.nih.gov/record/ui?ui=D026723"
            ],
            "type": "yesno",
            "id": "5a8714e261bb38fb24000005",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "The addition of poly(A) tails to eukaryotic nuclear mRNAs promotes their stability, export to the cytoplasm and translation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23989958",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Most eukaryotic genes express mRNAs with alternative polyadenylation sites at their 3' ends",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776204",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "text": "Polyadenylation is the non-template addition of adenosine nucleotides at the 3'-end of RNA, which occurs after transcription and generates a poly(A) tail up to 250-300 nucleotides long.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28537233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "Polyadenylation is a process of endonucleolytic cleavage of the mRNA, followed by addition of up to 250 adenosine residues to the 3' end of the mRNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Plant mitochondrial polyadenylated mRNAs are degraded by a 3'- to 5'-exoribonuclease activity, which proceeds unimpeded by stable secondary structures.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 770,
                    "text": "We show that a 3'- to 5'-exoribonuclease activity is responsible for the preferential degradation of polyadenylated mRNAs as compared with non-polyadenylated mRNAs, and that 20-30 adenosine residues constitute the optimal poly(A) tail size for inducing degradation of RNA substrates in vitro.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 748,
                    "text": "The diversity of polyadenylation sites suggests that mRNA polyadenylation in prokaryotes is a relatively indiscriminate process that can occur at all mRNA's 3'-ends and does not require specific consensus sequences as in eukaryotes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "Polyadenylation of premessenger RNAs occurs posttranscriptionally in the nucleus of eukaryotic cells by cleavage of the precursor and polymerization of adenosine residues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9223284",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1105,
                    "offsetInEndSection": 1186,
                    "text": "However, under certain conditions, poly(A) tracts may lead to mRNA stabilization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1219,
                    "text": "From these results, we propose that in plant mitochondria, poly(A) tails added at the 3' ends of mRNAs promote an efficient 3'- to 5'- degradation process..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Auxiliary downstream elements are required for efficient polyadenylation of mammalian pre-mRNAs.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9611233",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 622,
                    "text": "Transcription in these cells is polycistronic. Tens to hundreds of protein-coding genes of unrelated function are arrayed in long clusters on the same DNA strand. Polycistrons are cotranscriptionally processed by trans-splicing at the 5' end and polyadenylation at the 3' end, generating monocistronic units ready for degradation or translation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17267594",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "We have devised a simple chromatographic procedure which isolates five polyadenylation factors that are required for polyadenylation of eukaryotic mRNA. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1684936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "During mammalian oocyte maturation, protein synthesis is mainly controlled through cytoplasmic polyadenylation of stored maternal mRNAs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "Identification and characterization of a polyadenylated small RNA (s-poly A+ RNA) in dinoflagellates.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2579655",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 1058,
                    "text": "Thus, polyadenylation seems to be a major component of the RNA editing machinery that affects overlapping genes in animal mitochondria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9020972",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Pre-mRNA 3'-end processing, the process through which almost all eukaryotic mRNAs acquire a poly(A) tail is generally inhibited during the cellular DNA damage",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940037",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Almost all eukaryotic mRNAs possess 3' ends with a polyadenylate (poly(A)) tail.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22400011",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "We previously demonstrated, by limited mutagenesis, that conserved sequence elements within the 5' end of influenza virus virion RNA (vRNA) are required for the polyadenylation of mRNA in vitro.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9733864",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Polyadenylation of mRNA precursors by poly(A) polymerase depends on two specificity factors and their recognition sequences",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8440247",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "The majority of eukaryotic pre-mRNAs are processed by 3'-end cleavage and polyadenylation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19576221",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Formation of mRNA 3' termini involves cleavage of an mRNA precursor and polyadenylation of the newly formed end. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "The polyadenylation of RNA is a near-universal feature of RNA metabolism in eukaryotes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26730730",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "The mechanism of RNA degradation in Escherichia coli involves endonucleolytic cleavage, polyadenylation of the cleavage product by poly(A) polymerase, and exonucleolytic degradation by the exoribonucleases, ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12601000",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "The addition of poly(A)-tails to RNA is a process common to almost all organisms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738135",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "The addition of poly(A) tails to RNA is a phenomenon common to all organisms examined so far. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16282984",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "The addition of poly(A)-tails to RNA is a phenomenon common to almost all organisms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18177749",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 69,
                    "text": "Polyadenylation contributes to the destabilization of bacterial mRNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is nicotinamide effective for skin cancer prevention?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25561219",
                "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                "http://www.ncbi.nlm.nih.gov/pubmed/24798949",
                "http://www.ncbi.nlm.nih.gov/pubmed/19804594",
                "http://www.ncbi.nlm.nih.gov/pubmed/23349012"
            ],
            "ideal_answer": [
                "Yes, oral nicotinamide is safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012878",
                "http://www.disease-ontology.org/api/metadata/DOID:3451",
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4273660",
                "http://www.biosemantics.org/jochem#4273660",
                "http://www.disease-ontology.org/api/metadata/DOID:4159"
            ],
            "type": "yesno",
            "id": "56c03d1fef6e39474100001a",
            "snippets": [
                {
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 341,
                    "text": "Nicotinamide (vitamin B3) has been shown to have protective effects against damage caused by UV radiation and to reduce the rate of new premalignant actinic keratoses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1820,
                    "text": "ESULTS: At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidence interval [CI], 4 to 38) in the nicotinamide group than in the placebo group (P=0.02). Similar differences were found between the nicotinamide group and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39]lower rate with nicotinamide, P=0.12) and new squamous-cell carcinomas (30% [95% CI, 0 to 51] lower rate, P=0.05). The number of actinic keratoses was 11% lower in the nicotinamide group than in the placebo group at 3 months (P=0.01), 14% lower at 6 months (P<0.001), 20% lower at 9 months (P<0.001), and 13% lower at 12 months (P=0.001).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2040,
                    "offsetInEndSection": 2192,
                    "text": "CONCLUSIONS: Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 70,
                    "offsetInEndSection": 281,
                    "text": "Nicotinamide is a safe, widely available vitamin that reduces the immune suppressive effects of UV, enhances DNA repair in keratinocytes and has shown promise in the chemoprevention of non-melanoma skin cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24798949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 871,
                    "offsetInEndSection": 1005,
                    "text": " In summary, nicotinamide, by enhancing DNA repair in melanocytes, is a potential agent for the chemoprevention of cutaneous melanoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24798949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 385,
                    "text": "Recent double-blinded randomized controlled Phase 2 studies in heavily sun-damaged individuals have shown that oral nicotinamide significantly reduces premalignant actinic keratoses, and may reduce new non-melanoma skin cancers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349012",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 357,
                    "text": "Nicotinamide (vitamin B3) prevents UV-induced immunosuppression and carcinogenesis in mice, and solar-simulated (ss) UV-induced immunosuppression in humans.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19804594",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1714,
                    "offsetInEndSection": 1940,
                    "text": "These results show that nicotinamide enhances two different pathways for repair of UV-induced photolesions, supporting nicotinamide's potential as an inexpensive, convenient and non-toxic agent for skin cancer chemoprevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349012",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 611,
                    "text": "Recent double-blinded randomized controlled Phase 2 studies in heavily sun-damaged individuals have shown that oral nicotinamide significantly reduces premalignant actinic keratoses, and may reduce new non-melanoma skin cancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349012",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1821,
                    "offsetInEndSection": 2193,
                    "text": "No noteworthy between-group differences were found with respect to the number or types of adverse events during the 12-month intervention period, and there was no evidence of benefit after nicotinamide was discontinued.CONCLUSIONS: Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 612,
                    "text": "Nicotinamide (vitamin B3) has been shown to have protective effects against damage caused by UV radiation and to reduce the rate of new premalignant actinic keratoses.METHODS: In this phase 3, double-blind, randomized, controlled trial, we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1333,
                    "offsetInEndSection": 1597,
                    "text": "Similar differences were found between the nicotinamide group and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39]lower rate with nicotinamide, P=0.12) and new squamous-cell carcinomas (30% [95% CI, 0 to 51] lower rate, P=0.05). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2021,
                    "offsetInEndSection": 2160,
                    "text": "Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Nicotinamide has shown potential as a safe and effective intervention for the prevention of malignant and premalignant skin lesions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25561219",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1749,
                    "offsetInEndSection": 1853,
                    "text": "Nicotinamide, which protected against both UVB and UVA, is a promising agent for skin cancer prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19804594",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is nintedanib effective for Idiopathic Pulmonary Fibrosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25628503",
                "http://www.ncbi.nlm.nih.gov/pubmed/24834811",
                "http://www.ncbi.nlm.nih.gov/pubmed/26039104",
                "http://www.ncbi.nlm.nih.gov/pubmed/25439569",
                "http://www.ncbi.nlm.nih.gov/pubmed/24782550",
                "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
                "http://www.ncbi.nlm.nih.gov/pubmed/24556663",
                "http://www.ncbi.nlm.nih.gov/pubmed/23818761",
                "http://www.ncbi.nlm.nih.gov/pubmed/26261848",
                "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                "http://www.ncbi.nlm.nih.gov/pubmed/25767391",
                "http://www.ncbi.nlm.nih.gov/pubmed/25430078",
                "http://www.ncbi.nlm.nih.gov/pubmed/26346347",
                "http://www.ncbi.nlm.nih.gov/pubmed/25635490"
            ],
            "ideal_answer": [
                "Yes, nintedanib is approved for Idiopathic Pulmonary Fibrosis treatment.  Nintedanib was shown to slow the decline in lung function, decrease acute exacerbations, decrease the annual rate of decline in forced vital capacity and increase time to acute exacerbation."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054990",
                "http://www.disease-ontology.org/api/metadata/DOID:0050156"
            ],
            "type": "yesno",
            "id": "56c048e2ef6e39474100001d",
            "snippets": [
                {
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 689,
                    "text": "In this review, we present the positive results of recently published clinical trials regarding therapy for IPF, with emphasis on pirfenidone and nintedanib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346347",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 1217,
                    "text": " In the Phase II TOMORROW trial, treatment with 150 mg of nintedanib twice daily showed a trend to slow the decline in lung function and significantly decrease acute exacerbations in patients with IPF, while showing an acceptable safety profile. The Phase III INPULSIS trials demonstrated a significant decrease in the annual rate of decline in forced vital capacity in IPF patients treated with 150 mg nintedanib twice daily. In the INPULSIS-2 trial, the time to the first acute exacerbation significantly increased in IPF patients who were treated with 150 mg of nintedanib twice daily.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1249,
                    "offsetInEndSection": 1372,
                    "text": " Effects on collagen secretion were compared with those of the drugs nintedanib and pirfenidone, recently approved for IPF.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26039104",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 558,
                    "text": "Nintedanib, an orally available, small-molecule tyrosine kinase inhibitor with selectivity for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) receptors has recently been shown, in two pivotal phase III studies, to effectively slow IPF disease progression. Consequently, nintedanib was given accelerated approval by the FDA in October 2014 for the treatment of IPF. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261848",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1027,
                    "offsetInEndSection": 1217,
                    "text": "Most recently, pirfenidone and nintedanib, two compounds with pleiotropic anti-fibrotic properties, have been proven effective in reducing functional decline and disease progression in IPF. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25767391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 289,
                    "text": "Meningococcal group B vaccine (Trumenba) to prevent more types of invasive meningococcal disease; antihemophilic factor (recombinant), porcine sequence (Obizur) to treat bleeding from acquired hemophilia A; and pirfenidone (Esbriet) and nintedanib (Ofev) for idiopathic pulmonary fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 412,
                    "offsetInEndSection": 628,
                    "text": " More importantly, the period ends with the publication of two groundbreaking studies that confirmed that two drugs, pirfenidone and nintedanib, slowed disease progression, leading to a historic approval by the FDA. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 630,
                    "text": "Nintedanib (Ofev(\u00ae)) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. Nintedanib has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of IPF, and for the second-line treatment in combination with docetaxel of locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumour histology. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 926,
                    "offsetInEndSection": 1037,
                    "text": "This article summarizes the milestones in the development of nintedanib leading to this first approval for IPF.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782550",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Nintedanib is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818761",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2247,
                    "offsetInEndSection": 2383,
                    "text": "These results suggest that nintedanib may impact the progressive course of fibrotic lung diseases such as idiopathic pulmonary fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 322,
                    "text": "Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirfenidone and nintedanib prevent about 50% of the decline in forced vital capacity typically seen in this disease; future trials are therefore unlikely to use placebo as a control group for ethical reasons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25439569",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 470,
                    "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 304,
                    "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 436,
                    "text": "Data from the Phase II TOMORROW study suggested that nintedanib 150\ufffdmg twice daily had clinical benefits with an acceptable safety profile.METHODS: The INPULSIS\ufffd trials are replicate Phase III, randomized, double-blind, studies comparing the efficacy and safety of nintedanib 150\ufffdmg twice daily with placebo in patients with IPF. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 297,
                    "text": "Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1615,
                    "offsetInEndSection": 2143,
                    "text": "The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 563,
                    "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "Nintedanib (Ofev(\ufffd)) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346347",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 542,
                    "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is PLK2 involved in alpha-synuclein phosphorylation in Parkinson disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                "http://www.ncbi.nlm.nih.gov/pubmed/21050448",
                "http://www.ncbi.nlm.nih.gov/pubmed/19004816"
            ],
            "ideal_answer": [
                "PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assayThese results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.",
                "Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy-diseased brains, interacts with, phosphorylates and enhances \u03b1-synuclein autophagic degradation in a kinase activity-dependent manner. These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.",
                "Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system  "
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "551910fa622b19434500000b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "An increase in \u03b1-synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 540,
                    "text": "Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy-diseased brains, interacts with, phosphorylates and enhances \u03b1-synuclein autophagic degradation in a kinase activity-dependent manner.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Polo-like kinase 2 regulates selective autophagic \u03b1-synuclein clearance and suppresses its toxicity in vivo",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1004,
                    "offsetInEndSection": 1219,
                    "text": "Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of \u03b1-synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 845,
                    "text": " \u03b1-Synuclein increased PLK2 levels and GSK-3\u03b2 activity and increased the levels of phosphorylated \u03b1-Synuclein and Tau",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21050448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of alpha-synuclein phosphorylated at Ser-129 (p-Ser-129)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 293,
                    "offsetInEndSection": 477,
                    "text": "Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to alpha-synuclein phosphorylation at Ser-129 in neurons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 566,
                    "text": "PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assay",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 859,
                    "offsetInEndSection": 975,
                    "text": "These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is apremilast effective for psoriatic arthritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
                "http://www.ncbi.nlm.nih.gov/pubmed/25633241",
                "http://www.ncbi.nlm.nih.gov/pubmed/27272887",
                "http://www.ncbi.nlm.nih.gov/pubmed/26644232",
                "http://www.ncbi.nlm.nih.gov/pubmed/27022911",
                "http://www.ncbi.nlm.nih.gov/pubmed/26806620",
                "http://www.ncbi.nlm.nih.gov/pubmed/26923915",
                "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                "http://www.ncbi.nlm.nih.gov/pubmed/27747762",
                "http://www.ncbi.nlm.nih.gov/pubmed/27836567",
                "http://www.ncbi.nlm.nih.gov/pubmed/25973439",
                "http://www.ncbi.nlm.nih.gov/pubmed/23134988",
                "http://www.ncbi.nlm.nih.gov/pubmed/22257911",
                "http://www.ncbi.nlm.nih.gov/pubmed/27307707",
                "http://www.ncbi.nlm.nih.gov/pubmed/27168275",
                "http://www.ncbi.nlm.nih.gov/pubmed/25827658",
                "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
                "http://www.ncbi.nlm.nih.gov/pubmed/23580094",
                "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                "http://www.ncbi.nlm.nih.gov/pubmed/27538241",
                "http://www.ncbi.nlm.nih.gov/pubmed/26660203",
                "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                "http://www.ncbi.nlm.nih.gov/pubmed/26807876",
                "http://www.ncbi.nlm.nih.gov/pubmed/26503917",
                "http://www.ncbi.nlm.nih.gov/pubmed/26792812"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1678805",
                    "o": "APREMILAST"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1678805",
                    "o": "http://linkedlifedata.com/resource/umls/label/A15589751"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15589751",
                    "o": "apremilast"
                }
            ],
            "ideal_answer": [
                "Yes, apremilast, an oral phosphodiesterase 4 inhibitor, is effective for psoriatic arthritis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015535",
                "http://www.disease-ontology.org/api/metadata/DOID:9008"
            ],
            "type": "yesno",
            "id": "5896e22078275d0c4a000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1638,
                    "offsetInEndSection": 1835,
                    "text": "CONCLUSIONS: Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52\u2005weeks. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "OBJECTIVE: To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the treatment of psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1495,
                    "text": "CONCLUSIONS: Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 269,
                    "text": " In particular, apremilast has been recently approved for the treatment of psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26806620",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538241",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 399,
                    "text": "As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the manufacturer of apremilast was invited to submit evidence for its clinical and cost effectiveness for the treatment of active psoriatic arthritis (PsA) for whom disease-modifying anti-rheumatic drugs (DMARDs) have been inadequately effective, not tolerated or contraindicated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272887",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 331,
                    "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 897,
                    "offsetInEndSection": 1095,
                    "text": "In patients with psoriatic arthritis, there are no clinical trials comparing apremilast with TNF alpha antagonists, and no interpretable trials of apremilast after failure of a TNF alpha antagonist.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 497,
                    "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.In the 24-week, placebo-controlled phase of PALACE 1, patients (N=504) were randomised (1:1:1) to placebo, apremilast 20 mg twice a day (BID) or apremilast 30 mg BID",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1563,
                    "offsetInEndSection": 1816,
                    "text": "No imbalance in major adverse cardiac events, serious or opportunistic infections, malignancies or laboratory abnormalities was observed.Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 583,
                    "text": "Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF- with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis.Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) showed a significant (P&lt;0.05) decrease after 85 days of treatment with apremilast 20 mg twice daily in 8 patients with active discoid lupus",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23134988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 397,
                    "text": "The purpose of this study is to give an overview of the new treatments approved by the U.S. Food and Drug Administration (FDA) for use in psoriatic arthritis (PsA).FDA has approved three new drugs for PsA: Certolizumab-pegol: a PEGylated Fc-free tumour necrosis factor inhibitor (TNFi); ustekinumab: an anti interleukin (IL)-12 and IL-23 mAb; and apremilast and oral phosphodiesterase 4 inhibitor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25633241",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1403,
                    "text": "In all trials, the drug had an acceptable safety profile, with the most common adverse effects of diarrhea, nausea, and headache.Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 597,
                    "text": "Apremilast is a well-tolerated and effective phosphodiesterase type 4 inhibitor that is indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27307707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 498,
                    "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.In the 24-week, placebo-controlled phase of PALACE 1, patients (N=504) were randomised (1:1:1) to placebo, apremilast 20 mg twice a day (BID) or apremilast 30 mg BID.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 961,
                    "text": "Newer drugs in the treatment armamentarium that have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580094",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 397,
                    "text": "To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the treatment of psoriasis and psoriatic arthritis.A PubMed search (1946 to December 2015) using the terms apremilast and CC-10004 was conducted to identify relevant articles.In vitro or in vivo evaluations of apremilast published in the English language were eligible for inclusion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1101,
                    "text": "In patients with psoriatic arthritis, there are no clinical trials comparing apremilast with TNF alpha antagonists, and no interpretable trials of apremilast after failure of a TNF alpha antagonist.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1563,
                    "offsetInEndSection": 1817,
                    "text": "No imbalance in major adverse cardiac events, serious or opportunistic infections, malignancies or laboratory abnormalities was observed.Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 581,
                    "text": "Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF- with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis.Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) showed a significant (P<0.05) decrease after 85 days of treatment with apremilast 20 mg twice daily in 8 patients with active discoid lupus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23134988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1700,
                    "offsetInEndSection": 1817,
                    "text": "Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1407,
                    "text": "Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "text": "Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973439",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 332,
                    "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "text": "Apremilast: A Review in Psoriasis and Psoriatic Arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Drug safety evaluation of apremilast for treating psoriatic arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827658",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Apremilast for the treatment of psoriatic arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503917",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22257911",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27747762",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Has ZP-PTH been tested in a phase II clinical trial?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20183917"
            ],
            "ideal_answer": [
                "Yes, ZP-PTH was successfully tested in a phase II clinical trial for the treatment of post-menopausal women with osteoporosis."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e7f69d2835f4e4777000021",
            "snippets": [
                {
                    "offsetInBeginSection": 1827,
                    "offsetInEndSection": 1952,
                    "text": "This system was successfully tested in a Phase 2 clinical trial for the treatment of post-menopausal women with osteoporosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20183917",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does RNA polymerase II have RNA cleavage activity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8798387",
                "http://www.ncbi.nlm.nih.gov/pubmed/12692127",
                "http://www.ncbi.nlm.nih.gov/pubmed/25764335",
                "http://www.ncbi.nlm.nih.gov/pubmed/1379232",
                "http://www.ncbi.nlm.nih.gov/pubmed/9869639",
                "http://www.ncbi.nlm.nih.gov/pubmed/1371280",
                "http://www.ncbi.nlm.nih.gov/pubmed/7513257",
                "http://www.ncbi.nlm.nih.gov/pubmed/8090778",
                "http://www.ncbi.nlm.nih.gov/pubmed/8312968",
                "http://www.ncbi.nlm.nih.gov/pubmed/21454497",
                "http://www.ncbi.nlm.nih.gov/pubmed/7503982",
                "http://www.ncbi.nlm.nih.gov/pubmed/17535246"
            ],
            "ideal_answer": [
                "In addition to RNA synthesis, multisubunit RNA polymerases (msRNAPs) support enzymatic reactions such as intrinsic transcript cleavage. The eukaryotic transcription factor TFIIS enhances elongation and nascent transcript cleavage activities of RNA polymerase II in a stalled elongation complex.",
                "In addition to RNA synthesis, multisubunit RNA polymerases (msRNAPs) support enzymatic reactions such as intrinsic transcript cleavage. The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase II.",
                "In addition to RNA synthesis, multisubunit RNA polymerases (msRNAPs) support enzymatic reactions such as intrinsic transcript cleavage. msRNAP active sites from different species appear to exhibit differential intrinsic transcript cleavage efficiency and have likely evolved to allow fine-tuning of the transcription process.",
                "In addition to RNA synthesis, multisubunit RNA polymerases (msRNAPs) support enzymatic reactions such as intrinsic transcript cleavage.",
                "The eukaryotic transcription factor TFIIS enhances elongation and nascent transcript cleavage activities of RNA polymerase II in a stalled elongation complex. The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase II",
                "Complexes of yeast RNA polymerase II and RNA are substrates for TFIIS-induced RNA cleavage. The RNA polymerase II elongation complex.",
                "yes",
                "The RNA polymerase II elongation complex.SII is an RNA polymerase II-binding protein that stimulates transcription elongation and also activates nascent transcript cleavage by RNA polymerase II in elongation complexes in vitroFactor-dependent transcription elongation involves nascent RNA cleavage.The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase IIThe eukaryotic transcription factor TFIIS enhances elongation and nascent transcript cleavage activities of RNA polymerase II in a stalled elongation complex.Here we show that in the presence of SII and nucleotides, transcript cleavage is detected during SII-dependent elongation but not during SII-independent transcription.Nascent RNA cleavage by arrested RNA polymerase II does not require upstream translocation of the elongation complex on DNA.In addition to RNA synthesis, multisubunit RNA polymerases (msRNAPs) support enzymatic reactions such as intrinsic transcript cleavage.msRNAP active sites from different species appear to exhibit differential intrinsic transcript cleavage efficiency and have likely evolved to allow fine-tuning of the transcription process.Complexes of yeast RNA polymerase II and RNA are substrates for TFIIS-induced RNA cleavage."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a468785966455904c00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "In addition to RNA synthesis, multisubunit RNA polymerases (msRNAPs) support enzymatic reactions such as intrinsic transcript cleavage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764335",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 325,
                    "text": "msRNAP active sites from different species appear to exhibit differential intrinsic transcript cleavage efficiency and have likely evolved to allow fine-tuning of the transcription process.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764335",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 635,
                    "text": "Here we show that a single amino-acid substitution in the trigger loop (TL) of Saccharomyces RNAP II, Rpb1 H1085Y, engenders a gain of intrinsic cleavage activity where the substituted tyrosine appears to participate in acid-base chemistry at alkaline pH for both intrinsic cleavage and nucleotidyl transfer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764335",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "The eukaryotic transcription factor TFIIS enhances elongation and nascent transcript cleavage activities of RNA polymerase II in a stalled elongation complex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase II",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 395,
                    "text": "By site-directed mutagenesis, we have demonstrated that invariant residues Asp-261 and Glu-262 of the nucleic acid-binding TFIIS Zn ribbon are critical for stimulation of both elongation and RNA cleavage activities of RNA polymerase II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Complexes of yeast RNA polymerase II and RNA are substrates for TFIIS-induced RNA cleavage.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7513257",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 324,
                    "text": "RNA in such RNA-RNA polymerase complexes undergoes reactions previously thought to be unique to nascent RNA in ternary complexes with DNA, including TFIIS-dependent cleavage and elongation by 3'-terminal addition of NMP from NTP.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7513257",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Nascent RNA cleavage by arrested RNA polymerase II does not require upstream translocation of the elongation complex on DNA.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7503982",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 341,
                    "offsetInEndSection": 509,
                    "text": "Here we show that in the presence of SII and nucleotides, transcript cleavage is detected during SII-dependent elongation but not during SII-independent transcription. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7503982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 775,
                    "text": "under typical transcription conditions, SII is necessary but insufficient to activate RNA cleavage. RNA cleavage could serve to move RNA polymerase II away from the transcriptional impediment and/or permit RNA polymerase II multiple attempts at RNA elongation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7503982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 293,
                    "text": "SII is an RNA polymerase II-binding protein that stimulates transcription elongation and also activates nascent transcript cleavage by RNA polymerase II in elongation complexes in vitro",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "The RNA polymerase II elongation complex. Factor-dependent transcription elongation involves nascent RNA cleavage.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 670,
                    "offsetInEndSection": 857,
                    "text": "Cleavage was not restricted to an elongation complex arrested at this particular site, showing that nascent RNA hydrolysis is a general property of RNA polymerase II elongation complexes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1379232",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "Elongation factor SII (also known as TFIIS) is an RNA polymerase II binding protein that allows bypass of template arrest sites by activating a nascent RNA cleavage reaction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798387",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "During gene transcription, the RNA polymerase (Pol) active center can catalyze RNA cleavage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21454497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 0,
                    "text": "During gene transcription, the RNA polymerase (Pol) active center can catalyze RNA cleavage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21454497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 0,
                    "text": "The eukaryotic transcription factor TFIIS enhances elongation and nascent transcript cleavage activities of RNA polymerase II in a stalled elongation complex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 244,
                    "text": "Rpb9, a small subunit of RNA polymerase II, enhances the cleavage stimulation activity of S-II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 848,
                    "offsetInEndSection": 996,
                    "text": "These results suggest that both S-II and Rpb9 maintain transcriptional fidelity by stimulating the cleavage activity intrinsic to RNA polymerase II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 947,
                    "offsetInEndSection": 1076,
                    "text": "It is also possible that the transcript cleavage activity of RNA polymerase II represents a proofreading function of the enzyme..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1371280",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Nascent RNA cleavage by arrested RNA polymerase II does not require upstream translocation of the elongation complex on DNA.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7503982",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Intrinsic transcript cleavage in yeast RNA polymerase II elongation complexes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692127",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does armodafinil improve fatigue of glioma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26902850"
            ],
            "ideal_answer": [
                "No. Eight week course of armodafinil did not improve fatigue or quality of life in glioma patients undergoing radiotherapy. However, this conclusion is based on one identified clinical trial."
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D005221",
                "https://meshb.nlm.nih.gov/record/ui?ui=D010361",
                "http://www.biosemantics.org/jochem#4216693",
                "https://meshb.nlm.nih.gov/record/ui?ui=D005910"
            ],
            "type": "yesno",
            "id": "5a76072283b0d9ea66000013",
            "snippets": [
                {
                    "offsetInBeginSection": 1316,
                    "offsetInEndSection": 1482,
                    "text": "CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 236,
                    "text": "We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1254,
                    "text": "Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI. Further analysis suggests no difference between the arms even after accounting for the potential bias of missing data. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1283,
                    "offsetInEndSection": 1521,
                    "text": "Treatment was well tolerated with few grade 3 or 4 toxicities.<br><b>CONCLUSIONS</b>: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1163,
                    "text": "Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1289,
                    "offsetInEndSection": 1441,
                    "text": "While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does nimotuzumab improve survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21575527",
                "http://www.ncbi.nlm.nih.gov/pubmed/19293809",
                "http://www.ncbi.nlm.nih.gov/pubmed/21483304",
                "http://www.ncbi.nlm.nih.gov/pubmed/23575267",
                "http://www.ncbi.nlm.nih.gov/pubmed/24521695",
                "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                "http://www.ncbi.nlm.nih.gov/pubmed/23782513",
                "http://www.ncbi.nlm.nih.gov/pubmed/24571331",
                "http://www.ncbi.nlm.nih.gov/pubmed/18094616",
                "http://www.ncbi.nlm.nih.gov/pubmed/23060940"
            ],
            "ideal_answer": [
                "Yes. Nimotuzumab improves survival of adult and pediatric patients diagnosed with glioblastoma and with other high-grade gliomas."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "54d901ec4b1fd0d33c000006",
            "snippets": [
                {
                    "offsetInBeginSection": 1369,
                    "offsetInEndSection": 1454,
                    "text": "The survival times were similar to those seen in historical data of standard therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24571331",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1446,
                    "text": "The survival time of a matched population treated at the same hospital with irradiation alone was decreased (median 8.0 and 12.2 mo for GBM and AA patients, respectively) compared with that of the patients who received nimotuzumab and curative-intent radiotherapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1571,
                    "offsetInEndSection": 1752,
                    "text": "This study, in a poor prognosis population, validates the previous data of survival gain after combining nimotuzumab and radiotherapy, in newly diagnosed high-grade glioma patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1534,
                    "offsetInEndSection": 1827,
                    "text": "The mean and median survival time for subjects treated with nimotuzumab was 31.06 and 17.76 vs. 21.07 and 12.63 months for the control group. CONCLUSIONS: In this randomized trial, nimotuzumab showed an excellent safety profile and significant survival benefit in combination with irradiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23782513",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 813,
                    "text": "Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23575267",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 223,
                    "text": " Recent clinical studies show that patients with malignant gliomas could benefit from nimotuzumab treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575527",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1679,
                    "offsetInEndSection": 1872,
                    "text": "CONCLUSIONS: Nimotuzumab in combination with chemotherapy has moderate activity in patients with malignant gliomas and the toxicities are well tolerable, therefore, worth further investigation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575527",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 322,
                    "text": "It has been evaluated in malignant brain tumors in adults and children, and shown to be therapeutically safe and effective in terms of increased survival and improved quality of life. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2046,
                    "offsetInEndSection": 2329,
                    "text": "Conclusions As used in this study, nimotuzumab demonstrated a broad safety profile, making it acceptable for chronic use, and implied clinical benefits in terms of increased survival and improved functional status in these patients, compared to findings described in the literature. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23060940",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2044,
                    "offsetInEndSection": 2326,
                    "text": "Conclusions As used in this study, nimotuzumab demonstrated a broad safety profile, making it acceptable for chronic use, and implied clinical benefits in terms of increased survival and improved functional status in these patients, compared to findings described in the literature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1570,
                    "offsetInEndSection": 1750,
                    "text": "This study, in a poor prognosis population, validates the previous data of survival gain after combining nimotuzumab and radiotherapy, in newly diagnosed high-grade glioma patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2046,
                    "offsetInEndSection": 2327,
                    "text": "Conclusions As used in this study, nimotuzumab demonstrated a broad safety profile, making it acceptable for chronic use, and implied clinical benefits in terms of increased survival and improved functional status in these patients, compared to findings described in the literature",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 814,
                    "offsetInEndSection": 1060,
                    "text": "A multicenter exploratory study combining nimotuzumab and radiotherapy showed disease control and an overall patient survival similar to previous experiences along with an improvement in the quality of patient survival and no severe side effects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 267,
                    "text": "Combining craniospinal irradiation (CSI) with concurrent temozolomide and nimotuzumab therapy may slightly improve tumor control and overall survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between bruxism and reflux?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22926484",
                "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                "http://www.ncbi.nlm.nih.gov/pubmed/22156738",
                "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                "http://www.ncbi.nlm.nih.gov/pubmed/19830044",
                "http://www.ncbi.nlm.nih.gov/pubmed/841409"
            ],
            "ideal_answer": [
                "Yes, bruxism is associated with reflux. Sleep bruxism is prevalent in GERD patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020186",
                "http://www.disease-ontology.org/api/metadata/DOID:2846",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002012",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005764",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001244",
                "http://www.disease-ontology.org/api/metadata/DOID:8534"
            ],
            "type": "yesno",
            "id": "530cefaaad0bf1360c00000f",
            "snippets": [
                {
                    "offsetInBeginSection": 1564,
                    "offsetInEndSection": 1647,
                    "text": "Sleep bruxism is prevalent in GERD patients, and GERD is highly associated with SB.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1219,
                    "text": "There was a statistical trend towards tooth wear progression being associated with gastric risk factors (p < 0.05). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22156738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 482,
                    "text": "This article presents a case report of a 27-year-old male smoker with tooth wear and dentin sensitivity caused by GERD associated with bruxism. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "The aim of this cross-over, randomized, single-blinded trial was to examine whether intra-esophageal acidification induces sleep bruxism (SB). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 741,
                    "text": "RMMA episodes including SB were induced by esophageal acidification. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 224,
                    "text": "Chronic regurgitation of gastric acids in patients with gastroesophageal reflux disease may cause dental erosion, which can lead in combination with attrition or bruxism to extensive loss of coronal tooth tissue.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830044",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 489,
                    "text": "This clinical report describes treatment of severe tooth wear of a gastroesophageal reflux disease patient who is 54-year-old Turkish male patient. After his medical treatment, severe tooth wear, bruxism and decreased vertical dimensions were determined. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830044",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 956,
                    "offsetInEndSection": 1084,
                    "text": "Gastroesophageal reflux disease by itself or in combination with attrition, abrasion or bruxism may be responsible for the loss.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830044",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 910,
                    "text": "The association between bruxism, feeding and smoking habits and digestive disorders may lead to serious consequences to dental and related structures, involving dental alterations (wear, fractures and cracks), periodontal signs (gingival recession and tooth mobility) and muscle-joint sensitivity, demanding a multidisciplinary treatment plan. This paper presents a case report in which bruxism associated with acid feeding, smoking habit and episodes of gastric reflow caused severe tooth wear and great muscular discomfort with daily headache episodes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 683,
                    "text": "The frequencies of RMMA, single short-burst, and clenching episodes were significantly higher during decreased esophageal pH episodes than those during other times. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 804,
                    "offsetInEndSection": 988,
                    "text": "These results suggest that most jaw muscle activities, ie, RMMA, single short-burst, and clenching episodes, occur in relation to gastroesophageal reflux mainly in the supine position.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2192,
                    "offsetInEndSection": 2328,
                    "text": "Nocturnal bruxism may be secondary to nocturnal gastroesophageal reflux, occurring via sleep arousal and often together with swallowing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is protein M3/6 a dual specificity phosphatase?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15888437",
                "http://www.ncbi.nlm.nih.gov/pubmed/11566103",
                "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                "http://www.ncbi.nlm.nih.gov/pubmed/8910287",
                "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                "http://www.ncbi.nlm.nih.gov/pubmed/11948422",
                "http://www.ncbi.nlm.nih.gov/pubmed/12524447",
                "http://www.ncbi.nlm.nih.gov/pubmed/12598532",
                "http://www.ncbi.nlm.nih.gov/pubmed/10915787",
                "http://www.ncbi.nlm.nih.gov/pubmed/23159405"
            ],
            "ideal_answer": [
                "M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs.",
                "Yes. Phosphatases play a particularly important role in this respect, by tightly controlling MAPK phosphorylation and activation. M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins.",
                "The protein M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016791",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054638",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054637",
                "http://www.uniprot.org/uniprot/DUS1_RAT",
                "http://www.uniprot.org/uniprot/DUS8_MOUSE",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008138",
                "http://www.uniprot.org/uniprot/DUS2_MOUSE",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004712",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054641",
                "http://www.uniprot.org/uniprot/DUS3_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0017017",
                "http://www.uniprot.org/uniprot/DUS8_HUMAN"
            ],
            "type": "yesno",
            "id": "5512cce26a8cde6b7200000c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Involvement of the dual-specificity phosphatase M3/6 in c-Jun N-terminal kinase inactivation following cerebral ischemia in the rat hippocampus.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 453,
                    "text": "The results revealed upregulation of dual-specificity phosphatase M3/6 (DUSP8) activity at 4\u00a0h of reperfusion in rat hippocampi. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 163,
                    "offsetInEndSection": 323,
                    "text": "This study examines the molecular mechanism underlying JNK dephosphorylation and inactivation evoked by dual-specificity phosphates following cerebral ischemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 677,
                    "text": "Phosphatases play a particularly important role in this respect, by tightly controlling MAPK phosphorylation and activation. M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 448,
                    "text": "Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 702,
                    "text": "M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 555,
                    "text": "Here we describe two new dual specificity phosphatases of the CL100/MKP-1 family that are selective for inactivating ERK or JNK/SAPK and p38 MAP kinases when expressed in COS-7 cells. M3/6 is the first phosphatase of this family to display highly specific inactivation of JNK/SAPK and p38 MAP kinases. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8910287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 319,
                    "text": "We previously demonstrated that the dual specificity phosphatases (DSPs) MKP7 and M3/6 bind the scaffold JNK-interacting protein-1 (JIP-1) and inactivate the bound subset of JNK (1).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15888437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 15,
                    "offsetInEndSection": 52,
                    "text": "the dual-specificity phosphatase M3/6",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 360,
                    "offsetInEndSection": 402,
                    "text": " dual-specificity phosphatase M3/6 (DUSP8)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 523,
                    "text": "M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 56,
                    "text": "the M3/6 dual-specificity phosphatase",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 447,
                    "text": "M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 693,
                    "text": "M3/6 is a dual-specificity phosphatase selective for JNK",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8910287",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Phosphorylation of the M3/6 dual-specificity phosphatase enhances the activation of JNK by arsenite.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 681,
                    "text": "Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12598532",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10915787",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 448,
                    "text": "M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 699,
                    "text": "M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 446,
                    "text": "M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 429,
                    "text": "Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11948422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 700,
                    "text": "M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters. Analysis of a delta-like domain.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10915787",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 451,
                    "text": "The results revealed upregulation of dual-specificity phosphatase M3/6 (DUSP8) activity at 4\u00a0h of reperfusion in rat hippocampi",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 680,
                    "text": "Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12598532",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 553,
                    "offsetInEndSection": 689,
                    "text": "Here we report that JIP-1 also binds the dual-specificity phosphatases MKP7 and M3/6 via a region independent of its JNK binding domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12524447",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "Differential regulation of M3/6 (DUSP8) signaling",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159405",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Are there any specific antidotes for rivaroxaban?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12871541",
                "http://www.ncbi.nlm.nih.gov/pubmed/23117666",
                "http://www.ncbi.nlm.nih.gov/pubmed/23312927",
                "http://www.ncbi.nlm.nih.gov/pubmed/19351313",
                "http://www.ncbi.nlm.nih.gov/pubmed/23821689",
                "http://www.ncbi.nlm.nih.gov/pubmed/24170233",
                "http://www.ncbi.nlm.nih.gov/pubmed/24103671",
                "http://www.ncbi.nlm.nih.gov/pubmed/23810130",
                "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
                "http://www.ncbi.nlm.nih.gov/pubmed/20858186",
                "http://www.ncbi.nlm.nih.gov/pubmed/23628464",
                "http://www.ncbi.nlm.nih.gov/pubmed/23953907",
                "http://www.ncbi.nlm.nih.gov/pubmed/23866358",
                "http://www.ncbi.nlm.nih.gov/pubmed/23460104",
                "http://www.ncbi.nlm.nih.gov/pubmed/23657589",
                "http://www.ncbi.nlm.nih.gov/pubmed/22353706",
                "http://www.ncbi.nlm.nih.gov/pubmed/23790307",
                "http://www.ncbi.nlm.nih.gov/pubmed/23634925",
                "http://www.ncbi.nlm.nih.gov/pubmed/22308807"
            ],
            "ideal_answer": [
                "Currently, there is no specific antidote for rivaroxaban"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931",
                "http://www.biosemantics.org/jochem#4243836"
            ],
            "type": "yesno",
            "id": "532f08b8d6d3ac6a34000029",
            "snippets": [
                {
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 490,
                    "text": "Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24103671",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 414,
                    "text": "he new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821689",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 592,
                    "text": "Given the absence of a specific antidote, the action to be taken in these situations must be defined. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810130",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1018,
                    "offsetInEndSection": 1176,
                    "text": "The fact that there is no specific antidote to reverse the anticoagulant action of the new anticoagulants can impair management of hemorrhagic complications; ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23790307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 200,
                    "offsetInEndSection": 537,
                    "text": "Like any new therapy, the potential benefits must be weighed against the potential challenges and one of the most concerning aspects of the new target-specific oral anticoagulants is the lack of a proven method to reverse their effect. Unlike the vitamin K antagonist, i.e. warfarin, there is no specific antidote for these medications. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23657589",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1598,
                    "text": "Two major drawbacks are on the one hand the risk of drug accumulation in kidney and/or liver disease and, on the other hand, the lack of specific antidotes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460104",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1741,
                    "text": "NOA also have other unresolved problems: drug interactions are still possible, specific coagulation test to assess them must be developed, and no specific antidote is currently available in case of hemorrhagic complication.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23312927",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1191,
                    "offsetInEndSection": 1333,
                    "text": "But they have disadvantages also, they depend on renal clearance, they can interact with other medicaments and they lack a specific antidote. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117666",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 957,
                    "text": "While these trial data are extremely encouraging, several practical issues (e.g., lack of specific antidote, safety of long-term treatment or cost-effectiveness in \"real-life\" clinical practice) still need to be elucidated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22353706",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 661,
                    "text": "In case of massive bleeding, management is unclear and none of these newer agents has a specific antidote that completely reverses its anticoagulant effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308807",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1935,
                    "offsetInEndSection": 2044,
                    "text": "The short half-life of these new agents compensates for the lack of any specific antidote in many instances. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22177763",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 750,
                    "text": "Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20858186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 865,
                    "text": "Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 731,
                    "text": "Increased use of dabigatran, rivaroxaban, and apixaban as oral anticoagulants for the treatment of atrial fibrillation and acute deep venous thrombosis has increased despite the lack of known antidotes to these medications.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23634925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 812,
                    "text": "There is no antidote for reversal and no reliable laboratory monitoring of the anticoagulant effect for emergency situations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628464",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1259,
                    "offsetInEndSection": 1570,
                    "text": "Further concerns about the use of NOAC in the elderly are the high prevalence of renal insufficiency in AF patients >75 years of age, the largely unknown risk of drug-drug and drug-food interactions, the lack of easily available laboratory monitoring tests of anticoagulant activity and the lack of an antidote.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 576,
                    "text": "Specific antidotes for the reversal of the anticoagulant effect of these drugs, such as monoclonal antibodies against the direct thrombin inhibitor dabigatran or recombinant Xa-analog in the case of factor Xa inhibitors, are still being investigated in early clinical trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23953907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1429,
                    "offsetInEndSection": 1596,
                    "text": "In early 2013 there is no antidote for dabigatran, rivaroxaban or apixaban, nor any specific treatment with proven efficacy for severe bleeding linked to these drugs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23866358",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Could Arimidex (anastrozole) cause hot flashes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21378354",
                "http://www.ncbi.nlm.nih.gov/pubmed/23452648",
                "http://www.ncbi.nlm.nih.gov/pubmed/17292609",
                "http://www.ncbi.nlm.nih.gov/pubmed/20975874",
                "http://www.ncbi.nlm.nih.gov/pubmed/20679610",
                "http://www.ncbi.nlm.nih.gov/pubmed/15494636",
                "http://www.ncbi.nlm.nih.gov/pubmed/14584060",
                "http://www.ncbi.nlm.nih.gov/pubmed/14675683",
                "http://www.ncbi.nlm.nih.gov/pubmed/18072256",
                "http://www.ncbi.nlm.nih.gov/pubmed/18728707",
                "http://www.ncbi.nlm.nih.gov/pubmed/12902876",
                "http://www.ncbi.nlm.nih.gov/pubmed/23314924",
                "http://www.ncbi.nlm.nih.gov/pubmed/23383974",
                "http://www.ncbi.nlm.nih.gov/pubmed/22677000",
                "http://www.ncbi.nlm.nih.gov/pubmed/22370325",
                "http://www.ncbi.nlm.nih.gov/pubmed/15508444"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10338338",
                    "o": "http://www.w3.org/2008/05/skos-xl#Label"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0878174",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11917539"
                }
            ],
            "ideal_answer": [
                "Yes. Hot flashes are one of the most common adverse effects of Arimidex."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019584",
                "http://www.biosemantics.org/jochem#4266381",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006358"
            ],
            "type": "yesno",
            "id": "516523fd298dcd4e51000055",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment report joint pain.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452648",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 789,
                    "offsetInEndSection": 967,
                    "text": "In the first 6 weeks, emergence of joint pain was associated with increase in general pain, fatigue, disturbed sleep, hot flashes, vaginal dryness, and decreased sexual activity.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452648",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 138,
                    "text": "Antiestrogen therapy can cause vasomotor symptoms similar to those occurring during menopause, including hot flashes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 455,
                    "text": "The purpose of this study was to assess the feasibility and safety of acupuncture for treatment of hot flashes in Korean patients with breast cancer receiving antiestrogen therapy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 715,
                    "offsetInEndSection": 857,
                    "text": "10 patients with breast cancer who were undergoing antiestrogen therapy with tamoxifen or anastrozole and who were suffering from hot flashes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1118,
                    "offsetInEndSection": 1199,
                    "text": "During treatment, severity of hot flashes was reduced by 70%-95% in all patients.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23383974",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 59,
                    "offsetInEndSection": 188,
                    "text": "anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314924",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 435,
                    "text": "The aim of this study is to evaluate the rate of bone fracture and bone mineral density (BMD) during anastrozole treatment in Japanese patients.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314924",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1054,
                    "offsetInEndSection": 1177,
                    "text": "Musculoskeletal disorders were the most common (26.1\u00a0%), and hot flashes were the second most common adverse event (7.9\u00a0%).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314924",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 177,
                    "text": "To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370325",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 455,
                    "offsetInEndSection": 592,
                    "text": "fulvestrant loading dose (LD) regimen followed by monthly injection plus 1 mg of anastrozole daily or to 1 mg of anastrozole daily alone.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370325",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1178,
                    "offsetInEndSection": 1373,
                    "text": "Incidences of prespecified adverse events (AEs) were similar. Hot flashes were more common in the experimental arm: 63 patients (24.6%) versus 35 patients (13.8%) in the standard arm (P = .0023).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370325",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 602,
                    "text": "The third-generation agents (anastrozole, letrozole, and exemestane) have been shown to be more effective and safer than the selective estrogen receptor modulators tamoxifen and raloxifen.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677000",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 976,
                    "offsetInEndSection": 1181,
                    "text": "AIs are well tolerated and cause a lower incidence of gynecological symptoms (vaginal bleeding, discharge, and endometrial neoplasia), venous thromboembolic events, and hot flashes compared with tamoxifen.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677000",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1360,
                    "offsetInEndSection": 1520,
                    "text": "Mood disturbances, somnolence, anxiety, fatigue, hot flashes, and memory impairment have been reported among patients receiving anastrozole as adjuvant therapy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677000",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 571,
                    "text": "Twenty-five PM-BC patients received, in sequence, leuprorelin, taxane-anthracycline induction chemotherapy, radiation therapy, a platinum-based intensification high-dose CT, followed by leuprorelin and anastrazole for five years.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378354",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1143,
                    "text": "Grade 4 hematologic toxicity was observed in all patients, no patient showed a decrease of cardiac ejection fraction and hot flashes and arthralgias were of moderate intensity.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21378354",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1551,
                    "offsetInEndSection": 1826,
                    "text": "Of the patients treated with anastrozole, 3 (37.5%) reported toxicity, with 1 report each of decreased libido, leg swelling, and depression (12.5%). Toxicity was reported in 2 patients taking letrozole (40%), with both reporting peripheral edema, and 1 reporting hot flashes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975874",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 652,
                    "text": "Patients were treated with goserelin 3.6 mg subcutaneous monthly and began anastrozole 1-mg daily 21 days after the first injection of goserelin.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679610",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1277,
                    "offsetInEndSection": 1369,
                    "text": "The most common adverse events were fatigue (50%), arthralgias (53%), and hot flashes (59%).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20679610",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 553,
                    "text": "These studies were designed to evaluate the safety and efficacy of AIs in the following clinical settings: 1) as initial adjuvant therapy (the Arimidex, Tamoxifen, Alone or in Combination trial, Breast International Group Trial 1-98),",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072256",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1274,
                    "text": "AIs were tolerated well, and patients who received them experienced fewer thrombolic events and less endometrial cancer, hot flashes, night sweats, and vaginal bleeding compared with patients who receive tamoxifen.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072256",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 523,
                    "text": "It has been suggested that the association of AI and GnRh analogues and AI could block the two routes of oestrogen production in males, and therefore this approach could increase efficacy. However, it could also enhance the rate of adverse events (hot flashes, sexual impotence, etc.).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292609",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15508444",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1527,
                    "text": "The most frequent harmful side effects were rise in total cholesterol, general fatigue, hot flashes and arthralgia (9.1%).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15508444",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 330,
                    "text": "We analyzed the changes in frequency and severity of menopausal symptoms in patients receiving tamoxifen or aromatase inhibitors and identified factors influencing these symptoms.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15494636",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 662,
                    "offsetInEndSection": 816,
                    "text": "Both first-line tamoxifen and aromatase inhibitors induced an increase in the occurrence and severity of hot flashes (p<0.0001 and p=0.014, respectively).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15494636",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 208,
                    "text": "To evaluate the efficacy and toxicity of the selective aromatase inhibitor anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic recurrent/persistent m\u00fcllerian cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14675683",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1507,
                    "offsetInEndSection": 1615,
                    "text": "Toxicity was modest (grade I) and infrequent, with the most common toxicities being fatigue and hot flashes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14675683",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 390,
                    "text": "The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14584060",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1813,
                    "offsetInEndSection": 2194,
                    "text": "in that endometrial cancer (P = 0.007), vaginal bleeding and discharge (P < 0.001 for both), cerebrovascular events (P < 0.001), venous thromboembolic events (P < 0.001), and hot flashes (P < 0.001) all occurred less frequently in the anastrozole group, whereas musculoskeletal disorders and fractures (P < 0.001 for both) continued to occur less frequently in the tamoxifen group.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14584060",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1173,
                    "text": "reduced nausea, hot flashes, and abdominal discomfort caused almost twice as many patients to prefer to continue with letrozole therapy than with anastrozole",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12902876",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Has intepirdine been evaluated in clinical trials? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101"
            ],
            "ideal_answer": [
                "Yes, intepirdine was in Phase III clinical trials in November 2017."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a9acba61d1251d03b000014",
            "snippets": [
                {
                    "offsetInBeginSection": 1569,
                    "offsetInEndSection": 1786,
                    "text": "Using small molecules blocking 5-HT6serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is factor XI deficient in Hemophilia C?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18378181",
                "http://www.ncbi.nlm.nih.gov/pubmed/18160615",
                "http://www.ncbi.nlm.nih.gov/pubmed/20485963",
                "http://www.ncbi.nlm.nih.gov/pubmed/1546275",
                "http://www.ncbi.nlm.nih.gov/pubmed/8277060"
            ],
            "ideal_answer": [
                "Factor XI deficiency is associated with a bleeding tendency called Hemophilia C."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006467",
                "http://www.disease-ontology.org/api/metadata/DOID:2229",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005173",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005172"
            ],
            "type": "yesno",
            "id": "51588c1ad24251bc05000094",
            "snippets": [
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 152,
                    "text": "Factor XI deficiency is a rare hematologic disorder. Hemophilia C (factor XI deficiency) affects both genders and it is usually asymptomatic,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485963",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Congenital factor XI deficiency (also known as the Rosenthal syndrome or hemophilia C)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18378181",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 290,
                    "text": "rare case of an acute cerebral aneurysm rupture in a patient with a known factor XI deficiency. Aneurysmal subarachnoid hemorrhage (SAH) accounts for a high mortality and morbidity rate. When SAH is associated with an inherited coagulation disorder such as hemophilia C",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18160615",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 162,
                    "text": "Factor XI deficiency (Hemophilia C)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8277060",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 47,
                    "text": "Factor XI deficiency, also called hemophilia C,",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1546275",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is  LRP1 interacting with Urokinase receptor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19008962",
                "http://www.ncbi.nlm.nih.gov/pubmed/11359936"
            ],
            "ideal_answer": [
                "Yes"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c5f0c5a1a4c55d80b00000f",
            "snippets": [
                {
                    "offsetInBeginSection": 367,
                    "offsetInEndSection": 581,
                    "text": " Interaction with a complex formed by uPA and its inhibitor PAI-1 induces cell surface down regulation and recycling of the receptor via the clathrin-coated pathway, a process dependent on the association to LRP-1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008962",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 328,
                    "text": "Here we investigated whether direct interaction between uPAR, a glycosyl-phosphatidylinositol-anchored protein, and LRP, a transmembrane receptor,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11359936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1062,
                    "text": "Direct binding of domain 3 (D3) of uPAR to LRP is required for clearance of uPA-PAI-1-occupied uPAR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11359936",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any link between CTF4 and CTF18 during sister chromatid cohesion?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                "http://www.ncbi.nlm.nih.gov/pubmed/17483413",
                "http://www.ncbi.nlm.nih.gov/pubmed/23334284",
                "http://www.ncbi.nlm.nih.gov/pubmed/19430531",
                "http://www.ncbi.nlm.nih.gov/pubmed/16962805",
                "http://www.ncbi.nlm.nih.gov/pubmed/14742714",
                "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                "http://www.ncbi.nlm.nih.gov/pubmed/23036200"
            ],
            "ideal_answer": [
                "Yes. CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. Absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045876",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007062",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007063"
            ],
            "type": "yesno",
            "id": "553cae13f32186855800000e",
            "snippets": [
                {
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1292,
                    "text": "Our results suggest that Elg1, Ctf4, and Ctf18 may coordinate the relative movement of the replication fork with respect to the cohesin ring",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19430531",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 880,
                    "text": "These data defined two cohesion pathways, one containing CSM3, TOF1, CTF4, and CHL1, and the second containing MRC1, CTF18, CTF8, and DCC1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17483413",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 1082,
                    "text": "Here we show that three proteins required for sister chromatid cohesion, Eco1, Ctf4, and Ctf18, are found at, and Ctf4 travels along chromosomes with, replication forks. The ring-shaped cohesin complex is loaded onto chromosomes before S phase in an ATP hydrolysis-dependent reaction. Cohesion establishment during DNA replication follows without further cohesin recruitment and without need for cohesin to re-engage an ATP hydrolysis motif that is critical for its initial DNA binding. This provides evidence for cohesion establishment in the context of replication forks and imposes constraints on the mechanism involved",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962805",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Sister-chromatid cohesion mediated by the alternative RF-CCtf18/Dcc1/Ctf8, the helicase Chl1 and the polymerase-alpha-associated protein Ctf4 is essential for chromatid disjunction during meiosis II",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 430,
                    "text": "In budding yeast, a specialized replication factor C called RF-C(Ctf18/Dcc1/Ctf8) and the DNA-polymerase-alpha-associated protein Ctf4 are required to maintain sister-chromatid cohesion in cells arrested for long periods in mitosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 810,
                    "text": "We also show that, in contrast to mitosis, RF-C(Ctf18/Dcc1/Cft8), Ctf4 and Chl1 are essential for chromosome segregation during meiosis and for the viability of meiotic products.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 614,
                    "text": "Ctf8p is a component of Ctf18-RFC, an alternative replication factor C-like complex required for efficient sister chromatid cohesion in Saccharomyces cerevisiae. We performed synthetic genetic array (SGA) analysis with a ctf8 deletion strain as a primary screen to identify other nonessential genes required for efficient sister chromatid cohesion. We then assessed proficiency of cohesion at three chromosomal loci in strains containing deletions of the genes identified in the ctf8 SGA screen. Deletion of seven genes (CHL1, CSM3, BIM1, KAR3, TOF1, CTF4, and VIK1) resulted in defective sister chromatid cohesion",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14742714",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Saccharomyces cerevisiae CTF18 and CTF4 are required for sister chromatid cohesion",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 587,
                    "text": "CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1325,
                    "offsetInEndSection": 1452,
                    "text": "The requirement for CTF4 and CTF18 in robust cohesion identifies novel roles for replication accessory proteins in this process",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 626,
                    "text": "Here we show that three proteins required for sister chromatid cohesion, Eco1, Ctf4, and Ctf18, are found at, and Ctf4 travels along chromosomes with, replication forks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962805",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Saccharomyces cerevisiae CTF18 and CTF4 are required for sister chromatid cohesion.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 324,
                    "text": "We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 430,
                    "text": "In budding yeast, a specialized replication factor C called RF-C(Ctf18/Dcc1/Ctf8) and the DNA-polymerase-alpha-associated protein Ctf4 are required to maintain sister-chromatid cohesion in cells arrested for long periods in mitosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 584,
                    "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Sister-chromatid cohesion mediated by the alternative RF-CCtf18/Dcc1/Ctf8, the helicase Chl1 and the polymerase-alpha-associated protein Ctf4 is essential for chromatid disjunction during meiosis II.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 858,
                    "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 587,
                    "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 629,
                    "text": "Here we show that three proteins required for sister chromatid cohesion, Eco1, Ctf4, and Ctf18, are found at, and Ctf4 travels along chromosomes with, replication forks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962805",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 326,
                    "text": "We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 431,
                    "text": "In budding yeast, a specialized replication factor C called RF-C(Ctf18/Dcc1/Ctf8) and the DNA-polymerase-alpha-associated protein Ctf4 are required to maintain sister-chromatid cohesion in cells arrested for long periods in mitosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 628,
                    "text": "Here we show that three proteins required for sister chromatid cohesion, Eco1, Ctf4, and Ctf18, are found at, and Ctf4 travels along chromosomes with, replication forks",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962805",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 586,
                    "text": "The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to facilitate sister chromatid cohesion",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 325,
                    "text": "We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11287619",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 663,
                    "offsetInEndSection": 831,
                    "text": "In addition to Eco1, several other factors contribute to cohesion establishment, including Ctf4, Ctf18, Tof1, Csm3, Chl1 and Mrc1, but little is known about their roles",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do de novo truncating mutations in WASF1 cause cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29961568"
            ],
            "ideal_answer": [
                "No, de novo heterozygous mutations in WASF1 cause a rare form of intellectual disability."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e36d498b5b409ea53000008",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29961568",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 1134,
                    "text": "Here, using exome sequencing and whole-genome sequencing, we identified three de novo truncating mutations in WAS protein family member 1 (WASF1) in five unrelated individuals with moderate to profound intellectual disability with autistic features and seizures. WASF1, also known as WAVE1, is part of the WAVE complex and acts as a mediator between Rac-GTPase and actin to induce actin polymerization. The three mutations connected by Matchmaker Exchange were c.1516C>T (p.Arg506Ter), which occurs in three unrelated individuals, c.1558C>T (p.Gln520Ter), and c.1482delinsGCCAGG (p.Ile494MetfsTer23). All three variants are predicted to partially or fully disrupt the C-terminal actin-binding WCA domain. Functional studies using fibroblast cells from two affected individuals with the c.1516C>T mutation showed a truncated WASF1 and a defect in actin remodeling. This study provides evidence that de\u00a0novo heterozygous mutations in WASF1 cause a rare form of intellectual disability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29961568",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does Uc.160 promote cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                "http://www.ncbi.nlm.nih.gov/pubmed/20802525"
            ],
            "ideal_answer": [
                "No. Uc.160+ is a T-UCR reported to be downregulated in human cancer. In addition, Uc.160+ could possibly have a tumor suppressive role in gastric cancer."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:162",
                "https://meshb.nlm.nih.gov/record/ui?ui=D009369"
            ],
            "type": "yesno",
            "id": "5a6d2558b750ff4455000036",
            "snippets": [
                {
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 1592,
                    "text": "We previously discovered the downregulation of T-UCR expression in gastric cancer (GC), indicating that T-UCRs could play an important role in GC biology. Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.METHODS: We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs. We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.RESULTS: On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach. Cancer-specific DNA methylation in the promoter region of Uc.160 was observed by bisulfite genomic DNA sequencing analysis. The effect of DNA methylation on Uc.160+ expression was further confirmed by reporter gene assay. We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.CONCLUSIONS: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 841,
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.<br><b>METHODS</b>: We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1391,
                    "offsetInEndSection": 1636,
                    "text": "We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.<br><b>CONCLUSIONS</b>: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 842,
                    "offsetInEndSection": 1168,
                    "text": "We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.<br><b>RESULTS</b>: On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1597,
                    "text": "CONCLUSIONS These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 490,
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1280,
                    "offsetInEndSection": 1494,
                    "text": "Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20802525",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 479,
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1465,
                    "offsetInEndSection": 1553,
                    "text": "These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any involvement of L1 retrotransposition in the Rett syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22159035",
                "http://www.ncbi.nlm.nih.gov/pubmed/24389010",
                "http://www.ncbi.nlm.nih.gov/pubmed/23057747",
                "http://www.ncbi.nlm.nih.gov/pubmed/21085180"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1514925",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11585268"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11585268",
                    "o": "retrotransposon transposition"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0035372",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18593781"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18593781",
                    "o": "rett syndrome"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1514925",
                    "o": "transposition, RNA-mediated"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1514925",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11610160"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11610160",
                    "o": "retrotransposition"
                }
            ],
            "ideal_answer": [
                "Yes. Recent studies indicate that long interspersed nuclear element-1 (L1) are mobilized in the genome of human neural progenitor cells and enhanced in Rett syndrome and ataxia telangiectasia."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015518",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020084",
                "http://www.disease-ontology.org/api/metadata/DOID:1206"
            ],
            "type": "yesno",
            "id": "58965a4178275d0c4a00000e",
            "snippets": [
                {
                    "offsetInBeginSection": 1585,
                    "offsetInEndSection": 2128,
                    "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition. Our data demonstrate that L1 retrotransposition can be controlled in a tissue-specific manner and that disease-related genetic mutations can influence the frequency of neuronal L1 retrotransposition. Our findings add a new level of complexity to the molecular events that can lead to neurological disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 725,
                    "offsetInEndSection": 903,
                    "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Recent studies indicate that long interspersed nuclear element-1 (L1) are mobilized in the genome of human neural progenitor cells and enhanced in Rett syndrome and ataxia telangiectasia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389010",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 594,
                    "text": "In addition, recent data indicate that engineered human L1s can undergo somatic retrotransposition in human neural progenitor cells and that an increase in human-specific L1 DNA content can be detected in the brains of normal controls, as well as in Rett syndrome patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22159035",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 896,
                    "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1576,
                    "offsetInEndSection": 1811,
                    "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 592,
                    "text": "In addition, recent data indicate that engineered human L1s can undergo somatic retrotransposition in human neural progenitor cells and that an increase in human-specific L1 DNA content can be detected in the brains of normal controls, as well as in Rett syndrome patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22159035",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1585,
                    "offsetInEndSection": 1819,
                    "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 725,
                    "offsetInEndSection": 901,
                    "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1585,
                    "offsetInEndSection": 1820,
                    "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 725,
                    "offsetInEndSection": 902,
                    "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Recent studies indicate that long interspersed nuclear element-1 (L1) are mobilized in the genome of human neural progenitor cells and enhanced in Rett syndrome and ataxia telangiectasia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389010",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a role of proton beam therapy in medulloblastoma treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16165914",
                "http://www.ncbi.nlm.nih.gov/pubmed/9231669",
                "http://www.ncbi.nlm.nih.gov/pubmed/25415685",
                "http://www.ncbi.nlm.nih.gov/pubmed/24105630",
                "http://www.ncbi.nlm.nih.gov/pubmed/9240650",
                "http://www.ncbi.nlm.nih.gov/pubmed/15637691",
                "http://www.ncbi.nlm.nih.gov/pubmed/26548600",
                "http://www.ncbi.nlm.nih.gov/pubmed/25927402",
                "http://www.ncbi.nlm.nih.gov/pubmed/16332594",
                "http://www.ncbi.nlm.nih.gov/pubmed/9112448",
                "http://www.ncbi.nlm.nih.gov/pubmed/12377335",
                "http://www.ncbi.nlm.nih.gov/pubmed/23322160",
                "http://www.ncbi.nlm.nih.gov/pubmed/22553304",
                "http://www.ncbi.nlm.nih.gov/pubmed/1310964",
                "http://www.ncbi.nlm.nih.gov/pubmed/16168831",
                "http://www.ncbi.nlm.nih.gov/pubmed/24187330",
                "http://www.ncbi.nlm.nih.gov/pubmed/23433794",
                "http://www.ncbi.nlm.nih.gov/pubmed/25403752",
                "http://www.ncbi.nlm.nih.gov/pubmed/15701271"
            ],
            "ideal_answer": [
                "Yes, proton beam therapy is used for treatment of medulloblastoma."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4058240",
                "http://www.disease-ontology.org/api/metadata/DOID:0050902",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061766",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011878",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008527"
            ],
            "type": "yesno",
            "id": "58850ac7e56acf5176000012",
            "snippets": [
                {
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 952,
                    "text": "All papers directly compared outcomes from protons with photons, five papers included medulloblastoma, four papers each included craniopharyngioma and low grade gliomas and three papers included ependymoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25927402",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1872,
                    "offsetInEndSection": 2212,
                    "text": "There are many indications of protontherapy for paediatric brain tumours in curative intent, either for localized treatment of ependymomas, germ-cell tumours, craniopharyngiomas, low-grade gliomas; or panventricular irradiation of pure non-secreting germinoma; or craniospinal irradiation of medulloblastomas and metastatic pure germinomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 360,
                    "text": "BACKGROUND: The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.METHODS: We developed a Markov model to describe health states of 6-year-old children with medulloblastoma after treatment with proton or X-ray radiotherapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "Evaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "BACKGROUND: To precisely calculate skin dose and thus to evaluate the relationship between the skin dose and permanent alopecia for pediatric medulloblastoma patients treated with proton beams.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1314,
                    "text": "CONCLUSIONS: Our results based on 12 patients provide a relationship between the skin dose and permanent alopecia for pediatric medulloblastoma patients treated with protons. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "PURPOSE: Efficacy and acute toxicity of proton craniospinal irradiation (p-CSI) were compared with conventional photon CSI (x-CSI) for adults with medulloblastoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1358,
                    "text": "CONCLUSIONS: This report is the first analysis of clinical outcomes for adult medulloblastoma patients treated with p-CSI. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "OBJECTIVE: To improve medulloblastoma proton therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 338,
                    "text": "The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.We developed a Markov model to describe health states of 6-year-old children with medulloblastoma after treatment with proton or X-ray radiotherapy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1311,
                    "offsetInEndSection": 1528,
                    "text": "All patients completed therapy without interruption.Our proton-beam technique for craniospinal irradiation of pediatric medulloblastoma has successfully reduced normal-tissue doses and acute treatment-related sequelae",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701271",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1146,
                    "offsetInEndSection": 1569,
                    "text": "For 6 MV x-rays > 60% of the dose prescribed to the target was delivered to 44% of the heart volume, while the proton beam was able to completely avoid the heart, the liver, and in all likelihood the thyroid and gonads as well.The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9231669",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1228,
                    "offsetInEndSection": 1515,
                    "text": "This review describes the role of radiation in general and proton therapy in particular for the treatment of medulloblastoma, central nervous system primitive neuroectodermal tumors, atypical teratoid/rhabdoid tumors, and the recently described embryonal tumor with multilayered rosettes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25415685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701271",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2674,
                    "offsetInEndSection": 3031,
                    "text": "Intensity-modulated radiotherapy did show more bladder dose reduction than the other techniques in pelvic sarcoma irradiation.CONCLUSIONS: In the diseases studied, using various techniques of 3D-CRT, electrons, IMRT, and protons, protons are most optimal in treating retinoblastomas, medulloblastomas (posterior fossa and craniospinal), and pelvic sarcomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16168831",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1185,
                    "offsetInEndSection": 1619,
                    "text": "For 6 MV x-rays>60% of the dose prescribed to the target was delivered to 44% of the heart volume, while the proton beam was able to completely avoid the heart, the liver, and in all likelihood the thyroid and gonads as well.CONCLUSION: The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 872,
                    "text": "In medulloblastoma, three posterior fossa irradiation techniques were analyzed: 3D-CRT, IMRT, and protons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16168831",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9231669",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1376,
                    "offsetInEndSection": 1573,
                    "text": "The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 42,
                    "text": "To improve medulloblastoma proton therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1366,
                    "offsetInEndSection": 1532,
                    "text": "Our proton-beam technique for craniospinal irradiation of pediatric medulloblastoma has successfully reduced normal-tissue doses and acute treatment-related sequelae.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701271",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16168831",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is CD99 encoded by MIC2 gene?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25007147",
                "http://www.ncbi.nlm.nih.gov/pubmed/8399135",
                "http://www.ncbi.nlm.nih.gov/pubmed/24322504",
                "http://www.ncbi.nlm.nih.gov/pubmed/17725386",
                "http://www.ncbi.nlm.nih.gov/pubmed/10941840",
                "http://www.ncbi.nlm.nih.gov/pubmed/9623916",
                "http://www.ncbi.nlm.nih.gov/pubmed/10492040",
                "http://www.ncbi.nlm.nih.gov/pubmed/24158076",
                "http://www.ncbi.nlm.nih.gov/pubmed/1867320",
                "http://www.ncbi.nlm.nih.gov/pubmed/15359120",
                "http://www.ncbi.nlm.nih.gov/pubmed/10782405",
                "http://www.ncbi.nlm.nih.gov/pubmed/11037347",
                "http://www.ncbi.nlm.nih.gov/pubmed/15978751",
                "http://www.ncbi.nlm.nih.gov/pubmed/9278313",
                "http://www.ncbi.nlm.nih.gov/pubmed/22356523",
                "http://www.ncbi.nlm.nih.gov/pubmed/23644663",
                "http://www.ncbi.nlm.nih.gov/pubmed/21063743",
                "http://www.ncbi.nlm.nih.gov/pubmed/22020966",
                "http://www.ncbi.nlm.nih.gov/pubmed/10688843"
            ],
            "ideal_answer": [
                "CD99 is a 32-kDa transmembrane glycoprotein that is encoded by the MIC2 gene  ",
                "CD99 is a transmembrane protein encoded by MIC2 gene. It is involved in multiple cellular functions, including cell adhesion and migration, apoptosis, cell differentiation, and regulation of protein trafficking, in either physiological or pathological conditions."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/CD99_HUMAN"
            ],
            "type": "yesno",
            "id": "55376b37bc4f83e82800000b",
            "snippets": [
                {
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 488,
                    "text": "We report 2 unusual cytogenetic findings in a pediatric Ewing sarcoma, an insertion of the MIC2 gene encoding CD99 from Xp to 10p and a submicroscopic deletion of the well-known tumor supressor gene KLF6",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322504",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 609,
                    "text": "We obtained the final diagnosis of ES/PNET by immunohistochemical molecular study with positive staining for the MIC2 gene product (CD99) and a Ewing sarcoma breakpoint region 1 (EWSR1) gene rearrangement",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24158076",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "text": "CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "CD99 is a 32-kDa transmembrane glycoprotein that is encoded by the MIC2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22020966",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 341,
                    "offsetInEndSection": 445,
                    "text": "The surgical specimens showed small round cell tumor with positive staining for MIC2 gene product (CD99)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "CD99 is a 32-kDa transmembrane glycoprotein that is encoded by the MIC2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22020966",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "The leukocyte surface molecule CD99 is an integral membrane glycoprotein encoded by the E2/MIC2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17725386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Human CD99, which is encoded by the mic2 gene, is a ubiquitous 32 kDa transmembrane protein.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15359120",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 374,
                    "text": "Human CD99 is a 32-kDa cell surface protein that is encoded by the MIC2 gene localized to the PAR1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978751",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 697,
                    "text": "The tumors displayed intense immunoreactivity in a membranous pattern for CD99, the cell surface glycoprotein encoded by the MIC2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10782405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "text": "CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "CD99, the product of the MIC2 gene, exhibits an erythroid-specific quantitative polymorphism coregulated with the polymorphism of the XG blood group gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10688843",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "CD99, the product of the MIC2 gene, exhibits an erythroid-specific quantitative polymorphism co-regulated with the Xga blood group polymorphism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10941840",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1031,
                    "offsetInEndSection": 1183,
                    "text": "Homology searches resulted in finding homologous sequences (totally about 40% homology) in the human MIC2 gene product (CD99; 32-kDa) of T lymphocytes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9623916",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Although considered a specific marker for Ewing's sarcoma/peripheral neuroectodermal tumour, the MIC2 gene product (CD99) has been immunolocalised in a variety of human tumours.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11037347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 615,
                    "text": "MIC2, the gene encoding the CD99 antigen, is found in the pseudoautosomal region of both the X and Y chromosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22356523",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 376,
                    "text": "Human CD99 is a 32-kDa cell surface protein that is encoded by the MIC2 gene localized to the PAR1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978751",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 699,
                    "text": "The tumors displayed intense immunoreactivity in a membranous pattern for CD99, the cell surface glycoprotein encoded by the MIC2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10782405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9278313",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10492040",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "The Ewing family of tumors (EFT) is characterized by high MIC2/CD99 expression and specific EWS/ETS gene rearrangements, resulting in different chimeric transcripts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10492040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 701,
                    "text": "The tumors displayed intense immunoreactivity in a membranous pattern for CD99, the cell surface glycoprotein encoded by the MIC2 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10782405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "Monoclonal antibody (MAb) HBA71, which was raised against Ewing's sarcoma cells, recognizes a cell-surface glycoprotein, p30/32MIC2, that is encoded by the MIC2 gene in the pseudoautosomal region of human chromosomes X and Y.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1867320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "text": "Monoclonal antibodies (mAbs) directed against E2, a 32-kDa transmembrane protein encoded by the MIC2 gene located in the pseudoautosomal region, induce a transbilayer movement of phosphatidylserine and, to a lesser extent, phosphatidylethanolamine in human thymocytes and a Jurkat T lymphocytes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8399135",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1037,
                    "offsetInEndSection": 1188,
                    "text": "Homology searches resulted in finding homologous sequences (totally about 40% homology) in the human MIC2 gene product (CD99; 32-kDa) of T lymphocytes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9623916",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "CD99 is a 32-kDa transmembrane glycoprotein that is encoded by the MIC2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22020966",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 444,
                    "text": "The surgical specimens showed small round cell tumor with positive staining for MIC2 gene product (CD99)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 487,
                    "text": "We report 2 unusual cytogenetic findings in a pediatric Ewing sarcoma, an insertion of the MIC2 gene encoding CD99 from Xp to 10p and a submicroscopic deletion of the well-known tumor supressor gene KLF6",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322504",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 617,
                    "text": "MIC2, the gene encoding the CD99 antigen, is found in the pseudoautosomal region of both the X and Y chromosomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22356523",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 1034,
                    "text": "Immunohistochemical analysis showed weak to moderate and partial staining for MIC2 (CD99) and WT1, respectively",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007147",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Human CD99, which is encoded by the mic2 gene, is a ubiquitous 32 kDa transmembrane protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15359120",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "The leukocyte surface molecule CD99 is an integral membrane glycoprotein encoded by the E2/MIC2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17725386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 566,
                    "offsetInEndSection": 700,
                    "text": "The tumors displayed intense immunoreactivity in a membranous pattern for CD99, the cell surface glycoprotein encoded by the MIC2 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10782405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 375,
                    "text": "Human CD99 is a 32-kDa cell surface protein that is encoded by the MIC2 gene localized to the PAR1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978751",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 506,
                    "offsetInEndSection": 618,
                    "text": "MIC2, the gene encoding the CD99 antigen, is found in the pseudoautosomal region of both the X and Y chromosomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22356523",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "CD99, the product of the MIC2 gene, exhibits an erythroid-specific quantitative polymorphism co-regulated with the Xga blood group polymorphism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10941840",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has the protein SIRT2 been associated to cervical cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25794641",
                "http://www.ncbi.nlm.nih.gov/pubmed/28776959"
            ],
            "ideal_answer": [
                "Yes.\nA progressive increase in the expression of both SIRT2 and SIRT7 was noted during cancer progression in the following order: normal\u2009<\u2009preneoplasia\u2009<\u2009cancer."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c8cfca70101eac870000005",
            "snippets": [
                {
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1013,
                    "text": " A progressive increase in the expression of both SIRT2 and SIRT7 was noted during cancer progression in the following order: normal\u2009<\u2009preneoplasia\u2009<\u2009cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794641",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 808,
                    "text": " We demonstrate that treatment of cervical cancer cells with a RhoGDI\u03b1-derived K52-trifluoroacetylated, substrate-derived peptidic sirtuin inhibitor severely impairs cell proliferation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28776959",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does ziconotide bind to N-type calcium channels?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11279062",
                "http://www.ncbi.nlm.nih.gov/pubmed/16831862",
                "http://www.ncbi.nlm.nih.gov/pubmed/16225359",
                "http://www.ncbi.nlm.nih.gov/pubmed/22608964",
                "http://www.ncbi.nlm.nih.gov/pubmed/20413151",
                "http://www.ncbi.nlm.nih.gov/pubmed/25456079",
                "http://www.ncbi.nlm.nih.gov/pubmed/10666532",
                "http://www.ncbi.nlm.nih.gov/pubmed/15578997",
                "http://www.ncbi.nlm.nih.gov/pubmed/16207099",
                "http://www.ncbi.nlm.nih.gov/pubmed/10834782",
                "http://www.ncbi.nlm.nih.gov/pubmed/20188724",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084632",
                "http://www.ncbi.nlm.nih.gov/pubmed/17063978",
                "http://www.ncbi.nlm.nih.gov/pubmed/16845440",
                "http://www.ncbi.nlm.nih.gov/pubmed/11059665",
                "http://www.ncbi.nlm.nih.gov/pubmed/21577088",
                "http://www.ncbi.nlm.nih.gov/pubmed/10666519",
                "http://www.ncbi.nlm.nih.gov/pubmed/15209164",
                "http://www.ncbi.nlm.nih.gov/pubmed/9315745",
                "http://www.ncbi.nlm.nih.gov/pubmed/25446431",
                "http://www.ncbi.nlm.nih.gov/pubmed/22428804",
                "http://www.ncbi.nlm.nih.gov/pubmed/17199507",
                "http://www.ncbi.nlm.nih.gov/pubmed/10436454",
                "http://www.ncbi.nlm.nih.gov/pubmed/22188924",
                "http://www.ncbi.nlm.nih.gov/pubmed/21992243",
                "http://www.ncbi.nlm.nih.gov/pubmed/19300539",
                "http://www.ncbi.nlm.nih.gov/pubmed/10547097"
            ],
            "ideal_answer": [
                "Yes, ziconotide/omega-conotoxin MVIIA blocks N-type calcium channels."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020864"
            ],
            "type": "yesno",
            "id": "56cf27293975bb303a000003",
            "snippets": [
                {
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 749,
                    "text": "Since this region partially overlaps with residues previously implicated in block of the channel by omega-conotoxin GVIA, we assessed the effects of mutations in the putative EF hand domain on channel block by omega-conotoxin GVIA and the structurally related omega-conotoxin MVIIA. Both of the toxins irreversibly block the activity of wild type alpha(1B) N-type channels. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11279062",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Despite their high sequence homology, the peptide neurotoxins omega-conotoxin MVIIA and MVIIC selectively block N- and P/Q-type calcium channels, respectively. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315745",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 637,
                    "text": " Binding assay for both N- and P/Q-type calcium channels showed that amino acid residues restricted to the N-terminal half are important for the recognition of N-type channels, whereas essential residues for P/Q-type channel recognition are widely spread over the whole omega-conotoxin molecule.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315745",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Ziconotide is a novel peptide that blocks the entry of calcium into neuronal N-type voltage-sensitive calcium channels, preventing the conduction of nerve signals.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16207099",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Ziconotide is a selective, potent and reversible blocker of neuronal N-type voltage-sensitive calcium channels (VSCCs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666532",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 456,
                    "text": "The therapeutic benefit of ziconotide derives from its potent and selective blockade of neuronal N-type voltage-sensitive calcium channels.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666532",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10834782",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16207099",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 854,
                    "text": "Thus, ziconotide is the first of a new class of agents--N-type calcium channel blockers, or NCCBs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1227,
                    "offsetInEndSection": 1342,
                    "text": "Ziconotide, formerly known also as SNX- 111, represents a new class of agents, the N-type calcium channel blockers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16845440",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 419,
                    "text": "The selective N-type calcium channel blocker ziconotide ameliorates severe chronic pain but has a narrow therapeutic window and requires intrathecal administration.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25456079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 429,
                    "offsetInEndSection": 594,
                    "text": "A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831862",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 982,
                    "offsetInEndSection": 1292,
                    "text": "As the clinically available analgesics, pregabalin (alpha2delta-subunit calcium channel ligand), ziconotide (N-type calcium channel blocker), mexiletine (sodium channel blocker), and duloxetine (serotonin and norepinephrine reuptake inhibitors) were evaluated in these neurochemically-induced allodynia models.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 626,
                    "text": "The present investigation was designed to assess the safety and analgesic efficacy of ziconotide, a new N-type calcium channel blocker, when administered intrathecally to patients with acute postoperative pain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10834782",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 395,
                    "offsetInEndSection": 588,
                    "text": "Inhibition of the N-type calcium channel by intrathecal administration of the channel-specific blocker omega-conotoxin MVIIA (ziconotide) is efficacious in the treatment of severe chronic pain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17199507",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "text": "Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19300539",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1924,
                    "offsetInEndSection": 2212,
                    "text": "In conclusion, present findings provide implication that the spinal anti-nociceptive mechanistic site of pregabalin is different from that of ziconotide, mexiletine, and duloxetine, and pregabalin could have a broader anti-nociceptive mechanism other than N-type calcium channel blockade.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Ziconotide (SNX-111), a selective blocker of neuronal N-type voltage-sensitive calcium channels, is antinociceptive when it is administered intrathecally.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666519",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 288,
                    "text": "A state-dependent Ca(V)2.2 inhibitor may provide an improved therapeutic window over ziconotide, the peptidyl Ca(V)2.2 inhibitor used clinically. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188924",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 273,
                    "text": "There is also human validation data from ziconotide, the CaV2.2-selective peptidyl inhibitor used clinically to treat refractory pain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25446431",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 432,
                    "text": "A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831862",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10436454",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9674897",
                "http://www.ncbi.nlm.nih.gov/pubmed/26605035",
                "http://www.ncbi.nlm.nih.gov/pubmed/16617304",
                "http://www.ncbi.nlm.nih.gov/pubmed/15734119",
                "http://www.ncbi.nlm.nih.gov/pubmed/8998528",
                "http://www.ncbi.nlm.nih.gov/pubmed/25523123",
                "http://www.ncbi.nlm.nih.gov/pubmed/12238021"
            ],
            "ideal_answer": [
                "Velocardial facial syndrome, otherwise known as Di George syndrome is caused by a deletion in chromosome 22.",
                "The deletion of chromosome 22q11.2 is involved in the majority of DiGeorge or velo-cardiofacial syndrome."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c97a08becadf2e73f000029",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 117,
                    "text": "The deletion of chromosome 22q11.2 is involved in the majority of DiGeorge or velo-cardiofacial syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15734119",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 451,
                    "text": "deletions of chromosome 7q11.23 (Williams syndrome), 15q11-q13 (Angelman syndrome, Prader-Willi syndrome) and 22q11 (Di George syndrome)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16617304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "text": "Submicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and Di George syndrome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9674897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "The 22q11.2 deletion syndrome (di George syndrome) is one of the most prevalent genetic disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26605035",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "UNLABELLED\nMost of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "text": "Submicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and Di George syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9674897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 364,
                    "text": "22q11.2DS has several presentations including Di George's syndrome, velo-cardio-facial syndrome or Shprintzen's syndrome and it is the most frequent microdeletion syndrome in the general population (prevalence estimated at 1/4000 births, de novo: 90%).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25523123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1088,
                    "offsetInEndSection": 1580,
                    "text": "Di George syndrome due to mutation on 22q or 10q) and can also result from microdeletion or point mutation (in the Shprintzen syndrome 70% represent microdeletion and 30% point mutation at 22q11, in Rubinstein-Taybi syndrome 10% cases result from microdeletions and 90% from point mutations); 7) Population incidence of microdeletions is high (1:4000 to 1:30,000) because their etiologic mechanism is related to the common unequal crossing over; 8) Imprinting plays a role in some cases, e.g.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12238021",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 265,
                    "text": "[Microdeletion of the chromosome 22q11 in children: apropos of a series of 49 patients].<AbstractText Label=\"UNLABELLED\">Most of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 488,
                    "text": "22q11.2DS has several presentations including Di George's syndrome, velo-cardio-facial syndrome or Shprintzen's syndrome and it is the most frequent microdeletion syndrome in the general population (prevalence estimated at 1/4000 births, de novo: 90%). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25523123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "<b>UNLABELLED</b>: Most of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Most of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can LB-100 downregulate miR-33?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28588271"
            ],
            "ideal_answer": [
                "No, LB-100 has been reported to modulate (upregulate) only miR-181b-1."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e2a04feaa19d74431000009",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28588271",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 683,
                    "offsetInEndSection": 989,
                    "text": "LB100 profoundly upregulates miR-181b-1, which we show directly binds to the 3' untranslated region of Bcl-2 mRNA leading to its translational inhibition. MiR-181b-1 ectopic overexpression further diminishes Bcl-2 expression leading to suppression of sAML cell growth, and enhancement of DNR cytotoxicity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28588271",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22965147"
            ],
            "ideal_answer": [
                "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c8857e975a4a5d219000009",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22965147",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 471,
                    "text": "Studies show that administration of apolipoprotein E (apoE) and apoE-derived small peptide mimetics protect AD mouse models against these AD-like features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22965147",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is durvalumab used for lung cancer treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29069302",
                "http://www.ncbi.nlm.nih.gov/pubmed/29303787",
                "http://www.ncbi.nlm.nih.gov/pubmed/29593890",
                "http://www.ncbi.nlm.nih.gov/pubmed/28585617",
                "http://www.ncbi.nlm.nih.gov/pubmed/28664936",
                "http://www.ncbi.nlm.nih.gov/pubmed/30489337",
                "http://www.ncbi.nlm.nih.gov/pubmed/28705024",
                "http://www.ncbi.nlm.nih.gov/pubmed/29239189",
                "http://www.ncbi.nlm.nih.gov/pubmed/30116683",
                "http://www.ncbi.nlm.nih.gov/pubmed/29958099",
                "http://www.ncbi.nlm.nih.gov/pubmed/28885881",
                "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
                "http://www.ncbi.nlm.nih.gov/pubmed/29760563",
                "http://www.ncbi.nlm.nih.gov/pubmed/30012210",
                "http://www.ncbi.nlm.nih.gov/pubmed/29545095",
                "http://www.ncbi.nlm.nih.gov/pubmed/28512504",
                "http://www.ncbi.nlm.nih.gov/pubmed/27196116",
                "http://www.ncbi.nlm.nih.gov/pubmed/28960263",
                "http://www.ncbi.nlm.nih.gov/pubmed/29140105",
                "http://www.ncbi.nlm.nih.gov/pubmed/30327351"
            ],
            "ideal_answer": [
                "Yes, Durvalumab is an anti-PDL-1 antibody that is used for treatment of non-small-cell lung cancer."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c5607aa07647bbc4b00000e",
            "snippets": [
                {
                    "offsetInBeginSection": 1047,
                    "offsetInEndSection": 1253,
                    "text": " In the phase III PACIFIC trial consolidation with durvalumab, an anti-PDL-1 antibody, was associated with survival benefit in patients diagnosed with LA-NSCLC who responded to concurrent chemoradiotherapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30489337",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 628,
                    "text": "METHODS: An electronic literature search was performed of public databases (MEDLINE, Excerpta Medica dataBASE [EMBASE], and Cochrane) and conference proceedings for trials using PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) in patients with NSCLC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960263",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Durvalumab in non-small-cell lung cancer patients: current developments.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29140105",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 463,
                    "text": "Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the \u226525% PD-L1+ population.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29140105",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 550,
                    "offsetInEndSection": 964,
                    "text": "Six drugs including one CTLA-4 blocker (ipilimumab), two PD-1 blockers (nivolumab and pembrolizumab) and three PD-L1 blockers (atezolizumab, avelumab and durvalumab) are approved for the treatment of different types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and Merkel cell cancer as well as hematological tumors such as classic Hodgkin's lymphoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069302",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 421,
                    "text": "PURPOSE OF REVIEW: The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab and nivolumab or programmed cell death ligand 1 such as atezolizumab, durvalumab and avelumab have shown favorable efficacy results in this patient population in the first-line and second-line setting.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29303787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 1073,
                    "text": "In addition, preclinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti-PD-1/PD-L1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs in patients with stage III NSCLC. A preliminary report of a randomized phase III trial, the PACIFIC trial, demonstrated an impressive increase in median progression-free survival with consolidative durvalumab, a PD-L1 inhibitor, compared with observation after cCRT. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 330,
                    "text": "ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28705024",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 970,
                    "offsetInEndSection": 1337,
                    "text": "The PACIFIC trial assessing durvalumab after standard chemoradiotherapy for locally advanced NSCLC has already met its primary endpoint and the potential of durvalumab will be reinforced if phase III randomized studies of first-line (MYSTIC trial) and second or subsequent (ARCTIC trial) lines of therapy demonstrate superiority over the current standard of care.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28705024",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does oncogene-induced DNA replication stress inhibit genomic instability?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23204322"
            ],
            "ideal_answer": [
                "No, oncogene-induced DNA replication stress is thought to drive genomic instability."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5ab9032afcf4565872000018",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Oncogene-induced DNA replication stress is thought to drive genomic instability in cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204322",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1278,
                    "text": "We propose that single-stranded DNA generated in response to oncogene-induced replication stress compromises the repair of deaminated cytosines and other damaged bases, leading to the observed SNS mutator phenotype.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204322",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Could bioprinting be used in regenerative medicine against bone disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21798570",
                "http://www.ncbi.nlm.nih.gov/pubmed/25866560",
                "http://www.ncbi.nlm.nih.gov/pubmed/25093879",
                "http://www.ncbi.nlm.nih.gov/pubmed/25376489"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0049608",
                    "o": "D004194"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0049941",
                    "o": "D001847"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0032080",
                    "o": "D001842"
                }
            ],
            "ideal_answer": [
                "The developments in bioprinting (3D cell printing) techniques will be used in regenerative medicine and may allow the fabrication of customized implants for patients suffering in bone diseases in the future, once several technological limitations are addressed."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008511",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001847",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062028",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044968",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006801",
                "http://www.disease-ontology.org/api/metadata/DOID:0080001"
            ],
            "type": "yesno",
            "id": "5713968e1174fb175500000d",
            "snippets": [
                {
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 866,
                    "text": "Before 3D Printing can be used routinely for the regeneration of complex tissues (e.g. bone, cartilage, muscles, vessels, nerves in the craniomaxillofacial complex), and complex organs with intricate 3D microarchitecture (e.g. liver, lymphoid organs), several technological limitations must be addressed. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25866560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 714,
                    "offsetInEndSection": 1463,
                    "text": "It is expected that these new findings will give an innovation boost for the development of scaffolds for bone repair and reconstruction, which began with the use of bioinert materials, followed by bioactive materials and now leading to functional regenerative tissue units. These new developments have become possible with the discovery of the morphogenic activity of bioinorganic polymers, biocalcit, bio-polyphosphate and biosilica that are formed by a biogenic, enzymatic mechanism, a driving force along with the development of novel rapid-prototyping three-dimensional (3D) printing methods and bioprinting (3D cell printing) techniques that may allow a fabrication of customized implants for patients suffering in bone diseases in the future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1459,
                    "offsetInEndSection": 1933,
                    "text": "These new developments have become possible with the discovery of the morphogenic activity of bioinorganic polymers, biocalcit, bio-polyphosphate and biosilica that are formed by a biogenic, enzymatic mechanism, a driving force along with the development of novel rapid-prototyping three-dimensional (3D) printing methods and bioprinting (3D cell printing) techniques that may allow a fabrication of customized implants for patients suffering in bone diseases in the future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 1100,
                    "text": "3D bioprinting has already been used for the generation and transplantation of several tissues, including multilayered skin, bone, vascular grafts, tracheal splints, heart tissue and cartilaginous structures.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25093879",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1202,
                    "offsetInEndSection": 1464,
                    "text": "a driving force along with the development of novel rapid-prototyping three-dimensional (3D) printing methods and bioprinting (3D cell printing) techniques that may allow a fabrication of customized implants for patients suffering in bone diseases in the future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 990,
                    "offsetInEndSection": 1464,
                    "text": "These new developments have become possible with the discovery of the morphogenic activity of bioinorganic polymers, biocalcit, bio-polyphosphate and biosilica that are formed by a biogenic, enzymatic mechanism, a driving force along with the development of novel rapid-prototyping three-dimensional (3D) printing methods and bioprinting (3D cell printing) techniques that may allow a fabrication of customized implants for patients suffering in bone diseases in the future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376489",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Turcot syndrome associated with glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24310308",
                "http://www.ncbi.nlm.nih.gov/pubmed/9505220",
                "http://www.ncbi.nlm.nih.gov/pubmed/2165772",
                "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                "http://www.ncbi.nlm.nih.gov/pubmed/10921328",
                "http://www.ncbi.nlm.nih.gov/pubmed/8127448",
                "http://www.ncbi.nlm.nih.gov/pubmed/11339660",
                "http://www.ncbi.nlm.nih.gov/pubmed/3032534",
                "http://www.ncbi.nlm.nih.gov/pubmed/8025896",
                "http://www.ncbi.nlm.nih.gov/pubmed/16000562",
                "http://www.ncbi.nlm.nih.gov/pubmed/11907360",
                "http://www.ncbi.nlm.nih.gov/pubmed/22676959",
                "http://www.ncbi.nlm.nih.gov/pubmed/2540108",
                "http://www.ncbi.nlm.nih.gov/pubmed/16144131",
                "http://www.ncbi.nlm.nih.gov/pubmed/19822006",
                "http://www.ncbi.nlm.nih.gov/pubmed/16960645",
                "http://www.ncbi.nlm.nih.gov/pubmed/11975096",
                "http://www.ncbi.nlm.nih.gov/pubmed/9343324",
                "http://www.ncbi.nlm.nih.gov/pubmed/15701281",
                "http://www.ncbi.nlm.nih.gov/pubmed/6307612",
                "http://www.ncbi.nlm.nih.gov/pubmed/23119205",
                "http://www.ncbi.nlm.nih.gov/pubmed/8387650",
                "http://www.ncbi.nlm.nih.gov/pubmed/9695069",
                "http://www.ncbi.nlm.nih.gov/pubmed/17138070",
                "http://www.ncbi.nlm.nih.gov/pubmed/23320220",
                "http://www.ncbi.nlm.nih.gov/pubmed/19156169",
                "http://www.ncbi.nlm.nih.gov/pubmed/7515658",
                "http://www.ncbi.nlm.nih.gov/pubmed/10223463",
                "http://www.ncbi.nlm.nih.gov/pubmed/6274254",
                "http://www.ncbi.nlm.nih.gov/pubmed/23729388",
                "http://www.ncbi.nlm.nih.gov/pubmed/9508118"
            ],
            "triples": [
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMSL2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "Turcot syndrome with glioblastoma, 276300"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMSL2",
                    "o": "PMSL2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COCA2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "Turcot syndrome with glioblastoma, 276300"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COCA2",
                    "o": "COCA2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MLH1"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MLH1",
                    "o": "MLH1"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MLH1",
                    "o": "http://www.dbpedia.org/resource/MLH1"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC4"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC4",
                    "o": "HNPCC4"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC2"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC2",
                    "o": "HNPCC2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMS2"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMS2",
                    "o": "PMS2"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMS2",
                    "o": "http://www.dbpedia.org/resource/PMS2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156",
                    "o": "http://www.dbpedia.org/resource/Turcot_syndrome"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156",
                    "o": "Turcot_syndrome"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/treat",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/primaryAccessionNo",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "DB03431"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "Adenosine-5'-Diphosphate"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/secondaryAccessionNumber",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "expt00436"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/chemicalIupacName",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/possibleDiseaseTarget",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/chemicalIupacName",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl (dihydroxyphosphinothioyloxy-hydroxyphosphoryl) hydrogen phosphate"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/primaryAccessionNo",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "DB02930"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "Phosphothiophosphoric Acid-Adenylate Ester"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/secondaryAccessionNumber",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "expt00458"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/treat",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/possibleDiseaseTarget",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7628038",
                    "o": "C3938"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608078",
                    "o": "MMRCS"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615647",
                    "o": "BRAIN TUMOR-POLYPOSIS SYNDROME 1"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608079"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18467817",
                    "o": "Turcot syndrome"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608080",
                    "o": "BTPS1"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608080"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16615647"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608078"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608081"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16749653"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7628038"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7628038",
                    "o": "Turcot Syndrome"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608079",
                    "o": "MMR DEFICIENCY"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615646",
                    "o": "CHILDHOOD CANCER SYNDROME"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16609958",
                    "o": "BTP1 SYNDROME"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18458641"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16749653",
                    "o": "Turcot syndrome (disorder)"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458641",
                    "o": "CNS tumors with Familial polyposis of the colon"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16615646"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18467817"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16611904",
                    "o": "MISMATCH REPAIR CANCER SYNDROME"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16619491"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16609958"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608081",
                    "o": "TURCOT SYNDROME"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16611904"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16619491",
                    "o": "MISMATCH REPAIR DEFICIENCY"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458641",
                    "o": "C536928"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18467817",
                    "o": "C536928"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608078",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608079",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608080",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608081",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16609958",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16611904",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615646",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615647",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16619491",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608078",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608079",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608080",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608081",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16609958",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16611904",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615646",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615647",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16619491",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458641",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18467817",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7628038",
                    "o": "NCI Thesaurus"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16749653",
                    "o": "Metathesaurus Names"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#definition",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "NCI: The syndrome of polyposis coli, colon cancer and brain tumors."
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520870"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R69865242",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108937798"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/omim",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://bio2rdf.org/omim:120436"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R119892539",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54264357",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527990"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520871"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533303",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108535497",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54326923"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512677",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527985",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108535496",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/chromosomalLocation",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/3p21.3"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292285"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508498",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533841",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/omim",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://bio2rdf.org/omim:600259"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108535497"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533304"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292286"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108513938",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520859"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507257",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/omimPage",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600259"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527988",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292287"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527984",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533841"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R69798948",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108537658"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292288"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108513096",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533302"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226085",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R69830643"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520857"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226396",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108514384",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108535496"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507331",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533303"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292289"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54393456"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108514872"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226673",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108541476",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520869"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527986",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520858"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54263586",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527985"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512676",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527989",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520868"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R119807587"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533302",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108513097",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R120073491",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527986"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520867"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226105",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512678",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508077",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108537658",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108506793",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520856"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R119807589"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520866"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527987"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54438032"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108541476"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512226",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108510291",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520865"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R69877248",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108536636",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527984"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520855"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R119807588"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527988"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226224",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54438031"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527990",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520864"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520854"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R113837386",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527987",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508424",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527989"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108536636"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508968",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#inScheme",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R69826314"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520863"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520874"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R113845414"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520862"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226336",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533304",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507918",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R119979672",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54166689",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/chromosomalLocation",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/7p22"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520861"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507347",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508425",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108937799",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520872"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292290"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R69817576"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/class",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Cancer"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/class",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Cancer"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54228336",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520860"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520873"
                }
            ],
            "ideal_answer": [
                "Yes, Turcot syndrome is associated with glioblastoma. Turcot syndrome is an autosomal recessive disorder clinically characterized by the occurrence of primary glial tumors of the central nervous system, including glioblastoma, and adenomatous colonic polyps during the first or second decades of life, with a spectrum of clinical features such as \"caf\u00e9-au-lait\" spots, axillary freckling, and hyperpigmented spots."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3073",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "http://www.disease-ontology.org/api/metadata/DOID:225",
                "http://www.disease-ontology.org/api/metadata/DOID:3068",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005909"
            ],
            "type": "yesno",
            "id": "533581f5d6d3ac6a3400004d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 330,
                    "text": "Turcot syndrome is an autosomal recessive disorder clinically characterized by the occurrence of primary tumors of the central nervous system and adenomatous colonic polyps during the first or second decades of life, with a spectrum of clinical features such as \"caf\u00e9-au-lait\" spots, axillary freckling, and hyperpigmented spots. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23320220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 541,
                    "text": "We present the case of a 20-year-old male with a clinical presentation of both glioblastoma multiforme and multiple adenomatous colonic polyps. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23320220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 316,
                    "text": "Turcot syndrome (TS) is a rare hereditary disorder clinically characterized by the occurrence of primary tumors of the colon and the central nervous system (CNS). Here we present the case of an 11-year-old boy with a synchronous clinical presentation of both glioblastoma multiforme (GBM) and colonic adenocarcinoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23119205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 681,
                    "text": "Based on this case study, the synchronous presentation of glioblastoma multiforme and adenocarcinoma of the colon might suggest a shorter survival rate for patients with Turcot syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23119205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 526,
                    "text": "A 15-year-old boy was admitted with the diagnosis of colonic polyposis, and during a 2-year follow-up, he underwent operation for right parieto-occipital anaplastic astrocytoma, left-side colonic non-Hodgkin lymphoma (NHL) and cerebella glioblastoma which were all confirmed by histology. Although cases of Turcot's syndrome (TS) (colonic polyposis and primary brain tumour occurring in the same patient) have been previously described, association with haematological malignancy is rare. We hereby report such a case with TS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22676959",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156169",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 567,
                    "offsetInEndSection": 696,
                    "text": " Biallelic mutations of MMR genes are associated with pediatric cancers, including glial tumors, in Turcot syndrome type 1 (TS1).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156169",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Glioblastomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: a clinicopathological study of 3 cases.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 141,
                    "text": "Turcot syndrome (TS) is a rare genetic disorder of DNA mismatch repair predisposing to glioblastoma (GBM) in the type 1 variant. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 242,
                    "text": "We report the clinicopathological and genetic features of 3 gliomas in TS type 1 patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1739,
                    "text": "We conclude that 1) the giant cell variant of GBM is overrepresented in TS; 2) gliosarcomas may also be encountered; and 3) survival is often favorable, despite histological anaplasia and exuberant proliferation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17138070",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17138070",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Familial glioblastoma multiforme is a rather uncommon entity, being in most cases associated to known genetic disorders (as Turcot syndrome, Li-Fraumeni syndrome, neurofibromatosis, etc.). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960645",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 331,
                    "text": "Turcot syndrome (MIM276300) has been described as the association of central nervous system malignant tumors and familial colorectal cancer and has been reported to be both a dominant and recessive disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16000562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1380,
                    "offsetInEndSection": 1568,
                    "text": "We report here the first identification of a homozygous mutation in MSH6 in a family with childhood-onset brain tumor, lymphoma, colorectal cancer, and neurofibromatosis type 1 phenotype. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16000562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1141,
                    "offsetInEndSection": 1388,
                    "text": "Of the 21 patients, 12 have died (10 after relapse, with a median time to progression for the whole series of 14 months; one with intratumoral bleeding at 40 months after diagnosis; and one affected by Turcot syndrome for duodenal cancer relapse).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701281",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "[Glioblastoma multiforme as a manifestation of Turcot syndrome].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975096",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 451,
                    "text": "In the present case, a 60-year-old patient with glioblastoma multiforme and a history of hereditary malignomas is described as an example of a HNPCC-associated Turcot's syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 426,
                    "text": "Computed tomography brain scan and computed tomography-guided biopsy revealed a left frontoparietal glioblastoma multiforme. This case illustrates the rare presentation of Turcot syndrome-a hereditary colorectal polyposis syndrome-in an older adult.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11907360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Turcot syndrome is the association of colorectal polyposis with primary neuroepithelial tumors of the central nervous system such as glioblastoma and medulloblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10921328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 771,
                    "offsetInEndSection": 879,
                    "text": "Brain tumor is mainly diagnosed as glioblastoma or astrocytoma and mismatch repair genes might be involved. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10921328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 348,
                    "text": "Patients with Turcot syndrome (TS) are predisposed to colon tumors and primary brain tumors, typically glioblastomas or medulloblastomas. The authors describe a patient with TS featuring a known germline mutation of exon 5 of the hPMS2 mismatch repair gene who developed two metachronous glioblastomas, both with distinct oligodendroglial features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10223463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 831,
                    "text": "Because this patient had an unusual underlying condition and his tumor had a unique histological appearance for TS, it was hypothesized that this genetic defect may predispose to malignant gliomas with oligodendroglial features. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10223463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 407,
                    "text": "Turcot Syndrome caused by APC gene develops medulloblastoma and Turcot Syndrome caused by mismatch repair gene develops glioblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9695069",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 271,
                    "text": "It is characterized by central nervous system (CNS) neoplasms and gastrointestinal polyposis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9508118",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 563,
                    "text": "Seven months after resection of this Dukes' C2 adenocarcinoma, she presented with a second primary CNS tumor, a glioblastoma multiforme.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9508118",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "The Turcot syndrome has been defined as the simultaneous presence of multiple polyposis of the colon and a malignant brain tumor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 485,
                    "text": "The case of a 47-year-old man submitted to a right hemicolectomy for cancer and polyposis, following a series of endoscopic polypectomies and, finally, removal of left temporal glioma is here presented.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2254,
                    "offsetInEndSection": 2381,
                    "text": " Two of 13 showed microsatellite instability, one of which in a patient with Turcot syndrome, the other in gliomatosis cerebri.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9343324",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "The Turcot syndrome (TS) is a rare, probably autosomal recessive, disorder characterized by development of primary neuroepithelial tumors of the central nervous system (CNS) and numerous adenomatous colorectal polyps. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7515658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 857,
                    "text": "However, no somatic mutations in APC were found among 91 neuroepithelial tumors (medulloblastoma, glioblastoma, astrocytoma, and oligodendroglioma), whether sporadic or associated with TS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7515658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 378,
                    "text": "Such syndromes include neurofibromatosis type 2, neurofibromatosis type 1, Li-Fraumeni syndrome, as well as von Hippel-Lindau disease, tuberous sclerosis, and Turcot syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8025896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 76,
                    "offsetInEndSection": 242,
                    "text": "This patient's case deals with the association between a glioblastoma, anaplastic glioma (WHO Grade III) and colonic adenocarcinoma based on familial polyposis coli. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8127448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "The authors describe two patients with the association of polyposis-coli and central nervous system tumor (Turcot's syndrome). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2165772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "We report a case of Turcot's syndrome in a 20-year old man with multiple adenomatous polyps of the colon and glioblastoma multiforme. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2540108",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "Another unusual autopsy case of the Turcot syndrome is reported in a 23-year-old woman with polyposis coli, who developed primary carcinoma of the jejunum and glioblastoma multiforme of the left frontal lobe. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6307612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 291,
                    "text": "Turcot syndrome represents the unique and discrete occurrence of polyposis coli with glioblastoma multiforme, medulloblastoma, or both.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6274254",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Sarcolipin a regulatory/inhibitory protein of the Calcium ATPase SERCA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                "http://www.ncbi.nlm.nih.gov/pubmed/17515962",
                "http://www.ncbi.nlm.nih.gov/pubmed/18081313",
                "http://www.ncbi.nlm.nih.gov/pubmed/12237298",
                "http://www.ncbi.nlm.nih.gov/pubmed/20833651",
                "http://www.ncbi.nlm.nih.gov/pubmed/12032137",
                "http://www.ncbi.nlm.nih.gov/pubmed/22561503",
                "http://www.ncbi.nlm.nih.gov/pubmed/22496245",
                "http://www.ncbi.nlm.nih.gov/pubmed/16036219",
                "http://www.ncbi.nlm.nih.gov/pubmed/16365042",
                "http://www.ncbi.nlm.nih.gov/pubmed/17971438",
                "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                "http://www.ncbi.nlm.nih.gov/pubmed/19631655",
                "http://www.ncbi.nlm.nih.gov/pubmed/15556994",
                "http://www.ncbi.nlm.nih.gov/pubmed/22961106",
                "http://www.ncbi.nlm.nih.gov/pubmed/23455424",
                "http://www.ncbi.nlm.nih.gov/pubmed/21697544",
                "http://www.ncbi.nlm.nih.gov/pubmed/23341466"
            ],
            "ideal_answer": [
                "Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR) and it is a newly identified regulator of the sarco/endoplasmic reticulum Ca(2+)-ATPase (Serca) pump.  SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure. Sarcolipin is a key regulator of SERCA2a in atria.",
                "Sarcolipin (SLN) has emerged as an important regulator of the atrial sarcoplasmic reticulum (SR) Ca2+ transport.Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR). It has 31 amino acid residues; SLN and phopholamban (PLB) are belong to the same protein family, so they have similar physiological functions. SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4264789",
                "http://www.uniprot.org/uniprot/SARCO_MOUSE",
                "http://www.uniprot.org/uniprot/SARCO_HUMAN",
                "http://www.uniprot.org/uniprot/SARCO_RAT",
                "http://www.uniprot.org/uniprot/SARCO_RABIT",
                "http://www.uniprot.org/uniprot/AT2A_CHIOP",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053498"
            ],
            "type": "yesno",
            "id": "55016397e9bde69634000006",
            "snippets": [
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 896,
                    "text": "The activity of SERCA is regulated by two small, homologous membrane proteins called phospholamban (PLB, also known as PLN) and sarcolipin (SLN). Detailed structural information explaining this regulatory mechanism has been lacking, and the structural features defining the pathway through which cytoplasmic Ca(2+) enters the intramembranous binding sites of SERCA have remained unknown.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23455424",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 265,
                    "text": "Sarco(endo)plasmic reticulum Ca(2+)ATPase (SERCA) pump activity is modulated by phospholamban (PLB) and sarcolipin (SLN) in cardiac and skeletal muscle. Recent data suggest that SLN could play a role in muscle thermogenesis by promoting uncoupling of the SERCA pump",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23341466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 88,
                    "offsetInEndSection": 260,
                    "text": "Here we show that sarcolipin (Sln), a newly identified regulator of the sarco/endoplasmic reticulum Ca(2+)-ATPase (Serca) pump, is necessary for muscle-based thermogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22961106",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 397,
                    "text": "Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR). It has 31 amino acid residues; SLN and phopholamban (PLB) are belong to the same protein family, so they have similar physiological functions. SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Sarcolipin (SLN) is a key regulator of sarco(endo)plasmic reticulum (SR) Ca(2+)-ATPase (SERCA), and its expression is altered in diseased atrial myocardium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1233,
                    "offsetInEndSection": 1433,
                    "text": "Together, these findings indicate that ablation of SLN results in increased SERCA activity and SR Ca(2+) load, which, in turn, could cause abnormal intracellular Ca(2+) handling and atrial remodeling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Sarcolipin (SLN) inhibits sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA) pumps.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697544",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1552,
                    "offsetInEndSection": 1909,
                    "text": "These results show that 1) SLN regulates Ca(2+)-ATPase activity thereby regulating contractile kinetics in at least some skeletal muscles, 2) the functional significance of SLN is graded to the endogenous SLN expression level, and 3) SLN inhibitory effects on SERCA function are relieved in response to repeated contractions thus enhancing relaxation rates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697544",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 684,
                    "text": "The SERCA pump was constitutively activated in both atrial and ventricular chambers of the mouse heart by ablating its key regulators, phospholamban (PLN) and sarcolipin (SLN). The double-knockout (dKO) mice for PLN and SLN showed increased SERCA pump activity, Ca(2+) transients and SR Ca(2+) load, and developed cardiac hypertrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833651",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1006,
                    "offsetInEndSection": 1194,
                    "text": "Our findings also emphasize the need for dynamic regulation of the SERCA pump by PLN and/or SLN to maintain cardiac contractility in normal conditions and during pathophysiological states.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833651",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Sarcolipin (SLN) has emerged as an important regulator of the atrial sarcoplasmic reticulum (SR) Ca2+ transport.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631655",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 281,
                    "text": "The inhibitory effect of SLN on cardiac SR Ca2+ ATPase (SERCA) pump can be relieved by beta-adrenergic stimulation, which indicates that SLN is a reversible inhibitor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631655",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Sarcolipin is a novel regulator of cardiac sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) and is expressed abundantly in atria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1054,
                    "offsetInEndSection": 1249,
                    "text": "Our study documented that sarcolipin is a key regulator of SERCA2a in atria. Importantly, our data demonstrate the existence of distinct modulators for the SERCA pump in the atria and ventricles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 494,
                    "text": "Sarcoplasmic reticulum (SR) Ca(2+) ATPase (SERCA) is a membrane protein that catalyzes the ATP-dependent transport of Ca(2+) from the cytosol to the SR. The activity of SERCA is inhibited by phospholamban (PLN) and sarcolipin (SLN), and all these proteins participate in maintaining the normal intracellular calcium handling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17515962",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "Sarcolipin (SLN) is an integral membrane protein that is expressed in both skeletal and cardiac muscle, where it inhibits SERCA (calcium ATPase) by lowering its apparent Ca2+ affinity in a manner similar to that of its homologue phospholamban (PLN).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1061,
                    "offsetInEndSection": 1271,
                    "text": "Remarkably, each domain of SLN behaves in a manner similar to that of the corresponding domains in PLN, supporting the hypothesis that both SLN and PLN bind SERCA in the same groove and with similar mechanisms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 516,
                    "text": "The role of sarcolipin (SLN) in cardiac physiology was critically evaluated by generating a transgenic (TG) mouse model in which the SLN to sarco(endoplasmic)reticulum (SR) Ca(2+) ATPase (SERCA) ratio was increased in the ventricle. Overexpression of SLN decreases SR calcium transport function and results in decreased calcium transient amplitude and rate of relaxation. SLN TG hearts exhibit a significant decrease in rates of contraction and relaxation when assessed by ex vivo work-performing heart preparations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16365042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1160,
                    "offsetInEndSection": 1296,
                    "text": "We conclude that SLN is a novel regulator of SERCA pump activity, and its inhibitory effect can be reversed by beta-adrenergic agonists.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16365042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Sarcolipin, a homologue of phospholamban, regulates Ca2+ uptake through the interaction with sarcoplasmic reticulum Ca2+ ATPase (SERCA) and is predominantly expressed in the atrial muscle.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16036219",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Sarcolipin (SLN) and phospholamban (PLN) are effective inhibitors of the sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15556994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1450,
                    "text": "These results show that NF-SLN expression impairs muscle contractile function by inhibiting SERCA function and diminishing sarcoplasmic reticulum Ca(2+) stores.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12237298",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 299,
                    "text": "Sarcolipin (SLN) is an inhibitor of sarco(endo)plasmic reticulum Ca(2+)-ATPases (SERCAs) in vitro, but its function in vivo has not been defined. NF-SLN cDNA (SLN tagged N-terminally with a FLAG epitope) was introduced into rat soleus muscle in one hindlimb by plasmid injection and electrotransfer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12237298",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "Sarcolipin (SLN), a regulator of the sarco(endo)plasmic reticulum Ca(2+)-ATPase of fast-twitch skeletal muscle (SERCA1a), is also expressed in cardiac and slow-twitch skeletal muscles where phospholamban (PLN) and SERCA2a are expressed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12032137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Sarco(endo)plasmic reticulum calcium ATPase (SERCA) inhibition by sarcolipin is encoded in its luminal tail.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "The sarco(endo)plasmic reticulum calcium ATPase (SERCA) is regulated in a tissue-dependent manner via interaction with the short integral membrane proteins phospholamban (PLN) and sarcolipin (SLN).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "Phospholamban (PLN) and sarcolipin (SLN) are two single-pass membrane proteins that regulate Ca2+-ATPase (SERCA), an ATP-driven pump that translocates calcium ions into the lumen of the sarcoplasmic reticulum, initiating muscle relaxation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18081313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "The sarco(endo)plasmic reticulum calcium ATPase (SERCA) is regulated in a tissue-dependent manner via interaction with the short integral membrane proteins phospholamban (PLN) and sarcolipin (SLN)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23362265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "[Research progress of sarcolipin-a new regulatory protein of sarcoplasmic reticulum Ca2+ ATPase].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561503",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 238,
                    "text": "Phospholamban (PLN) and sarcolipin (SLN) are two single-pass membrane proteins that regulate Ca2+-ATPase (SERCA), an ATP-driven pump that translocates calcium ions into the lumen of the sarcoplasmic reticulum, initiating muscle relaxation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18081313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "text": "Sarcolipin (SLN) is an integral membrane protein that is expressed in both skeletal and cardiac muscle, where it inhibits SERCA (calcium ATPase) by lowering its apparent Ca2+ affinity in a manner similar to that of its homologue phospholamban (PLN)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16519897",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has MLE4901 been tested in phase III clinical trials?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28385352"
            ],
            "ideal_answer": [
                "No, MLE4901 has been tested in phase 2, randomised, double-blind, placebo-controlled trial."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e5437ffb761aafe09000002",
            "snippets": [
                {
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 533,
                    "text": "METHODS\n\nThis phase 2, randomised, double-blind, placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal hot flushes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385352",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385352",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine produced by different companies?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27457797"
            ],
            "ideal_answer": [
                "No, the Fluzone Intradermal vaccine and the Fluzone Intradermal Quadrivalent vaccine are produced by Sanofi Pasteur."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e7f5cc5835f4e4777000015",
            "snippets": [
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 569,
                    "text": "An intradermal version of Fluzone\u00ae split-virion inactivated trivalent influenza vaccine, containing 9\u00a0\u00b5g hemagglutinin per strain of A/H1N1, A/H3N2, and one B lineage virus (Fluzone Intradermal, Sanofi Pasteur), became available in the US during the 2011-2012 influenza season for adults 18-64\u00a0years of age. In advance of the 2015-2016 season, Fluzone Intradermal was replaced with Fluzone Intradermal Quadrivalent vaccine, which contains 9\u00a0\u00b5g hemagglutinin per strain of the two A-strain viruses and both B-strain lineage viruses (Victoria and Yamagata).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27457797",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is pregabalin effective for treatment of patients with restless leg syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23859128",
                "http://www.ncbi.nlm.nih.gov/pubmed/22851801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18656214",
                "http://www.ncbi.nlm.nih.gov/pubmed/24521108",
                "http://www.ncbi.nlm.nih.gov/pubmed/17489946",
                "http://www.ncbi.nlm.nih.gov/pubmed/23746768",
                "http://www.ncbi.nlm.nih.gov/pubmed/24363103",
                "http://www.ncbi.nlm.nih.gov/pubmed/23385700",
                "http://www.ncbi.nlm.nih.gov/pubmed/22937989",
                "http://www.ncbi.nlm.nih.gov/pubmed/24119681",
                "http://www.ncbi.nlm.nih.gov/pubmed/23304742",
                "http://www.ncbi.nlm.nih.gov/pubmed/20466589",
                "http://www.ncbi.nlm.nih.gov/pubmed/24899755",
                "http://www.ncbi.nlm.nih.gov/pubmed/22570552",
                "http://www.ncbi.nlm.nih.gov/pubmed/20427750",
                "http://www.ncbi.nlm.nih.gov/pubmed/23771546",
                "http://www.ncbi.nlm.nih.gov/pubmed/23703310",
                "http://www.ncbi.nlm.nih.gov/pubmed/23524988"
            ],
            "ideal_answer": [
                "Yes, numerous evidence from clinical trials indicate that pregabalic is effective for treatment of patients diagnosed with restless leg syndrome."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4236113"
            ],
            "type": "yesno",
            "id": "54cf4a0ef693c3b16b00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 1504,
                    "offsetInEndSection": 1784,
                    "text": "CONCLUSIONS: This study demonstrated improvements in objective and subjective measures of sleep maintenance and sleep architecture with pregabalin compared with placebo and pramipexole. Effects of pregabalin on periodic limb movement arousal index were comparable to pramipexole. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24899755",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2175,
                    "offsetInEndSection": 2372,
                    "text": "CONCLUSIONS: Pregabalin provided significantly improved treatment outcomes as compared with placebo, and augmentation rates were significantly lower with pregabalin than with 0.5 mg of pramipexole.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521108",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1095,
                    "offsetInEndSection": 1318,
                    "text": "The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24363103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 905,
                    "text": "Pregabalin has been established as effective for up to 1 year in treating RLS/WED (Level A evidence). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859128",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2827,
                    "offsetInEndSection": 2982,
                    "text": "In the group of anticonvulsants, only the trials performed with \u03b1\u2082\u03b4 ligands such as gabapentin, gabapentin enacarbil, and pregabalin showed good efficacy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1395,
                    "offsetInEndSection": 1619,
                    "text": "Alternative or additional pharmacologic treatment with a lower level of overall quality of evidence includes opioids (codeine, tramadol, and oxycodone) and anticonvulsants (gabapentin, gabapentin enacarbil, and pregabalin). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 1116,
                    "text": "There is sufficient evidence to conclude that dopamine agonists such as rotigotine transdermal patch, pramipexole, ropinirole, gabapentin enacarbil, pregabalin and gabapentin are effective in the short-term treatment of RLS and rotigotine, followed by gabapentin enacarbil, ropinirole, pramipexole and gabapentin for long-term treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23524988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 818,
                    "text": "Calcium channel alpha-2-delta ligands (gabapentin, gabapentin enacarbil, and pregabalin) provide alternative therapies for RLS especially in patients with augmentation, impulse control disorders, or hypersomnia induced by dopamine agonists. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2129,
                    "offsetInEndSection": 2381,
                    "text": "Alpha-2-delta ligands (gabapentin enacarbil, gabapentin, and pregabalin) increased the number of IRLS responders (RR=1.66; [95% CI: 1.33 to 2.09], k=3, high strength of evidence) and mean change in IRLS symptom scores (k=3, high strength of evidence). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23304742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1193,
                    "offsetInEndSection": 1408,
                    "text": "RECOMMENDATIONS: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 810,
                    "text": "Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22851801",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1565,
                    "text": "CONCLUSIONS: In this 6-week phase 2b study, pregabalin reduced RLS symptoms in patients with moderate-to-severe idiopathic RLS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20466589",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1974,
                    "offsetInEndSection": 2206,
                    "text": "CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that pregabalin is effective for the treatment of restless legs syndrome and improves sleep architecture and periodic limb movements in placebo-unresponsive patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427750",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2493,
                    "offsetInEndSection": 2634,
                    "text": "In severe, refractory or neuropathy-associated RLS, antiepileptic (gabapentin, pregabalin) or opioid (oxycodone, tramadol) drugs can be used.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18656214",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1094,
                    "offsetInEndSection": 1315,
                    "text": "The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24363103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1935,
                    "offsetInEndSection": 2139,
                    "text": "This study provides Class II evidence that pregabalin is effective for the treatment of restless legs syndrome and improves sleep architecture and periodic limb movements in placebo-unresponsive patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427750",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1163,
                    "offsetInEndSection": 1360,
                    "text": "Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the protein lefty an inhibitor of nodal?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26506307",
                "http://www.ncbi.nlm.nih.gov/pubmed/25669884",
                "http://www.ncbi.nlm.nih.gov/pubmed/25672326",
                "http://www.ncbi.nlm.nih.gov/pubmed/25684355",
                "http://www.ncbi.nlm.nih.gov/pubmed/26377939"
            ],
            "ideal_answer": [
                "Yes, lefty is an inhibitor of nodal."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "58a93877ee23e0236b000001",
            "snippets": [
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 178,
                    "text": "The expression of lefty, an inhibitor of nodal is often reduced in tumor cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25672326",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 416,
                    "text": " Nodal, and an inhibitor, Lefty.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684355",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1029,
                    "offsetInEndSection": 1097,
                    "text": "as well as the expression of Lefty, an inhibitor of nodal signaling,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26377939",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 648,
                    "text": "he Nodal inhibitor lefty",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 367,
                    "text": "The morphogen Nodal was proposed to form a long-range signaling gradient via a reaction-diffusion system, on the basis of differential diffusion rates of Nodal and its antagonist Lefty.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26506307",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can Alzheimer's disease related miRNAs be detected in patients' blood?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23030236",
                "http://www.ncbi.nlm.nih.gov/pubmed/23054683",
                "http://www.ncbi.nlm.nih.gov/pubmed/21548758",
                "http://www.ncbi.nlm.nih.gov/pubmed/22155483",
                "http://www.ncbi.nlm.nih.gov/pubmed/23435408",
                "http://www.ncbi.nlm.nih.gov/pubmed/23528227",
                "http://www.ncbi.nlm.nih.gov/pubmed/21709374",
                "http://www.ncbi.nlm.nih.gov/pubmed/19936094"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/10477709",
                    "o": "Blood"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/10339464",
                    "o": "http://purl.uniprot.org/pubmed/10339464"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/10572112",
                    "o": "Blood"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/11110714",
                    "o": "Blood"
                }
            ],
            "ideal_answer": [
                "Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001773",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001798",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016229",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023582",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544"
            ],
            "type": "yesno",
            "id": "5156beb4d24251bc05000089",
            "snippets": [
                {
                    "offsetInBeginSection": 469,
                    "offsetInEndSection": 783,
                    "text": "miRNAs are aberrantly expressed in AD, and these have been implicated in the regulation of amyloid-\u03b2 (A\u03b2) peptide, tau, inflammation, cell death, and other aspects which are the main pathomechanisms of AD. In addition, regulation of miRNAs varies in blood, and cerebral spinal fluid may indicate alterations in AD.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23054683",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 407,
                    "text": "miRNA microarray analysis was carried out on blood of rats at 1 week and 2 months after injection. RESULTS: Many up- and downregulated miRNAs were detected.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030236",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 712,
                    "text": "Blood miRNAs could be useful as biomarkers for exposure to nanoparticles. miR-298 regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1) in Alzheimer's disease.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030236",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 484,
                    "text": " We previously studied microRNAs (miRNAs) in AD autopsy brain samples and reported a connection between miR-137, -181c, -9, -29a/b and AD, through the regulation of ceramides. In this study, the potential role of these miRNAs as diagnostic markers for AD was investigated. We identified that these miRNAs were down-regulated in the blood serum of probable AD patients. ",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155483",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 399,
                    "text": "287 with Alzheimer disease (AD) as compared with 344 age- and gender-matched controls. In addition, we evaluated expression levels of hnRNP-A1 and its regulatory microRNA (miR)-590-3p in blood cells from patients and controls.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548758",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1470,
                    "text": "Decreased relative expression levels of hsa-miR-590-3p was observed in patients with AD versus controls (0.685\u2009\u00b1\u20090.080 versus 0.931\u2009\u00b1\u20090.111, p\u2009=\u20090.079), and correlated negatively with hnRNP-A1 mRNA levels (r\u2009=\u2009-0.615, p\u2009=\u20090.0237).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548758",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 809,
                    "text": "expression analysis of Sp1 and its regulatory microRNAs (hsa-miR-29b and hsa-miR-375) has been performed in peripheral blood mononuclear cells (PBMCs), together with Sp1 protein analysis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1308,
                    "offsetInEndSection": 1427,
                    "text": "Significantly decreased relative expression levels of hsa-miR-29b, but not of hsa-miR-375, were observed in AD patients",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1520,
                    "offsetInEndSection": 1684,
                    "text": "Sp1 and its regulatory hsa-miR-29b are deregulated in AD patients, possibly leading to aberrant production of downstream target genes involved in the pathogenesis. ",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 863,
                    "offsetInEndSection": 1282,
                    "text": "We previously observed that miR-137, -181c, -9, and 29a/b post-transcriptionally regulate SPT levels, and the corresponding miRNA levels in the blood sera are potential diagnostic biomarkers for AD. Here, we observe a negative correlation between cortical A\u03b242 and sera A\u03b242, and a positive correlation between cortical miRNA levels and sera miRNA levels suggesting their potential as noninvasive diagnostic biomarkers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528227",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Can the Micro-C XL method achieve mononucleosome resolution?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27723753"
            ],
            "ideal_answer": [
                "Yes. Micro-C XL is an improved method for analysis of chromosome folding at mononucleosome resolution."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "587dfde9ae05ffb474000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Micro-C XL: assaying chromosome conformation from the nucleosome to the entire genome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 538,
                    "text": "Micro-C XL provides a single assay to interrogate chromosome folding at length scales from the nucleosome to the full genome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the abnormal dosage of ultraconserved elements disfavored in cancer cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25340765"
            ],
            "ideal_answer": [
                "No. Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:162"
            ],
            "type": "yesno",
            "id": "56c0708eef6e39474100001f",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 1335,
                    "text": "We begin by showing that depletion for UCEs characterizes the most recent large-scale human CNV datasets and then find that even newly formed de novo CNVs, which have passed through meiosis at most once, are significantly depleted for UCEs. In striking contrast, CNVs arising specifically in cancer cells are, as a rule, not depleted for UCEs and can even become significantly enriched. This observation raises the possibility that CNVs that arise somatically and are relatively newly formed are less likely to have established a CNV profile that is depleted for UCEs. Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state. In support of this latter explanation, somatic CNVs that are not associated with disease are depleted for UCEs. Finally, we show that it is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time, suggesting that depletion may be established through selection against UCE-disrupting CNVs without the requirement for meiotic divisions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 954,
                    "text": "Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is microRNA(miRNA) 29 involved in post-ischemic cardiac remodeling?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20971881",
                "http://www.ncbi.nlm.nih.gov/pubmed/20959496",
                "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                "http://www.ncbi.nlm.nih.gov/pubmed/20733099",
                "http://www.ncbi.nlm.nih.gov/pubmed/18723672"
            ],
            "ideal_answer": [
                "miRNA 29 is involved in post-ischemic myocardial remodeling in particular in the peri-infarctual zone.  miRNA 29 produces apoptosis and enhances fibrotic response."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0035196",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010586",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010587",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
            ],
            "type": "yesno",
            "id": "513f4025bee46bd34c000011",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "Myocardial ischaemia/reperfusion (I/R)-induced remodelling generally includes cell death (necrosis and apoptosis), myocyte hypertrophy, angiogenesis, cardiac fibrosis, and myocardial dysfunction. I",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 590,
                    "offsetInEndSection": 754,
                    "text": "In addition, miR-21, -24, -133, -210, -494, and -499 appear to protect myocytes against I/R-induced apoptosis, whereas miR-1, -29, -199a, and -320 promote apoptosis",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 813,
                    "text": "Myocardial fibrosis can be regulated by the miR-29 family",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1053,
                    "text": "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20959496",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 620,
                    "offsetInEndSection": 1357,
                    "text": "Among the MI-regulated miRNAs are members of the miR-29 family, which are down-regulated in the region of the heart adjacent to the infarct. The miR-29 family targets a cadre of mRNAs that encode proteins involved in fibrosis, including multiple collagens, fibrillins, and elastin. Thus, down-regulation of miR-29 would be predicted to derepress the expression of these mRNAs and enhance the fibrotic response. Indeed, down-regulation of miR-29 with anti-miRs in vitro and in vivo induces the expression of collagens, whereas over-expression of miR-29 in fibroblasts reduces collagen expression. We conclude that miR-29 acts as a regulator of cardiac fibrosis and represents a potential therapeutic target for tissue fibrosis in general.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18723672",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24458521"
            ],
            "ideal_answer": [
                "Compared to age-matched controls, fibronectin levels in DMD patients were found to be significantly increased, whereas in patients with Becker muscular dystrophy, Bethlem myopathy, or myasthenia gravis were close to the control levels. Additionally, progressive elevation in fibronectin levels was observed in longitudinal samples from DMD patients followed up for a period of 6 months up to 4 years. Therefore, fibronectin is a serum biomarker for Duchenne muscular dystrophy.",
                "Fibronectin is a serum biomarker for Duchenne muscular dystrophy"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5715c16dcb4ef8864c000004",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Fibronectin is a serum biomarker for Duchenne muscular dystrophy",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 792,
                    "offsetInEndSection": 1186,
                    "text": "There was a significant increase in fibronectin levels in DMD patients compared to age-matched controls. Fibronectin levels in patients with Becker muscular dystrophy, Bethlem myopathy, or myasthenia gravis were comparable to control levels. Progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1222,
                    "offsetInEndSection": 1355,
                    "text": "This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Fibronectin is a serum biomarker for Duchenne muscular dystrophy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1034,
                    "offsetInEndSection": 1356,
                    "text": "Progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years.CONCLUSION AND CLINICAL RELEVANCE: This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 755,
                    "offsetInEndSection": 859,
                    "text": "There was a significant increase in fibronectin levels in DMD patients compared to age-matched controls.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 997,
                    "offsetInEndSection": 1150,
                    "text": "Progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1285,
                    "text": "This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1286,
                    "text": "Progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years. This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1381,
                    "text": "This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients. \u00a9 2014 The Authors PROTEOMICS - Clinical Applications Published by Wiley-VCH Verlag GmbH & Co.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 997,
                    "text": "There was a significant increase in fibronectin levels in DMD patients compared to age-matched controls. Fibronectin levels in patients with Becker muscular dystrophy, Bethlem myopathy, or myasthenia gravis were comparable to control levels.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 1151,
                    "text": "Fibronectin levels in patients with Becker muscular dystrophy, Bethlem myopathy, or myasthenia gravis were comparable to control levels. Progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Fibronectin is a serum biomarker for Duchenne muscular dystrophy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1286,
                    "text": "This study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458521",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can Systemic Lupus Erythematosus cause seizures?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18813701",
                "http://www.ncbi.nlm.nih.gov/pubmed/15985581",
                "http://www.ncbi.nlm.nih.gov/pubmed/22492779",
                "http://www.ncbi.nlm.nih.gov/pubmed/28387089",
                "http://www.ncbi.nlm.nih.gov/pubmed/15557494",
                "http://www.ncbi.nlm.nih.gov/pubmed/17875548",
                "http://www.ncbi.nlm.nih.gov/pubmed/29208845",
                "http://www.ncbi.nlm.nih.gov/pubmed/29103182"
            ],
            "ideal_answer": [
                "In the extant literature, an increased risk of seizures has been described in several inflammatory/autoimmune disorders, including systemic lupus erythematosus (SLE)",
                "Yes, Systemic Lupus Erythematosus s an autosomal recessive disorder can cause seizures.",
                "Yes, Seizure can be caused by Systemic Lupus Erythematosus."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e4c06d96d0a27794100002e",
            "snippets": [
                {
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 852,
                    "text": "The mean \u00b1 SD age at SLE diagnosis and at onset of PRES was 25.02 \u00b1 13.78 and 28.31 \u00b1 12.61\u00a0years, respectively. Seizure was the most common presenting symptom, as seen in 28 episodes, followed by acute severe headache in 17,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29103182",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 254,
                    "text": "Epilepsy is characterized by a relevant epidemiological and clinical burden. In the extant literature, an increased risk of seizures has been described in several inflammatory/autoimmune disorders, including systemic lupus erythematosus (SLE).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29208845",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Seizures are one of the most serious neuropsychiatric manifestations of systemic lupus erythematous (SLE). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28387089",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "The aim of this study was to describe the frequency , attribution , outcome and predictors of seizures in systemic lupus erythematosus ( SLE",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492779",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "OBJECTIVE\nTo evaluate the frequency and risk factors of epileptic seizures in a large cohort of patients with systemic lupus erythematosus (SLE).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15557494",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 586,
                    "text": "Epileptic seizures occurred at the onset of SLE symptoms in 19 (31.6%) and after the onset of SLE in 41 of 60 (68.3%) patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15557494",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Epileptic seizures and EEG features in juvenile systemic lupus erythematosus.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18813701",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1164,
                    "offsetInEndSection": 1266,
                    "text": "CONCLUSIONS\nEpileptic seizures were observed in 11.2% of systemic lupus erythematosus (SLE) patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15557494",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1411,
                    "offsetInEndSection": 1533,
                    "text": "CONCLUSIONS\nSeizures tend to occur early in the course of systemic lupus erythematosus, and contribute to damage accrual.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17875548",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1379,
                    "offsetInEndSection": 1488,
                    "text": "Seizures tend to occur early in the course of systemic lupus erythematosus, and contribute to damage accrual.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17875548",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "To determine the factors associated with seizures in systemic lupus erythematosus (SLE).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985581",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1424,
                    "offsetInEndSection": 1527,
                    "text": "Neurologic manifestations, in special epileptic seizures, are frequent in systemic lupus erythematosus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18813701",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can TAD disruption lead to disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27111891",
                "http://www.ncbi.nlm.nih.gov/pubmed/28408976",
                "http://www.ncbi.nlm.nih.gov/pubmed/30086749",
                "http://www.ncbi.nlm.nih.gov/pubmed/29990539",
                "http://www.ncbi.nlm.nih.gov/pubmed/30241613",
                "http://www.ncbi.nlm.nih.gov/pubmed/30374058",
                "http://www.ncbi.nlm.nih.gov/pubmed/26862051",
                "http://www.ncbi.nlm.nih.gov/pubmed/22495304",
                "http://www.ncbi.nlm.nih.gov/pubmed/25959774"
            ],
            "ideal_answer": [
                "TAD boundaries are insulators of genomic neighborhoods. \u03a4he disruption of these structures by genomic rearrangements can result in gene misexpression and disease.",
                "We discuss how the disruption of these structures by genomic rearrangements can result in gene misexpression and disease."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ca61176ecadf2e73f00004e",
            "snippets": [
                {
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 954,
                    "text": "its perturbation will lead to human disease, highlighting the accumulating evidence that links the diverse 3D genome architecture components to a multitude of human diseases and the emerging mechanisms by which 3D genome derangement causes disease phenotypes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29990539",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "text": "TAD boundaries are insulators of genomic neighborhoods. In this issue, Sun et\u00a0al. show that disease-associated tandem repeats are located to TAD boundaries and affect their insulation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30241613",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 773,
                    "text": "Recent studies of TAD boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter-enhancer interactions in the affected TADs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 941,
                    "text": "Similar boundary disruptions in certain cancers can result in oncogene overexpression, and CTCF binding sites at boundaries appear to be hyper-mutated across cancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 546,
                    "text": "the disruption of these structures by genomic rearrangements can result in gene misexpression and disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26862051",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 35,
                    "text": "TAD disruption as oncogenic driver.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 409,
                    "text": "Recent studies have shown that TAD disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 277,
                    "text": "Disruption of TAD boundaries results in aberrant gene expression by exposing genes to inappropriate regulatory elements.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 625,
                    "text": "However, it is not clear to which extent TAD regions are conserved in evolution and whether disruption of TADs by evolutionary rearrangements can alter gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 239,
                    "offsetInEndSection": 409,
                    "text": "Disruption of this organization by structural variations can lead to ectopic interactions between enhancers and promoters, and to alteration of genes expression patterns.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374058",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 456,
                    "text": "Disruption of TADs can result in altered gene expression and is associated to genetic diseases and cancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Deletion in 2q35 excluding the IHH gene leads to fetal severe limb anomalies and suggests a disruption of chromatin architecture.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374058",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 315,
                    "text": "We demonstrate that disruption of TADs can rewire long-range regulatory architecture and result in pathogenic phenotypes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959774",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 312,
                    "text": "Disruption of TAD boundaries results in aberrant gene expression by exposing genes to inappropriate regulatory elements. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 583,
                    "text": "Disruption of TADs can result in altered gene expression and is associated to genetic diseases and cancers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1187,
                    "text": "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 854,
                    "text": "Recent studies of TAD boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter-enhancer interactions in the affected TADs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 444,
                    "text": "Recent studies have shown that TAD disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 538,
                    "text": "Disruption of this organization by structural variations can lead to ectopic interactions between enhancers and promoters, and to alteration of genes expression patterns. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374058",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1021,
                    "text": "Similar boundary disruptions in certain cancers can result in oncogene overexpression, and CTCF binding sites at boundaries appear to be hyper-mutated across cancers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 584,
                    "offsetInEndSection": 752,
                    "text": "However, it is not clear to which extent TAD regions are conserved in evolution and whether disruption of TADs by evolutionary rearrangements can alter gene expression. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is PRDM9 essential for meiosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29674518",
                "http://www.ncbi.nlm.nih.gov/pubmed/19997497",
                "http://www.ncbi.nlm.nih.gov/pubmed/24634223",
                "http://www.ncbi.nlm.nih.gov/pubmed/23190393",
                "http://www.ncbi.nlm.nih.gov/pubmed/30161134",
                "http://www.ncbi.nlm.nih.gov/pubmed/29478809"
            ],
            "ideal_answer": [
                "PRDM9 is essential for the progression through early meiotic prophase, including double strand break repair, homologous chromosome pairing, and sex body formation during spermatogenesis.",
                "In aggregate, our data indicate that domains typically involved in regulation of gene expression do not serve that role in PRDM9, but are likely involved in setting the proper chromatin environment for initiation and completion of homologous recombination. PRDM9 Methyltransferase Activity Is Essential for Meiotic DNA Double-Strand Break Formation at Its Binding Sites.",
                "yes, Our findings do not identify the nature of the underlying DNA sequences, but argue against the proposed role of Prdm9 as an essential transcription factor in mouse meiosis",
                "Prdm9, is a meiosis-specific protein that trimethylates h3k4 and controls the activation of recombination hot spots. It is an essential enzyme in the progression of early meiotic prophase.",
                "Yes. PRDM9 is an evolutionarily conserved protein that is essential for meiosis.",
                "In many eukaryotes, sites of meiotic recombination, also called hotspots, are regions of accessible chromatin, but in many vertebrates, their location follows a distinct pattern and is specified by PR domain-containing protein 9 (PRDM9). PRDM9 Methyltransferase Activity Is Essential for Meiotic DNA Double-Strand Break Formation at Its Binding Sites.",
                "Yes, PRDM9 is essential for meiosis.",
                "Yes. PRDM9 is an RNA-binding protein that is essential for meiosis.",
                "Yes. PRDM9 is an essential factor for meiosis.",
                "PRDM9 Methyltransferase Activity Is Essential for Meiotic DNA Double-Strand Break Formation at Its Binding Sites.",
                "PRDM9 is essential for the progression through early meiotic prophase, including double strand break repair, homologous chromosome pairing, and sex body formation during spermatogenesis. PRDM9 (PR domain-containing protein 9) is a meiosis-specific protein that trimethylates H3K4 and controls the activation of recombination hot spots."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d3856ca7bc3fee31f000016",
            "snippets": [
                {
                    "offsetInBeginSection": 1468,
                    "offsetInEndSection": 1639,
                    "text": "Our findings do not identify the nature of the underlying DNA sequences, but argue against the proposed role of Prdm9 as an essential transcription factor in mouse meiosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19997497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "PRDM9 gene polymorphism may not be associated with defective spermatogenesis in the Chinese Han population",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190393",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "PRDM9 is essential for the progression through early meiotic prophase, including double strand break repair, homologous chromosome pairing, and sex body formation during spermatogenesis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190393",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "PRDM9 (PR domain-containing protein 9) is a meiosis-specific protein that trimethylates H3K4 and controls the activation of recombination hot spots. It is an essential enzyme in the progression of early meiotic prophase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24634223",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 404,
                    "text": "In many eukaryotes, sites of meiotic recombination, also called hotspots, are regions of accessible chromatin, but in many vertebrates, their location follows a distinct pattern and is specified by PR domain-containing protein 9 (PRDM9). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30161134",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 739,
                    "offsetInEndSection": 1252,
                    "text": " We found that although the post-SET zinc finger and the KRAB domains are not essential for the methyltransferase activity of PRDM9 in cell culture, the KRAB domain mutant mice show only residual PRDM9 methyltransferase activity and undergo meiotic arrest. In aggregate, our data indicate that domains typically involved in regulation of gene expression do not serve that role in PRDM9, but are likely involved in setting the proper chromatin environment for initiation and completion of homologous recombination.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29674518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "PRDM9 Methyltransferase Activity Is Essential for Meiotic DNA Double-Strand Break Formation at Its Binding Sites.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29478809",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is apixaban effective for treatment of acute venous thromboembolism?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18393142",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084658",
                "http://www.ncbi.nlm.nih.gov/pubmed/22153026",
                "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
                "http://www.ncbi.nlm.nih.gov/pubmed/23808982",
                "http://www.ncbi.nlm.nih.gov/pubmed/24554904",
                "http://www.ncbi.nlm.nih.gov/pubmed/19014462",
                "http://www.ncbi.nlm.nih.gov/pubmed/22795419",
                "http://www.ncbi.nlm.nih.gov/pubmed/23233582",
                "http://www.ncbi.nlm.nih.gov/pubmed/19308891",
                "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
                "http://www.ncbi.nlm.nih.gov/pubmed/24278706",
                "http://www.ncbi.nlm.nih.gov/pubmed/23822763",
                "http://www.ncbi.nlm.nih.gov/pubmed/23117646"
            ],
            "ideal_answer": [
                "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.",
                "Yes, apixaban is effective for treatment of acute venous thromboembolismis. Apixiban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013923",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020246",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054556",
                "http://www.biosemantics.org/jochem#4243936"
            ],
            "type": "yesno",
            "id": "52fc94572059c6d71c000070",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1132,
                    "text": "These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1718,
                    "offsetInEndSection": 1898,
                    "text": "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 186,
                    "text": "To critically review the effectiveness of the novel oral anticoagulants (rivaroxaban, dabigatran, ximelagatran, and apixaban) in the treatment of acute venous thromboembolism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2087,
                    "offsetInEndSection": 2308,
                    "text": "ompared with vitamin K antagonists, the novel oral anticoagulants had a similar risk of recurrence of acute venous thromboembolism and all cause mortality, though rivaroxaban was associated with a reduced risk of bleeding",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 329,
                    "text": "Nowadays, the new anticoagulants, such as dabigatran, rivaroxaban and apixaban, show potential advantages over classical treatments. These agents inhibit specific coagulation factors and are administered orally at fixed doses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117646",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1192,
                    "offsetInEndSection": 1308,
                    "text": "In a recently completed phase III trial, apixaban also demonstrated promising efficacy and safety in that indication",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795419",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 419,
                    "text": "the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18393142",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the BRAFV600E mutation have an effect on clinical response to radioiodine therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26780618",
                "http://www.ncbi.nlm.nih.gov/pubmed/29549631",
                "http://www.ncbi.nlm.nih.gov/pubmed/30312216",
                "http://www.ncbi.nlm.nih.gov/pubmed/26838744"
            ],
            "ideal_answer": [
                "Yes, it has been suggested that patients with papillary thyroid cancer (PTC) harbouring the BRAF(V600E) mutation have a worse prognosis."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e4adcbe6d0a277941000017",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 165,
                    "text": "Preclinical studies showed that BRAF mutation significantly reduced radioiodine uptake and decreased the sensitivity to radioactive iodine (RAI) therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30312216",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1422,
                    "offsetInEndSection": 1667,
                    "text": "The status of BRAF mutation may not affect the clinical response to RAI therapy for patients with PTMC with intermediate-risk to high-risk features. More trials examining the role of BRAF mutation in guiding postoperative RAI therapy are needed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30312216",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1523,
                    "offsetInEndSection": 1786,
                    "text": "our results suggest that the combination of BRAFV600E+ve mutation and MIBI-ve scintigraphy may be considered a negative prognostic clue, which predicts the absence of radioiodine uptake at pT-WBS in DTC patients with incomplete bio-chemical response to first RAIT",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29549631",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1421,
                    "offsetInEndSection": 1616,
                    "text": "The results indicate that BRAF(V600E) mutation is correlated with a lower expression of NIS in PTCs without HT, suggesting the radioiodine-refractory effects during RIA therapy in these patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26838744",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Tofacitinib effective for Ulcerative Colitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                "http://www.ncbi.nlm.nih.gov/pubmed/27663846",
                "http://www.ncbi.nlm.nih.gov/pubmed/28503977",
                "http://www.ncbi.nlm.nih.gov/pubmed/28164724",
                "http://www.ncbi.nlm.nih.gov/pubmed/28158411",
                "http://www.ncbi.nlm.nih.gov/pubmed/27140405",
                "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
                "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
                "http://www.ncbi.nlm.nih.gov/pubmed/28790099",
                "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
                "http://www.ncbi.nlm.nih.gov/pubmed/28475384",
                "http://www.ncbi.nlm.nih.gov/pubmed/26608188"
            ],
            "ideal_answer": [
                "Yes. Tofacitinib, an oral small-molecule Janus kinase inhibitor, is effective in the treatment of moderate-severe ulcerative colitis. It is also effective treatment of rheumatoid arthritis and autoimmune encephalomyelitis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:8577",
                "https://meshb.nlm.nih.gov/record/ui?ui=D016896",
                "https://meshb.nlm.nih.gov/record/ui?ui=D003093"
            ],
            "type": "yesno",
            "id": "5a723edd2dc08e987e00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 1027,
                    "text": "Tofacitinib, inhibiting signalling via all Janus kinase family members, was effective in phase 2 and 3 trials in moderate-severe ulcerative colitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158411",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 564,
                    "text": "Among them, Janus kinase (JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF na\u00efve and anti-TNF experienced patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28164724",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1116,
                    "text": "Near future conventional drug options include oral agents such as tofacitinib and mongersen. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28475384",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 781,
                    "text": "Tofacitinib showed dose related efficacy for induction therapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503977",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2243,
                    "offsetInEndSection": 2404,
                    "text": "CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 96,
                    "offsetInEndSection": 295,
                    "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "<b>BACKGROUND</b>: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1932,
                    "offsetInEndSection": 2444,
                    "text": "Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was associated with increased lipid levels.<br><b>CONCLUSIONS</b>: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 96,
                    "offsetInEndSection": 294,
                    "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790099",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2249,
                    "offsetInEndSection": 2409,
                    "text": "CONCLUSIONS In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 409,
                    "text": "Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn's disease according to phase 2 trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27663846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2066,
                    "offsetInEndSection": 2252,
                    "text": "CONCLUSIONS Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1996,
                    "offsetInEndSection": 2285,
                    "text": "Three patients treated with tofacitinib had an absolute neutrophil count of less than 1500.<br><b>CONCLUSIONS</b>: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 2467,
                    "text": "tofacitinib an oral small molecule janus kinase inhibitor was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial we further evaluated the efficacy of tofacitinib as induction and maintenance therapy we conducted three phase 3 randomized double blind placebo controlled trials of tofacitinib therapy in adults with ulcerative colitis in the octave induction 1 and 2 trials 598 and 541 patients respectively who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib 10 mg twice daily or placebo for 8 weeks the primary end point was remission at 8 weeks in the octave sustain trial 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib either 5 mg or 10 mg twice daily or placebo for 52 weeks the primary end point was remission at 52 weeks in the octave induction 1 trial remission at 8 weeks occurred in 18 5 of the patients in the tofacitinib group versus 8 2 in the placebo group p 0 007 in the octave induction 2 trial remission occurred in 16 6 versus 3 6 p 0 001 in the octave sustain trial remission at 52 weeks occurred in 34 3 of the patients in the 5 mg tofacitinib group and 40 6 in the 10 mg tofacitinib group versus 11 1 in the placebo group p 0 001 for both comparisons with placebo in the octave induction 1 and 2 trials the rates of overall infection and serious infection were higher with tofacitinib than with placebo in the octave sustain trial the rate of serious infection was similar across the three treatment groups and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo across all three trials adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo as compared with placebo tofacitinib was associated with increased lipid levels in patients with moderately to severely active ulcerative colitis tofacitinib was more effective as induction and maintenance therapy than placebo funded by pfizer octave induction 1 octave induction 2 and octave sustain clinicaltrials gov numbers nct01465763 nct01458951 and nct01458574 respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 2176,
                    "text": "ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective one additional treatment may be tofacitinib cp 690 550 an oral inhibitor of janus kinases 1 2 and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2 which is expected to block signaling involving gamma chain containing cytokines including interleukins 2 4 7 9 15 and 21 these cytokines are integral to lymphocyte activation function and proliferation in a double blind placebo controlled phase 2 trial we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis patients were randomly assigned to receive tofacitinib at a dose of 0 5 mg 3 mg 10 mg or 15 mg or placebo twice daily for 8 weeks the primary outcome was a clinical response at 8 weeks defined as an absolute decrease from baseline in the score on the mayo scoring system for assessment of ulcerative colitis activity possible score 0 to 12 with higher scores indicating more severe disease of 3 or more and a relative decrease from baseline of 30 or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an absolute rectal bleeding subscore of 0 or 1 the primary outcome clinical response at 8 weeks occurred in 32 48 61 and 78 of patients receiving tofacitinib at a dose of 0 5 mg p 0 39 3 mg p 0 55 10 mg p 0 10 and 15 mg p 0 001 respectively as compared with 42 of patients receiving placebo clinical remission defined as a mayo score 2 with no subscore 1 at 8 weeks occurred in 13 33 48 and 41 of patients receiving tofacitinib at a dose of 0 5 mg p 0 76 3 mg p 0 01 10 mg p 0 001 and 15 mg p 0 001 respectively as compared with 10 of patients receiving placebo there was a dose dependent increase in both low density and high density lipoprotein cholesterol three patients treated with tofacitinib had an absolute neutrophil count of less than 1500 patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo funded by pfizer clinicaltrials gov number nct00787202.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 851,
                    "text": "recently several medical treatments for ulcerative colitis uc have been developed including 5 aminosalicylic acids 5 asas corticosteroids thiopurine calcineurin inhibitors and anti tumor necrosis factor tnf \u03b1 treatments treatment options including calcineurin inhibitors and anti tnf treatment for refractory uc are discussed in this article furthermore upcoming treatments are introduced such as golimumab vedolizumab ajm300 tofacitinib budesonide foamwill be used as one treatment option in patients with distal colitis herbal medicine such as qing dai is also effective for active uc and may be useful for patients who are refractory to anti tnf\u03b1 treatments in the near future physicians will able to use many different treatments for uc patients however we should not forget 5 asa and corticosteroids as the fundamental treatments for uc patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1420,
                    "text": "the inflammatory diseases ulcerative colitis and crohn s disease constitute the two main forms of inflammatory bowel disease ibd they are characterized by chronic relapsing inflammation of the gastrointestinal tract significantly impacting on patient quality of life and often requiring prolonged treatment existing therapies for ibd are not effective for all patients and an unmet need exists for additional therapies to induce and maintain remission here we describe the mechanism of action of the janus kinase jak inhibitor tofacitinib for the treatment of ibd and the effect of jak inhibition on the chronic cycle of inflammation that is characteristic of the disease the pathogenesis of ibd involves a dysfunctional response from the innate and adaptive immune system resulting in overexpression of multiple inflammatory cytokines many of which signal through jaks thus jak inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in ibd thereby interrupting the cycle of inflammation tofacitinib is an oral small molecule jak inhibitor that is being investigated as a targeted immunomodulator for ibd clinical development of tofacitinib and other jak inhibitors is ongoing with the aspiration of providing new treatment options for ibd that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608188",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is invasion and metastasis one of the hallmarks of cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19662202"
            ],
            "ideal_answer": [
                "Yes, invasion and metastasis are one of the so-called hallmarks of cancer."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009362",
                "http://www.disease-ontology.org/api/metadata/DOID:162",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009361",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369"
            ],
            "type": "yesno",
            "id": "5316d4fcb166e2b806000005",
            "snippets": [
                {
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 601,
                    "text": "The pathogenesis of MM involves the accumulation of extensive cytogenetic changes, as well as cancer-related phenotypic alterations that facilitate tumor cell survival, invasion and metastasis. This review presents current knowledge regarding the biological characteristics of this disease that are linked to the so-called hallmarks of cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19662202",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any urine biomarkers for bladder cancer diagnosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24139504",
                "http://www.ncbi.nlm.nih.gov/pubmed/24578952",
                "http://www.ncbi.nlm.nih.gov/pubmed/22559832",
                "http://www.ncbi.nlm.nih.gov/pubmed/24183881",
                "http://www.ncbi.nlm.nih.gov/pubmed/18070176",
                "http://www.ncbi.nlm.nih.gov/pubmed/24306957",
                "http://www.ncbi.nlm.nih.gov/pubmed/18923359",
                "http://www.ncbi.nlm.nih.gov/pubmed/24140246",
                "http://www.ncbi.nlm.nih.gov/pubmed/19181545",
                "http://www.ncbi.nlm.nih.gov/pubmed/22426337",
                "http://www.ncbi.nlm.nih.gov/pubmed/22615872",
                "http://www.ncbi.nlm.nih.gov/pubmed/22888342",
                "http://www.ncbi.nlm.nih.gov/pubmed/20960509",
                "http://www.ncbi.nlm.nih.gov/pubmed/23764080",
                "http://www.ncbi.nlm.nih.gov/pubmed/19565266",
                "http://www.ncbi.nlm.nih.gov/pubmed/23094052",
                "http://www.ncbi.nlm.nih.gov/pubmed/20082749",
                "http://www.ncbi.nlm.nih.gov/pubmed/24212086",
                "http://www.ncbi.nlm.nih.gov/pubmed/22792272",
                "http://www.ncbi.nlm.nih.gov/pubmed/23945108",
                "http://www.ncbi.nlm.nih.gov/pubmed/20657287",
                "http://www.ncbi.nlm.nih.gov/pubmed/24281040",
                "http://www.ncbi.nlm.nih.gov/pubmed/15341676",
                "http://www.ncbi.nlm.nih.gov/pubmed/23300915"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7638941",
                    "o": "C16181"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7638941",
                    "o": "Cancer Biomarkers Research Group"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1516166",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7638941"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7638941",
                    "o": "NCI Thesaurus"
                }
            ],
            "ideal_answer": [
                "Bladder cancer is any of several types of malignancy arising from the epithelial lining of the urinary bladder. Rarely the bladder is involved by non-epithelial cancers, such as lymphoma or sarcoma. It is a disease in which abnormal cells multiply without control in the bladder.The bladder is a hollow, muscular organ that stores urine; it is located in the pelvis. The most common type of bladder cancer recapitulates the normal histology of the urothelium and is known as transitional cell carcinoma or more properly urothelial cell carcinoma. It is estimated that there are 383,000 cases of bladder cancer worldwide",
                "Yes, there are. Urine biomarkers for bladder cancer diagnosis range from voided urine cytology and the UroVysion\u00ae cytogenetic test, to fluorescence in situ hybridisation (FISH), ImmunoCyt, NMP22, Bladder Tumor Antigen, BLCA-1, BLCA-4, hyaluronic acid, hyaluronidase, Lewis X antigen, microsatellite analysis, Quanticyt, soluble Fas, Survivin, telomerase, IL-8, MMP-9 and 10, PAI-1, VEGF, ANG, CA9 and APOE."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001749",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014554",
                "http://www.disease-ontology.org/api/metadata/DOID:6933",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014556",
                "http://www.disease-ontology.org/api/metadata/DOID:4007",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001743",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055088",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054316",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042241",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415",
                "http://www.uniprot.org/uniprot/BLCAP_HUMAN",
                "http://www.disease-ontology.org/api/metadata/DOID:11054"
            ],
            "type": "yesno",
            "id": "52cb9b9b03868f1b0600002d",
            "snippets": [
                {
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1517,
                    "text": "CONCLUSIONS: Several gene-based urinary biomarkers have demonstrated promise in initial studies, which now need to be rigorously validated in the clinical setting for them to be translated into clinically useful tests in diagnosis, surveillance or risk-stratification of bladder cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1606,
                    "offsetInEndSection": 1865,
                    "text": " Novel promising markers are in various stages of clinical testing, and a panel of biomarkers may serve in the future as a feasible alternative to urine cytology and cystoscopy for the screening, detection, and follow-up of non-muscle invasive bladder cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15341676",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1130,
                    "text": "RESULTS: Seven of the 8 urine biomarkers were increased in subjects with bladder cancer relative to those without bladder cancer. The 7 biomarkers were assessed in a new model, which had an AUROC of 0.88 (95% CI 0.84-0.93), and 74% sensitivity and 90% specificity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23764080",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1644,
                    "text": "The study provides further evidence that the reported panel of diagnostic biomarkers can reliably achieve the noninvasive detection of bladder cancer with higher sensitivity than currently available urine based assays.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23764080",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 1417,
                    "text": "The urinary concentrations of 14 biomarkers (IL-8, MMP-9, MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. An 8-biomarker model achieved the most accurate BCa diagnosis (sensitivity 92%, specificity 97%), but a combination of 3 of the 8 biomarkers (IL-8, VEGF, and APOE) was also highly accurate (sensitivity 90%, specificity 97%). For comparison, the commercial BTA-Trak ELISA test achieved a sensitivity of 79% and a specificity of 83%, and voided urine cytology detected only 33% of BCa cases in the same cohort. These data show that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23094052",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 10,
                    "offsetInEndSection": 401,
                    "text": ": Histopathological grading of papillary urothelial tumors (PUTs) of the urinary bladder is subjective and poorly reproducible. We investigated the relationship between the expression of frequently deregulated microRNAs (miRNAs) as well as their target genes (ZEB1/ZEB2) and bladder cancer histopathological grade in an attempt to find a miRNA that might allow more reliable grading of PUTs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24306957",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1429,
                    "offsetInEndSection": 1914,
                    "text": "The Mcm5 immunoassay is a non-invasive test for identifying patients with urothelial cancers with similar accuracy to the FDA-approved NMP22 ELISA Test Kit. The combination of Mcm5 plus NMP22 improves the detection of UCC and identifies 95% of clinically significant disease. Trials of a commercially developed Mcm5 assay suitable for an end-user laboratory alongside NMP22 are required to assess their potential clinical utility in improving diagnostic and surveillance care pathways.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22792272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1738,
                    "offsetInEndSection": 1959,
                    "text": "HYAL-1 and HAS1 expression predicted BCa metastasis, and HYAL-1 expression also predicted disease-specific survival. Furthermore, the combined HAS2-HYAL-1 biomarker detected BCa and significantly predicted its recurrence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 124,
                    "text": "Cancer biomarkers are the backbone for the implementation of individualized approaches to bladder cancer (BCa). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 676,
                    "text": "Through genomic and proteomic profiling of urine, we have identified a panel of biomarkers associated with the presence of BCa. In this study, we evaluated the utility of three of these biomarkers, interleukin 8 (IL-8), Matrix metallopeptidase 9 (MMP-9) and Syndecan in the diagnosis of BCa through urinalysis. METHODS: Voided urines from 127 subjects, cancer subjects (n = 64), non-cancer subjects (n = 63) were analyzed. The protein concentrations of IL-8, MMP-9, and Syndecan were assessed by enzyme-linked immunosorbent assay (ELISA).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1653,
                    "offsetInEndSection": 1998,
                    "text": ". There was an association between differences in individual biomarkers and differences in protein levels over time, particularly in control patients. Collectively, our findings identify caveats intrinsic to the common practice of protein standardization in biomarker discovery studies conducted on urine, particularly in patients with hematuria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300915",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is aganglionic megacolon a feature of Down syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23045564",
                "http://www.ncbi.nlm.nih.gov/pubmed/18075983",
                "http://www.ncbi.nlm.nih.gov/pubmed/2309705",
                "http://www.ncbi.nlm.nih.gov/pubmed/12028658"
            ],
            "ideal_answer": [
                "Down syndrome (DS) is recognized by characteristic facial features, intellectual disability, and an increased risk for cardiac malformations and duodenal atresia. Recently, Hirschsprung disease (HSCR), or congenital aganglionic megacolon, has been seen more often among patients with DS."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:14250"
            ],
            "type": "yesno",
            "id": "550311dae9bde69634000018",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 286,
                    "text": "Down syndrome (DS) is recognized by characteristic facial features, intellectual disability, and an increased risk for cardiac malformations and duodenal atresia. Recently, Hirschsprung disease (HSCR), or congenital aganglionic megacolon, has been seen more often among patients with DS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23045564",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 1078,
                    "text": "Of the 17 patients with HD who were studied, 10 were isolated (58.8%) and seven (41.1%) were associated to other structural abnormalities and psychomotor retardation. Three of the cases in this latter group were due to chromosome pathology (trisomy 21, Down syndrome)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18075983",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 408,
                    "text": "The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy. The patient condition improved after a colostomy performed in the setting of the treatment of Hirschprung disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 760,
                    "text": "Hirschsprung disease, or congenital aganglionic megacolon, is commonly assumed to be a sex-modified multifactorial trait. To test this hypothesis, complex segregation analysis was performed on data on 487 probands and their families. Demographic information on probands and the recurrence risk to relatives of probands are presented. An increased sex ratio (3.9 male:female) and an elevated risk to sibs (4%), as compared with the population incidence (0.02%), are observed, with the sex ratio decreasing and the recurrence risk to sibs increasing as the aganglionosis becomes more extensive. Down syndrome was found at an increased frequency among affected individuals but not among their unaffected sibs, and the increase was not associated with maternal age",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2309705",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Intestinal microvillous atrophy in a patient with Down syndrome and aganglionic megacolon.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 293,
                    "text": " The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 294,
                    "text": "The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 293,
                    "text": "The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do Crocus sativus extracts loosen the blood-brain barrier?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28471166"
            ],
            "ideal_answer": [
                "No, in vitro and in vivo experiments show that the Crocus sativus extract increases the tightness of a cell-based blood-brain barrier (BBB)."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c891e5575a4a5d219000012",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid \u03b2 Load and Related Toxicity in 5XFAD Mice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 1120,
                    "text": "In vitro results showed that Crocus sativus extract increases the tightness of a cell-based blood-brain barrier (BBB) model and enhances transport of A\u03b2. Further in vivo studies confirmed the effect of Crocus sativus extract (50 mg/kg/day, added to mice diet) on the BBB tightness and function that was associated with reduced A\u03b2 load and related pathological changes in 5XFAD mice used as an AD model. Reduced A\u03b2 load could be explained, at least in part, by Crocus sativus extract effect to enhance A\u03b2 clearance pathways including BBB clearance, enzymatic degradation and ApoE clearance pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has silicon been used in treatment of  incontinence ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20065535",
                "http://www.ncbi.nlm.nih.gov/pubmed/9690182",
                "http://www.ncbi.nlm.nih.gov/pubmed/10711555",
                "http://www.ncbi.nlm.nih.gov/pubmed/15582258",
                "http://www.ncbi.nlm.nih.gov/pubmed/12806798",
                "http://www.ncbi.nlm.nih.gov/pubmed/15183554",
                "http://www.ncbi.nlm.nih.gov/pubmed/22687358",
                "http://www.ncbi.nlm.nih.gov/pubmed/22933007",
                "http://www.ncbi.nlm.nih.gov/pubmed/10838378"
            ],
            "ideal_answer": [
                "Yes"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012828",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012825",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014549"
            ],
            "type": "yesno",
            "id": "536172d17d100faa09000009",
            "snippets": [
                {
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 1026,
                    "text": "an artificial anal sphincter. Worldwide, there are two established devices on the market: the artificial bowel sphincter\u00ae (ABS) from A. M. S. (Minnetonka, MN, USA) and the soft anal band\u00ae from A. M. I. (Feldkirch, Austria). How to implant the artificial anal sphincter? Both devices consist of a silicon cuff which can be filled with fluid.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22933007",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 208,
                    "offsetInEndSection": 326,
                    "text": "The InVance\u2122 system uses a silicon-coated polyester sling positioned under the bulbar urethra via a perineal incision.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22687358",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 869,
                    "text": "Through a perineal incision three titanium screws with a polipropylene suture were inserted in each ischiopubic rami, and a silicon/polipropylene mesh (Invance) is affixed to them, compressing the bulbar urethra",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20065535",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 450,
                    "text": "surgical treatment of female stress urinary incontinence with a trans-obturator sub-urethral tape of Uratape (Porg\u00e9s). METHODS: Treatment and follow up of their complication were performed at the CHRU of Lille. RESULTS: In both cases, this complication is related to prolonged vaginal exposition of the tape. Vaginal erosion always occurs next to the silicon coated section of the tape",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15582258",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 578,
                    "offsetInEndSection": 705,
                    "text": "A non-elastic, polypropylene tape (UraTape, Mentor-Porg\u00e8s) with a silicon coated central part was placed under the mid-urethra.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183554",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1441,
                    "offsetInEndSection": 1767,
                    "text": " Stress incontinence is a rare complication in men, usually following prostatic surgery. It can be treated conservatively with pelvic floor training and alpha-adrenergic receptor agonists and if necessary surgically with submucosal collagen or silicon injections in the sphincter area or implantation of a sphincter prosthesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806798",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 339,
                    "text": "The Femassist is a medical-grade silicon dome-shaped device, worn over the urethra and held securely via suction and a commercially available adhesive lotion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10838378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 142,
                    "text": "To examine the performance of a silicon urinary control device for nonsurgical management of women with genuine stress incontinence",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711555",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 524,
                    "text": "The \"FemAssist\" is a dome-shaped medical grade silicon device intended to be worn over the external urethral meatus and held in place by suction and an adhesive gel. Thirty eight women with varying degrees of genuine stress urinary incontinence (GSUI) or mixed incontinence on multichannel urodynamic testing were fitted with one of two sizes of \"FemAssist",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9690182",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between bruxism and reflux",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                "http://www.ncbi.nlm.nih.gov/pubmed/23937680",
                "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                "http://www.ncbi.nlm.nih.gov/pubmed/19830044"
            ],
            "ideal_answer": [
                "There is an association between bruxism and reflux."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057045",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004942",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020186",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005764",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002012"
            ],
            "type": "yesno",
            "id": "52f8a7eb2059c6d71c000052",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 326,
                    "text": "Rhythmic masticatory muscle activity, including sleep bruxism (SB), can be induced in healthy individuals by experimental esophageal acidification, which plays an important role in the pathogenesis of gastroesophageal reflux disease (GERD). However, no robust evidence supports the association between SB and GERD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1564,
                    "offsetInEndSection": 1647,
                    "text": "Sleep bruxism is prevalent in GERD patients, and GERD is highly associated with SB.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1471,
                    "offsetInEndSection": 1670,
                    "text": "Our large-scale cross-sectional study found that problem behaviors in adolescents were associated with sleep problems, including sleep bruxism, as well as lifestyle and food habits and GERD symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23937680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 741,
                    "text": "The frequencies of EMG bursts, rhythmic masticatory muscle activity (RMMA) episodes, grinding noise, and the RMMA/microarousal ratio were significantly higher in the 20-minute period after acidic infusion than after saline infusion. RMMA episodes including SB were induced by esophageal acidification. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21248360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Direct restorative treatment of dental erosion caused by gastroesophageal reflux disease associated with bruxism:",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 480,
                    "text": "This article presents a case report of a 27-year-old male smoker with tooth wear and dentin sensitivity caused by GERD associated with bruxism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23738993",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Dental wear caused by association between bruxism and gastroesophageal reflux disease:",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 699,
                    "offsetInEndSection": 909,
                    "text": "This paper presents a case report in which bruxism associated with acid feeding, smoking habit and episodes of gastric reflow caused severe tooth wear and great muscular discomfort with daily headache episodes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19089153",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 988,
                    "text": "most jaw muscle activities, ie, RMMA, single short-burst, and clenching episodes, occur in relation to gastroesophageal reflux mainly in the supine position.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Association between nocturnal bruxism and gastroesophageal reflux.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2192,
                    "offsetInEndSection": 2328,
                    "text": "Nocturnal bruxism may be secondary to nocturnal gastroesophageal reflux, occurring via sleep arousal and often together with swallowing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14655925",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is cariprazine effective for treatment of bipolar disorder?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28843918",
                "http://www.ncbi.nlm.nih.gov/pubmed/24048386",
                "http://www.ncbi.nlm.nih.gov/pubmed/23361832",
                "http://www.ncbi.nlm.nih.gov/pubmed/27190727",
                "http://www.ncbi.nlm.nih.gov/pubmed/30323605",
                "http://www.ncbi.nlm.nih.gov/pubmed/27396597",
                "http://www.ncbi.nlm.nih.gov/pubmed/28343051",
                "http://www.ncbi.nlm.nih.gov/pubmed/26586950",
                "http://www.ncbi.nlm.nih.gov/pubmed/28478771",
                "http://www.ncbi.nlm.nih.gov/pubmed/27059102",
                "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
                "http://www.ncbi.nlm.nih.gov/pubmed/27274384",
                "http://www.ncbi.nlm.nih.gov/pubmed/25562205",
                "http://www.ncbi.nlm.nih.gov/pubmed/23966785",
                "http://www.ncbi.nlm.nih.gov/pubmed/25056368",
                "http://www.ncbi.nlm.nih.gov/pubmed/30470662",
                "http://www.ncbi.nlm.nih.gov/pubmed/26510944",
                "http://www.ncbi.nlm.nih.gov/pubmed/29119668",
                "http://www.ncbi.nlm.nih.gov/pubmed/26655189",
                "http://www.ncbi.nlm.nih.gov/pubmed/30372510",
                "http://www.ncbi.nlm.nih.gov/pubmed/25532076"
            ],
            "ideal_answer": [
                "Yes, cariprazine is effective for bipolar disorder."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c61bacae842deac67000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "BACKGROUND: We evaluated the safety/tolerability of longer-term open-label treatment with cariprazine in patients who had responded to cariprazine for acute bipolar mania.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843918",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 252,
                    "text": "Cariprazine is FDA approved for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1467,
                    "offsetInEndSection": 1741,
                    "text": "DISCUSSION: Cariprazine-treated patients with bipolar I disorder attained clinically significant improvement in manic symptoms as shown by significantly greater rates of response and remission versus placebo; improvement in manic symptoms did not induce depressive symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29017067",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "OBJECTIVE: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28478771",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "<b>BACKGROUND</b>: Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30372510",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is thyroid hormone therapy indicated in patients with heart failure?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2189307",
                "http://www.ncbi.nlm.nih.gov/pubmed/18171701",
                "http://www.ncbi.nlm.nih.gov/pubmed/17710084",
                "http://www.ncbi.nlm.nih.gov/pubmed/9485134",
                "http://www.ncbi.nlm.nih.gov/pubmed/23660007",
                "http://www.ncbi.nlm.nih.gov/pubmed/8936682",
                "http://www.ncbi.nlm.nih.gov/pubmed/8936683",
                "http://www.ncbi.nlm.nih.gov/pubmed/9312172",
                "http://www.ncbi.nlm.nih.gov/pubmed/15604125",
                "http://www.ncbi.nlm.nih.gov/pubmed/23369135",
                "http://www.ncbi.nlm.nih.gov/pubmed/15572044",
                "http://www.ncbi.nlm.nih.gov/pubmed/19808346",
                "http://www.ncbi.nlm.nih.gov/pubmed/19778808",
                "http://www.ncbi.nlm.nih.gov/pubmed/19917524",
                "http://www.ncbi.nlm.nih.gov/pubmed/10194658",
                "http://www.ncbi.nlm.nih.gov/pubmed/8333798",
                "http://www.ncbi.nlm.nih.gov/pubmed/22009366",
                "http://www.ncbi.nlm.nih.gov/pubmed/12145478",
                "http://www.ncbi.nlm.nih.gov/pubmed/8353891",
                "http://www.ncbi.nlm.nih.gov/pubmed/10474790",
                "http://www.ncbi.nlm.nih.gov/pubmed/12165115",
                "http://www.ncbi.nlm.nih.gov/pubmed/12165118",
                "http://www.ncbi.nlm.nih.gov/pubmed/18221125",
                "http://www.ncbi.nlm.nih.gov/pubmed/19506112",
                "http://www.ncbi.nlm.nih.gov/pubmed/20100314",
                "http://www.ncbi.nlm.nih.gov/pubmed/17893267",
                "http://www.ncbi.nlm.nih.gov/pubmed/19125327",
                "http://www.ncbi.nlm.nih.gov/pubmed/7954115",
                "http://www.ncbi.nlm.nih.gov/pubmed/23837113"
            ],
            "ideal_answer": [
                "There are several experimental and clinical evidences of the potential benefits of Thyroid hormone replacement therapy in heart failure. Initial clinical data showed also a good safety profile and tolerance of TH replacement therapy in patients withheart failure. \nHowever currently there is no indication to treat patients with heart failure withTHreplacementtherapy."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020249",
                "http://www.disease-ontology.org/api/metadata/DOID:6000",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006333",
                "http://www.disease-ontology.org/api/metadata/DOID:9651",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054143"
            ],
            "type": "yesno",
            "id": "531b4269b166e2b80600003e",
            "snippets": [
                {
                    "offsetInBeginSection": 1252,
                    "offsetInEndSection": 1405,
                    "text": "Patients with chronic heart failure and subclinical hypothyroidism significantly improved their physical performance when normal TSH levels were reached.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23660007",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1613,
                    "offsetInEndSection": 1870,
                    "text": "Early and sustained physiological restoration of circulating L-T3 levels after MI halves infarct scar size and prevents the progression towards heart failure. This beneficial effect is likely due to enhanced capillary formation and mitochondrial protection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100314",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1818,
                    "offsetInEndSection": 2006,
                    "text": "These data indicate that T(3) replacement to euthyroid levels improves systolic function and tends to improve diastolic function, potentially through changes in myocardial gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808346",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 751,
                    "offsetInEndSection": 951,
                    "text": "In these patients, the administration of synthetic triiodothyronine (T(3)) was well tolerated and induced significant improvement in cardiac function without increased heart rate and metabolic demand.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18221125",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1939,
                    "offsetInEndSection": 2077,
                    "text": "In DC patients, short-term synthetic L-T(3) replacement therapy significantly improved neuroendocrine profile and ventricular performance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18171701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 909,
                    "offsetInEndSection": 1277,
                    "text": "Triiodothyronine was well tolerated without episodes of ischemia or clinical arrhythmia. There was no significant change in heart rate or metabolic rate and there was minimal increase in core temperature. Cardiac output increased with a reduction in systemic vascular resistance in patients receiving the largest dose, consistent with a peripheral vasodilatory effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9485134",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does thyroid hormone signaling affect microRNAs expression in the heart?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22541436",
                "http://www.ncbi.nlm.nih.gov/pubmed/22525353",
                "http://www.ncbi.nlm.nih.gov/pubmed/21149577",
                "http://www.ncbi.nlm.nih.gov/pubmed/17379774"
            ],
            "ideal_answer": [
                "YES"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/THA_LITCT",
                "http://www.uniprot.org/uniprot/THB_SHEEP",
                "http://www.uniprot.org/uniprot/THA_MOUSE",
                "http://www.uniprot.org/uniprot/THAA_PAROL",
                "http://www.uniprot.org/uniprot/THA_PYGAD",
                "http://www.uniprot.org/uniprot/THA_CHICK",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.uniprot.org/uniprot/THA_APTPA",
                "http://www.uniprot.org/uniprot/THB_CAIMO",
                "http://www.biosemantics.org/jochem#4275389",
                "http://www.uniprot.org/uniprot/THA_PIG",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988",
                "http://www.uniprot.org/uniprot/THBA_XENLA",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327",
                "http://www.uniprot.org/uniprot/THB_PAROL",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021",
                "http://www.uniprot.org/uniprot/THA_HIPHI",
                "http://www.uniprot.org/uniprot/THB_DANRE",
                "http://www.uniprot.org/uniprot/THB_RAT",
                "http://www.uniprot.org/uniprot/THAA_DANRE",
                "http://www.uniprot.org/uniprot/THA_ELECQ",
                "http://www.uniprot.org/uniprot/THAA_XENLA",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683",
                "http://www.uniprot.org/uniprot/THA_SPAAU",
                "http://www.uniprot.org/uniprot/THA_NECMA",
                "http://www.uniprot.org/uniprot/THB_HUMAN",
                "http://www.uniprot.org/uniprot/THA_HUMAN",
                "http://www.biosemantics.org/jochem#4250045",
                "http://www.uniprot.org/uniprot/THB_LITCT",
                "http://www.uniprot.org/uniprot/THA_SHEEP",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284",
                "http://www.uniprot.org/uniprot/THB_CHICK",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887",
                "http://www.uniprot.org/uniprot/THA_RAT",
                "http://www.uniprot.org/uniprot/THA_ONCMY",
                "http://www.uniprot.org/uniprot/THA_CAIMO",
                "http://www.uniprot.org/uniprot/THA_SALSA",
                "http://www.uniprot.org/uniprot/THB_MOUSE",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974"
            ],
            "type": "yesno",
            "id": "516c1041298dcd4e51000070",
            "snippets": [
                {
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 364,
                    "text": "e show that the heart regulates systemic energy homeostasis via MED13, a subunit of the Mediator complex, which controls transcription by thyroid hormone and other nuclear hormone receptors. MED13, in turn, is negatively regulated by a heart-specific microRNA, miR-208a.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541436",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1179,
                    "offsetInEndSection": 1240,
                    "text": "On the other hand, T\u2083 treatment increased miR-350 expression.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525353",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 906,
                    "offsetInEndSection": 1079,
                    "text": "Through a bioinformatics screening using TargetScan, we identified thyroid hormone receptor \u03b21 (TR\u03b21), which negatively regulates \u03b2-MHC transcription, as a target of miR-27a",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149577",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1336,
                    "offsetInEndSection": 1441,
                    "text": "hese findings suggested that miR-27a regulates \u03b2-MHC gene expression by targeting TR\u03b21 in cardiomyocytes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149577",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 500,
                    "text": "We found that a cardiac-specific microRNA (miR-208) encoded by an intron of the alphaMHC gene is required for cardiomyocyte hypertrophy, fibrosis, and expression of betaMHC in response to stress and hypothyroidism.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17379774",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1081,
                    "offsetInEndSection": 1334,
                    "text": "Moreover, miR-27a was demonstrated to modulate \u03b2-MHC gene regulation via thyroid hormone signaling and to be upregulated during the differentiation of mouse embryonic stem (ES) cells or in hypertrophic hearts in association with \u03b2-MHC gene upregulation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149577",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Can simvastatin alleviate depressive symptoms?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25827645"
            ],
            "ideal_answer": [
                "Yes, simvastatin decreases depressive symptoms."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c010e09133db5eb78000024",
            "snippets": [
                {
                    "offsetInBeginSection": 712,
                    "offsetInEndSection": 1091,
                    "text": "Simvastatin-treated patients experienced significantly more reductions in HDRS scores compared to the placebo group by the end of the trial (p=0.02). Early improvement and response rates were significantly greater in the simvastatin group than the placebo group (p=0.02 and p=0.01, respectively) but remission rate was not significantly different between the two groups (p=0.36).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827645",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1280,
                    "text": "In conclusion, simvastatin seems to be a safe and effective adjuvant therapy for patients suffering from major depressive disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827645",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is alemtuzumab effective for remission induction in patients diagnosed with T-cell prolymphocytic leukemia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15453953",
                "http://www.ncbi.nlm.nih.gov/pubmed/17118783",
                "http://www.ncbi.nlm.nih.gov/pubmed/15757437",
                "http://www.ncbi.nlm.nih.gov/pubmed/12950233",
                "http://www.ncbi.nlm.nih.gov/pubmed/23512246",
                "http://www.ncbi.nlm.nih.gov/pubmed/23211022",
                "http://www.ncbi.nlm.nih.gov/pubmed/16720203",
                "http://www.ncbi.nlm.nih.gov/pubmed/16645226",
                "http://www.ncbi.nlm.nih.gov/pubmed/22517037",
                "http://www.ncbi.nlm.nih.gov/pubmed/22649104",
                "http://www.ncbi.nlm.nih.gov/pubmed/11535503",
                "http://www.ncbi.nlm.nih.gov/pubmed/11986948",
                "http://www.ncbi.nlm.nih.gov/pubmed/23645660",
                "http://www.ncbi.nlm.nih.gov/pubmed/15869731",
                "http://www.ncbi.nlm.nih.gov/pubmed/21948296",
                "http://www.ncbi.nlm.nih.gov/pubmed/10561018",
                "http://www.ncbi.nlm.nih.gov/pubmed/23233647"
            ],
            "ideal_answer": [
                "Yes, alemtuzumab (anti-CD52, Campath-1H) is effective for remission induction in patients diagnosed with T-cell prolymphocytic leukemia. Alemtuzumab can be administered in combination with other chemotherapeutic agents or as mono-therapy. Response rate to alemtuzumab is more than 90%. Alemtuzumab therapy is associated with improved survival of T-cell prolymphocytic leukemia patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4002029",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015461",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012074"
            ],
            "type": "yesno",
            "id": "530cefaaad0bf1360c000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512246",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 318,
                    "text": "A central need in this historically refractory tumor is the controlled evaluation of multiagent chemotherapy and its combination with the currently most active single agent, alemtuzumab. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1489,
                    "offsetInEndSection": 1581,
                    "text": "FMC-A is a safe and efficient protocol in T-PLL, which compares favorably to published data.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 773,
                    "text": "Currently, the best treatment for T-PLL is IV alemtuzumab, which has resulted in very high response rates of more than 90% when given as frontline treatment and a significant improvement in survival. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23233647",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 906,
                    "text": "The patient failed to respond to standard ALL induction chemotherapy, but achieved complete remission following treatment with a fludarabine and alemtuzumab-based regimen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23211022",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 401,
                    "text": "Here we present a rare case of concurrent T-PLL and Kaposi sarcoma who achieved a complete hematologic and cytogenetic remission after a very short course of treatment with alemtuzumab.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517037",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1035,
                    "offsetInEndSection": 1243,
                    "text": " Recent studies with single-agent alemtuzumab, an anti-CD52 monoclonal antibody, have shown improved response rates and survival in patients with T-cell prolymphocytic leukemia and cutaneous T-cell lymphoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16720203",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 510,
                    "offsetInEndSection": 696,
                    "text": "The CD52 antigen is expressed at high density on the malignant T-cells and therapy with alemtuzumab, a humanized IgG1 antibody that targets this antigen, has produced promising results. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16645226",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 707,
                    "text": "With the introduction of alemtuzumab, most patients who progressed despite treatment with pentostatin had a major response with a complete remission rate higher than that obtained with pentostatin when used as a first line.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15869731",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 227,
                    "text": "Alemtuzumab (anti-CD52, Campath-1H) has recently been shown to be effective in the treatment of a range of hematological malignancies, including B-cell chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12950233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 384,
                    "text": "Here we report the outcome of two patients with CD4-positive T cell prolymphocytic leukemia treated with CAMPATH-1H. Both patients responded rapidly to treatment and subsequently developed CD4 lymphopenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11986948",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11535503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 472,
                    "offsetInEndSection": 738,
                    "text": "CAMPATH-1H (30 mg) was administered intravenously 3 times weekly until maximal response. The overall response rate was 76% with 60% CR and 16% partial remission (PR). These responses were durable with a median disease-free interval of 7 months (range, 4-45 months). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11535503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1444,
                    "offsetInEndSection": 1570,
                    "text": "The conclusion is that CAMPATH-1H is an effective therapy in T-PLL, producing remissions in more than two thirds of patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11535503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1343,
                    "text": "For example, most patients with T-cell prolymphocytic leukemia, including those with large tumor burdens and high peripheral white blood cell counts, will enter complete remission using the antibody CAMPATH-1H without any evidence of tumor lysis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10561018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 1006,
                    "text": "Overall response rate to FMC was 68%, comprising 6 complete remissions (all bone-marrow confirmed) and 11 partial remissions. Alemtuzumab consolidation increased the intent-to-treat overall response rate to 92% (12 complete remissions; 11 partial remissions). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512246",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does epidural anesthesia for pain management during labor affect the Apgar score of the the infant?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28013485",
                "http://www.ncbi.nlm.nih.gov/pubmed/19466346"
            ],
            "ideal_answer": [
                "Epidural analgesia for labor pain management did not appear to have an immediate effect on neonatal status as determined by Apgar scores or in admissions to neonatal intensive care."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c56fd7407647bbc4b000013",
            "snippets": [
                {
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 1122,
                    "text": " We retrospectively analyzed 93 consecutive single-pregnancy patients who underwent cesarean section with combined spinal-epidural anesthesia. The patients were divided into two groups, depending on the use of 6% HES 130/0.4: group A (461\u00a0\u00b1\u00a0167\u00a0ml of saline-based HES was administered; 43 patients) and group B (HES not administered; 50 patients). The major outcome was umbilical cord chloride level at delivery. The volume infused from operating room admission until delivery was not significantly different between groups. The umbilical cord chloride level at delivery was statistically significantly higher in group A than in group B, but clinically similar (108\u00a0\u00b1\u00a02 vs. 107\u00a0\u00b1\u00a02\u00a0mmol/l, P\u00a0=\u00a00.02). No differences were observed in the Apgar score or other umbilical cord laboratory data at delivery (Na+, K+, pH, base excess)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28013485",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1845,
                    "offsetInEndSection": 2057,
                    "text": "CONCLUSION\nSubarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the Apgar score of newborns.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19466346",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1845,
                    "offsetInEndSection": 2057,
                    "text": "CONCLUSION Subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the Apgar score of newborns.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19466346",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is subdural empyema a complication of sinusitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16462969",
                "http://www.ncbi.nlm.nih.gov/pubmed/7810468",
                "http://www.ncbi.nlm.nih.gov/pubmed/17182345",
                "http://www.ncbi.nlm.nih.gov/pubmed/9217340",
                "http://www.ncbi.nlm.nih.gov/pubmed/30014307",
                "http://www.ncbi.nlm.nih.gov/pubmed/22030191",
                "http://www.ncbi.nlm.nih.gov/pubmed/12521560",
                "http://www.ncbi.nlm.nih.gov/pubmed/28806018",
                "http://www.ncbi.nlm.nih.gov/pubmed/25437686",
                "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                "http://www.ncbi.nlm.nih.gov/pubmed/29404826",
                "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                "http://www.ncbi.nlm.nih.gov/pubmed/12402493",
                "http://www.ncbi.nlm.nih.gov/pubmed/29682134",
                "http://www.ncbi.nlm.nih.gov/pubmed/29131135"
            ],
            "ideal_answer": [
                "Yes, subdural empyema can be a complication of sinusitis"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ca0c81eecadf2e73f000047",
            "snippets": [
                {
                    "offsetInBeginSection": 19,
                    "offsetInEndSection": 180,
                    "text": "Acute and chronic sinusitis can give rise to a wide array of intracranial and orbital complications. These complications include brain abscess, subdural empyema,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 323,
                    "text": " A computed tomography scan showed bilateral paranasal sinus disease, and magnetic resonance imaging showed a right frontal abscess and subdural empyema.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Frontal sinusitis complicated by a brain abscess and subdural empyema.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 292,
                    "text": "In older children, sinusitis and otitis media are usually the source for subdural empyem",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30014307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Subdural empyema as a complication of sinusitis in the pediatric population.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2077,
                    "offsetInEndSection": 2182,
                    "text": "Second, subdural empyema appears to arise in the setting of subacute rather than acute frontal sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 358,
                    "offsetInEndSection": 514,
                    "text": "Subdural empyema is a rare but potentially life-threatening complication following paranasal sinusitis and should be considered as a neurological emergency.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "[Subdural empyema as a complication of sinusitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "INTRODUCTION\nSubdural empyema is an uncommon but serious complication of sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 318,
                    "text": "Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 471,
                    "text": "Subdural empyema is a rare complication of sinusitis although very severe.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402493",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Subdural empyema is a rare complication of sinusitis in children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Subdural empyema is a rare but serious complication of paranasal sinusitis which may result in death or permanent disability in a significant proportion of cases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9217340",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 850,
                    "text": "We report a case of subdural empyema secondary to frontal sinusitis in an otherwise healthy immunocompetent adolescent boy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22030191",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 309,
                    "text": "Subdural empyema is a rare but life-threatening complication of paranasal sinusitis, otitis media, or mastoid disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Wolf in Sheep's Clothing Subdural Empyema: A Rare Complication of Acute Sinusitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806018",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Interhemispheric and Infratentorial Subdural Empyema with Preseptal Cellulitis as Complications of Sinusitis: A Case Report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Subdural empyema as a complication of sinusitis in the pediatric population.<AbstractText Label=\"OBJECTIVE\" NlmCategory=\"OBJECTIVE\">Sinusitis is a rare cause of intracranial infection in children. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "[Subdural empyema as a complication of sinusitis. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 335,
                    "text": "Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "text": "Streptococcus pluranimalium: A novel human pathogen?<AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">We present the first case of a subdural empyema caused by Streptococcus pluranimalium, in a healthy adolescent male as a possible complication of subclinical frontal sinusitis. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437686",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1283,
                    "text": "<AbstractText Label=\"DISCUSSION\" NlmCategory=\"CONCLUSIONS\">The diagnosis of subdural empyema as a complication of asymptomatic sinusitis in an immunocompetent patient with no history of fever or upper respiratory symptoms was unanticipated. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437686",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2329,
                    "offsetInEndSection": 2434,
                    "text": "Second, subdural empyema appears to arise in the setting of subacute rather than acute frontal sinusitis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Bifrontal decompressive craniectomy for acute subdural empyema.<AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Subdural empyema is an uncommon but serious complication of sinusitis. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 638,
                    "text": "Subdural empyema is a rare but potentially life-threatening complication following paranasal sinusitis and should be considered as a neurological emergency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 530,
                    "text": "We present a patient with subdural empyema in whom the diagnosis was delayed, followed by a discussion of suppurative complications of sinusitis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17182345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 607,
                    "text": "<AbstractText Label=\"CASE REPORT\" NlmCategory=\"METHODS\">We report an unusual case of sinusitis-associated acute subdural empyema in a 13-year-old patient, presenting in a catastrophic manner with acutely raised intracranial pressure. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 475,
                    "text": "The symptoms of subdural empyema may be mild and may be the same as those associated with sinusitis, or the infection may result in alteration of the level of consciousness and focal neurologic deficits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7810468",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 335,
                    "text": "We report the clinical and radiological course of an adolescent with a subdural empyema secondary to sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 602,
                    "text": "We report two cases of subdural empyema secondary to sinusitis in persons without impaired immunity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 48,
                    "text": "Subdural empyema as a complication of sinusitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 246,
                    "text": "Furthermore, subdural empyema usually is related to sinus infections, particularly those caused by Streptococcus milleri, an anaerobic organism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Subdural empyema is an uncommon but serious complication of sinusitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does replication timing affect the rate of somatic mutations?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23327985",
                "http://www.ncbi.nlm.nih.gov/pubmed/23422670",
                "http://www.ncbi.nlm.nih.gov/pubmed/22023572",
                "http://www.ncbi.nlm.nih.gov/pubmed/23271586",
                "http://www.ncbi.nlm.nih.gov/pubmed/12941181",
                "http://www.ncbi.nlm.nih.gov/pubmed/9560368",
                "http://www.ncbi.nlm.nih.gov/pubmed/19287383",
                "http://www.ncbi.nlm.nih.gov/pubmed/23821616",
                "http://www.ncbi.nlm.nih.gov/pubmed/22114361",
                "http://www.ncbi.nlm.nih.gov/pubmed/22046001",
                "http://www.ncbi.nlm.nih.gov/pubmed/24598232",
                "http://www.ncbi.nlm.nih.gov/pubmed/21666225"
            ],
            "ideal_answer": [
                "Mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome. All classes of substitutions are affected, suggesting a generalized mechanism involving replication time-dependent DNA damage. DNA repair systems, in general, are less efficient in late replicating heterochromatic regions compared to early replicating euchromatic regions of the genome. In yeast the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions. Limited evidence from one chromosome arm in Drosophila melanogaster suggests the opposite pattern, with regions overlapping early-firing origins showing increased levels of diversity and divergence. In humans DNA replication patterns help shape the mutational landscapes of normal and cancer genomes.",
                "Recent studies revealed a long suspected replication-timing effect on mutation rate, but the mechanisms that regulate the increase in mutation rate as the genome is replicated remain unclear. The mutations were distributed randomly throughout the genome, independent of replication timing. Here, we show that the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions. Interestingly, 5% of the single base pair substitutions might represent double-slippage events that occurred at the junction of immediately adjacent repeats, resulting in a shift in the repeat boundary.",
                "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5710dd61cf1c32585100002e",
            "snippets": [
                {
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 324,
                    "text": "Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19287383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 451,
                    "text": "ll classes of substitutions are affected, suggesting a generalized mechanism involving replication time-dependent DNA damage",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19287383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 602,
                    "text": "We show that mutation rate varies 6-fold across a single chromosome, that this variation is correlated with replication timing, and we propose a model to explain this variation that relies on the temporal separation of two processes for replicating past damaged DNA: error-free DNA damage tolerance and translesion synthesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21666225",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 264,
                    "text": "Recent studies revealed a long suspected replication-timing effect on mutation rate, but the mechanisms that regulate the increase in mutation rate as the genome is replicated remain unclear. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023572",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 459,
                    "text": "DNA repair systems, in general, are less efficient in late replicating heterochromatic regions compared to early replicating euchromatic regions of the genome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023572",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "The mutational profile of the yeast genome is shaped by replication",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114361",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 340,
                    "text": "the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 919,
                    "text": "Thus, we show that the leading replicating strands present an excess of C over G and of A over T in the genome of S. cerevisiae (reciprocally an excess of G + T over C + A in lagging strands)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Late-replicating domains have higher divergence and diversity in Drosophila melanogaster",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22046001",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 382,
                    "text": "Recent evidence also suggests that late replication is associated with high mutability in yeast.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22046001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 677,
                    "text": "Limited evidence from one chromosome arm in Drosophila melanogaster suggests the opposite pattern, with regions overlapping early-firing origins showing increased levels of diversity and divergence",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22046001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 731,
                    "offsetInEndSection": 981,
                    "text": "The mutation rate for DNA mismatch repair null strains was approximately 1 mutation per genome per generation, 225-fold greater than the wild-type rate. The mutations were distributed randomly throughout the genome, independent of replication timing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821616",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 218,
                    "text": "Many single-nucleotide substitutions in cancer genomes arise because of errors in DNA replication, which is spatio-temporally stratified.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 330,
                    "text": "Here we propose that DNA replication patterns help shape the mutational landscapes of normal and cancer genomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 603,
                    "text": "Using data on five fully sequenced cancer types and two personal genomes, we determined that the frequency of intergenic single-nucleotide substitution is significantly higher in late DNA replication timing regions, even after controlling for a number of genomic features",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 770,
                    "offsetInEndSection": 930,
                    "text": "we found that genomic regions in close spatial proximity to late-replicating domains display similar mutation spectra as the late-replicating regions themselves",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422670",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1047,
                    "offsetInEndSection": 1439,
                    "text": "In addition, certain chromosome rearrangements found in cancer cells and in cells exposed to ionizing radiation display a significant delay in replication timing of >3 hours that affects the entire chromosome(2,3). Recent work from our lab indicates that disruption of discrete cis-acting autosomal loci result in an extremely late replicating phenotype that affects the entire chromosome(4).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23271586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 510,
                    "text": "A conservative estimate is that at least 1-2% of new deleterious mutations affect some aspect of DNA replication, repair, or chromosome segregation. Since deleterious mutations can have an effect even as heterozygotes, this mutation accumulation can create an inherited background of late-acting mutations that themselves enhance mutation rate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12941181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 650,
                    "offsetInEndSection": 972,
                    "text": "Drake calculates that lytic RNA viruses display spontaneous mutation rates of approximately one per genome while most have mutation rates that are approximately 0.1 per genome (Drake 1993). This constancy of germline mutation rates among microbial species need not necessarily mean constancy of the somatic mutation rates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9560368",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "A recent flurry of reports correlates replication timing (RT) with mutation rates during both evolution and cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598232",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "DNA replication timing, genome stability and cancer: late and/or delayed DNA replication timing is associated with increased genomic instability.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23327985",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 510,
                    "text": "Since deleterious mutations can have an effect even as heterozygotes, this mutation accumulation can create an inherited background of late-acting mutations that themselves enhance mutation rate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12941181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2048,
                    "offsetInEndSection": 2229,
                    "text": "In addition, this method allows for the unambiguous identification of chromosomal rearrangements that correlate with changes in replication timing that affect the entire chromosome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23271586",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do thyroid hormone receptors change after brain injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/14761671",
                "http://www.ncbi.nlm.nih.gov/pubmed/24174657",
                "http://www.ncbi.nlm.nih.gov/pubmed/6329444"
            ],
            "ideal_answer": [
                "thyroid hormone receptors increase after brain injury"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001930",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988"
            ],
            "type": "yesno",
            "id": "533e50fdc45e13371400000f",
            "snippets": [
                {
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 984,
                    "text": "For example, the T3 receptor alpha was predominantly expressed in stroke-tissue, indicating that regeneration of nerves in stroke tissue may be facilitated by increased T3 receptor alpha expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14761671",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1044,
                    "text": "TR\u03b1 expression was also increased in human infants with IVH. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24174657",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1422,
                    "offsetInEndSection": 1595,
                    "text": "Thus, in infants with IVH the combined elevation in deiodinase-3 and reduction in deiodinase-2 decreases TH signaling that can be worsened by an increase in unliganded TR\u03b1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24174657",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 360,
                    "offsetInEndSection": 758,
                    "text": "A rapid increase of the total number of binding sites for T3 appeared within 30 min of ischemia and reached over 40% by 3 h. During the same 3-h period, the relative binding affinity was reduced by 25%. Upon recirculation after 30 min or 3 h of ischemia, a rapid reversal of measured T3 binding sites occurred, which progressed to 20-30% below the control value by the recirculation period of 3 h. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6329444",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is oxalate renal excretion increased after bariatric surgery?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21295813",
                "http://www.ncbi.nlm.nih.gov/pubmed/23821183",
                "http://www.ncbi.nlm.nih.gov/pubmed/16925274",
                "http://www.ncbi.nlm.nih.gov/pubmed/18701613",
                "http://www.ncbi.nlm.nih.gov/pubmed/18501812",
                "http://www.ncbi.nlm.nih.gov/pubmed/9689695",
                "http://www.ncbi.nlm.nih.gov/pubmed/23024163",
                "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
                "http://www.ncbi.nlm.nih.gov/pubmed/19762051",
                "http://www.ncbi.nlm.nih.gov/pubmed/19013593",
                "http://www.ncbi.nlm.nih.gov/pubmed/2218396",
                "http://www.ncbi.nlm.nih.gov/pubmed/16217311",
                "http://www.ncbi.nlm.nih.gov/pubmed/17222634",
                "http://www.ncbi.nlm.nih.gov/pubmed/22554593",
                "http://www.ncbi.nlm.nih.gov/pubmed/2669121"
            ],
            "ideal_answer": [
                "Bariatric surgery is associated with a significant risk of nephrolithiasis.\nEnteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy must be considered with the other risks of bariatric surgery\nHyperoxaluria in patients treated with bariatric surgery was found to be a result of hyperabsorption of oxalate",
                "Urinary oxalate increases after bariatric surgery"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007588",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002129",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015390",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010070",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D049088",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050110",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013502"
            ],
            "type": "yesno",
            "id": "52df887498d023950500000c",
            "snippets": [
                {
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 630,
                    "text": "Despite the fact that bariatric surgery-induced weight loss is associated with a significant decrease in morbidity and mortality and improvement in renal function, bariatric surgery has recently been shown to be associated with a significant risk of nephrolithiasis. The main risk factor for nephrolithiasis is increased excretion of urinary oxalate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20566568",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1444,
                    "offsetInEndSection": 1557,
                    "text": "Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy must be considered with the other risks of RYGBP.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16925274",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 724,
                    "text": "The urinary excretion of oxalate was high: 1.112 mumol/24 h (normal range: 55-400 mumol/24 h), and citrate excretion was low: 1.48 mmol/24 h (normal range: 2-5 mmol/24 h). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9689695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 981,
                    "text": "Hyperoxaluria in patients with JIB was found to be a result of hyperabsorption of oxalate, and these patients displayed altered oxalate kinetics with continued urinary excretion of orally administered 14C-oxalate for more than 48 hours. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1086,
                    "offsetInEndSection": 1517,
                    "text": "Malabsorption of calcium and low fasting urinary calcium excretion in the JIB patients were associated with high tubular reabsorption of calcium, the latter presumably attributable to a compensatory increase in circulating parathyroid hormone (PTH). In most recurrent renal stone formers the urinary calcium concentration was increased, with an inverse relationship to serum PTH, indicating intestinal hyperabsorption of calcium. A",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669121",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between TERT promoter mutation and survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23393205",
                "http://www.ncbi.nlm.nih.gov/pubmed/24937153",
                "http://www.ncbi.nlm.nih.gov/pubmed/23955565"
            ],
            "ideal_answer": [
                "Telomerase reverse transcriptase (TERT) promoter are associated with shorter survival of glioblastoma patients. Prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3073"
            ],
            "type": "yesno",
            "id": "55032bbfe9bde69634000032",
            "snippets": [
                {
                    "offsetInBeginSection": 993,
                    "offsetInEndSection": 1734,
                    "text": "Glioblastoma patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs. 10.5 months; P = 0.015) and multivariate analysis after adjusting for age and gender (HR 1.38, 95 % CI 1.01-1.88, P = 0.041). However, TERT mutations had no significant impact on patients' survival in multivariate analysis after further adjusting for other genetic alterations, or when primary and secondary glioblastomas were separately analysed. These results suggest that the prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations, which are a significant prognostic marker of better survival in patients with secondary glioblastomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1593,
                    "offsetInEndSection": 1825,
                    "text": "Patients with tumors lacking hTERT expression/TA showed a significant survival benefit (Kaplan-Meier test, both P < .01), which, however, was based exclusively on the younger patient subgroup (\u226460 y, both P < .005; >60 y, both ns). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 993,
                    "offsetInEndSection": 1133,
                    "text": "Glioblastoma patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955565",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does a linker histone exist in the yeast genome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22586276",
                "http://www.ncbi.nlm.nih.gov/pubmed/9516420",
                "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                "http://www.ncbi.nlm.nih.gov/pubmed/15046982",
                "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                "http://www.ncbi.nlm.nih.gov/pubmed/18687885",
                "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                "http://www.ncbi.nlm.nih.gov/pubmed/16342967",
                "http://www.ncbi.nlm.nih.gov/pubmed/11574687",
                "http://www.ncbi.nlm.nih.gov/pubmed/24023978",
                "http://www.ncbi.nlm.nih.gov/pubmed/15050829"
            ],
            "ideal_answer": [
                "Here, we present our results showing a connection between the linker histones, the higher-order chromatin structures, and the process of chronological lifespan of yeast cells. Characteristically, linker histone depleted chromatin generally exhibited longer chromatin loops than the wild-type. These results suggest that HHO1p may play a similar role to linker histones, but at restricted locations in the chromatin. The binding was structure specific, since the use of double-stranded DNA, or a mutant Hho1p in which the second DNA binding site of globular domain 1 was abolished, resulted in a significant decrease in bridged binding.",
                "Hho1p is a bona fide linker histone",
                "In Saccharomyces cerevisiae, HHO1 encodes a putative linker histone with very significant homology to histone H1. The putative linker histone in Saccharomyces cerevisiae, Hho1p, has two regions of sequence (GI and GII) that are homologous to the single globular domains of linker histones H1 and H5 in higher eukaryotes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015003",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012441",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678",
                "http://www.biosemantics.org/jochem#4278518",
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4278518",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657"
            ],
            "type": "yesno",
            "id": "5709152ecf1c325851000014",
            "snippets": [
                {
                    "offsetInBeginSection": 999,
                    "offsetInEndSection": 1034,
                    "text": "Hho1p is a bona fide linker histone",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9516420",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 248,
                    "text": "In Saccharomyces cerevisiae, HHO1 encodes a putative linker histone with very significant homology to histone H1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11574687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1089,
                    "text": "HHO1p may play a similar role to linker histones, but at restricted locations in the chromatin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11574687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "The putative linker histone in Saccharomyces cerevisiae, Hho1p, has two regions of sequence (GI and GII) that are homologous to the single globular domains of linker histones H1 and H5 in higher eukaryotes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15046982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "The Saccharomyces cerevisiae homologue of the linker histone H1, Hho1p, has two domains that are similar in sequence to the globular domain of H1 (and variants such as H5)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050829",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Two homologous domains of similar structure but different stability in the yeast linker histone, Hho1p",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050829",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Saccharomyces cerevisiae encodes a single linker histone, Hho1p, with two globular domains. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16342967",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "The Saccharomyces cerevisiae linker histone Hho1p, with two globular domains, can simultaneously bind to two four-way junction DNA molecules",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16342967",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 272,
                    "text": "Here, we show in yeast, that the presence of yeast linker histone Hho1p represses expression of a pol II transcribed gene (MET15) embedded in the rDNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18687885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Yeast linker histone Hho1p is required for efficient RNA polymerase I processivity and transcriptional silencing at the ribosomal DNA",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18687885",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Saccharomyces cerevisiae linker histone Hho1p is not essential for cell viability, and very little is known about its function in vivo. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "Saccharomyces cerevisiae linker histone Hho1p functionally interacts with core histone H4 and negatively regulates the establishment of transcriptionally silent chromatin",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 813,
                    "offsetInEndSection": 1133,
                    "text": " Unlike canonical linker histones in higher eukaryotes that have a single conserved globular domain, Hho1p possesses two globular domains. We show that the carboxyl-terminal globular domain of Hho1p is dispensable for its function, suggesting that the mode of Hho1p action is similar to that of canonical linker histones",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 440,
                    "text": "To identify new proteins involved in spore nuclear organization, we purified chromatin from mature spores and discovered a significant enrichment of the linker histone (Hho1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22586276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 621,
                    "offsetInEndSection": 837,
                    "text": "Hho1 chromatin immunoprecipitation followed by sequencing (ChIP-seq) revealed increased genome-wide binding in mature spores and provides novel in vivo evidence of the linker histone binding to nucleosomal linker DNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22586276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 327,
                    "text": "One of the peculiarities of S. cerevisiae cells is the unusual and less abundant linker histone, Hho1p.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Hho1p, the linker histone of Saccharomyces cerevisiae, is important for the proper chromatin organization in vivo",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 817,
                    "text": "Characteristically, linker histone depleted chromatin generally exhibited longer chromatin loops than the wild-type. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Saccharomyces cerevisiae linker histone-Hho1p maintains chromatin loop organization during ageing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023978",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 583,
                    "text": "Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 361,
                    "text": "Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 361,
                    "text": "Biochemical studies to date have not been able to identify the linker histone H1 protein in the budding yeast Saccharomyces cerevisiae. Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 361,
                    "text": "Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are conserved noncoding elements associated with the evolution of animal body plans?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19492354"
            ],
            "ideal_answer": [
                "Yes. Cis-regulatory inputs identified by CNEs arose during the \"re-wiring\" of regulatory interactions that occurred during early animal evolution. Consequently, different animal groups, with different core GRNs, contain alternative sets of CNEs. Due to the subsequent stability of animal body plans, these core regulatory sequences have been evolving in parallel under strong purifying selection in different animal groups."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56b8a222156496395c000001",
            "snippets": [
                {
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 1086,
                    "text": "Here, we discuss the evidence that CNEs are part of the core gene regulatory networks (GRNs) that specify alternative animal body plans. The major animal groups arose>550 million years ago. We propose that the cis-regulatory inputs identified by CNEs arose during the \"re-wiring\" of regulatory interactions that occurred during early animal evolution. Consequently, different animal groups, with different core GRNs, contain alternative sets of CNEs. Due to the subsequent stability of animal body plans, these core regulatory sequences have been evolving in parallel under strong purifying selection in different animal groups.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "text": "Conserved noncoding elements and the evolution of animal body plans.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Conserved noncoding elements and the evolution of animal body plans",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19492354",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is statin use associated with improved outcomes after aneurysmal subarachnoid hemorrhage?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16051891",
                "http://www.ncbi.nlm.nih.gov/pubmed/19875741",
                "http://www.ncbi.nlm.nih.gov/pubmed/19614959",
                "http://www.ncbi.nlm.nih.gov/pubmed/24323051",
                "http://www.ncbi.nlm.nih.gov/pubmed/19439205",
                "http://www.ncbi.nlm.nih.gov/pubmed/23392270",
                "http://www.ncbi.nlm.nih.gov/pubmed/20934152",
                "http://www.ncbi.nlm.nih.gov/pubmed/19458605",
                "http://www.ncbi.nlm.nih.gov/pubmed/16049199",
                "http://www.ncbi.nlm.nih.gov/pubmed/22709377",
                "http://www.ncbi.nlm.nih.gov/pubmed/23298376",
                "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                "http://www.ncbi.nlm.nih.gov/pubmed/23633351",
                "http://www.ncbi.nlm.nih.gov/pubmed/19912325",
                "http://www.ncbi.nlm.nih.gov/pubmed/18382320",
                "http://www.ncbi.nlm.nih.gov/pubmed/18658040",
                "http://www.ncbi.nlm.nih.gov/pubmed/23691312",
                "http://www.ncbi.nlm.nih.gov/pubmed/22929438",
                "http://www.ncbi.nlm.nih.gov/pubmed/17413047",
                "http://www.ncbi.nlm.nih.gov/pubmed/17029334",
                "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                "http://www.ncbi.nlm.nih.gov/pubmed/18691455",
                "http://www.ncbi.nlm.nih.gov/pubmed/19197830",
                "http://www.ncbi.nlm.nih.gov/pubmed/21556312",
                "http://www.ncbi.nlm.nih.gov/pubmed/17986515",
                "http://www.ncbi.nlm.nih.gov/pubmed/15730572",
                "http://www.ncbi.nlm.nih.gov/pubmed/21755120"
            ],
            "ideal_answer": [
                "Statin use after subarachnoid hemorrhage has been shown be associated with improved outcomes by some prospective clinical trials. It has been reported that statin use after subarachnoid hemorrhage reduced rates of vasospasm, delayed cerebral ischemia, and mortality. However, other authors have failed to find beneficial effect of statin use in subarachnoid hemorrhage patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019161",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013345",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017063",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010043"
            ],
            "type": "yesno",
            "id": "530e131b5937551c09000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "text": "Statins have been shown in two recent small phase I/II trials to be associated with a marked reduction in clinical and transcranial Doppler (TCD) evidence of vasospasm after aneurysmal subarachnoid haemorrhage (SAH). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 658,
                    "text": "Statins did not result in reduced TCD velocities, clinical or angiographic vasospasm, or improvements in global outcome at the time of hospital discharge. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 900,
                    "text": "There remains significant uncertainty as to the role of statins in preventing vasospasm after SAH.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 308,
                    "text": "Although the results of 2 randomized clinical trials demonstrated that statin decreases the incidence of symptomatic cerebral vasospasm after aSAH, retrospective studies have failed to confirm this.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1473,
                    "offsetInEndSection": 1825,
                    "text": "There were no differences in the incidence of symptomatic vasospasm (25.3 vs 30.5%; p = 0.277), in-hospital mortality rate (18 vs 15%; p = 0.468), length of hospitalization (21 +/- 15 vs 19 +/- 12 days; p = 0.281), or poor outcome at discharge (Glasgow Outcome Scale Scores 1-2: 21.7 vs 18.2%; p = 0.416) between the simvastatin and nonstatin cohorts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1882,
                    "offsetInEndSection": 2126,
                    "text": "The uniform introduction of simvastatin did not reduce the incidence of symptomatic cerebral vasospasm, death, or poor outcome in patients with aSAH. Simvastatin was well tolerated, but its benefit may be less than has been previously reported.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 254,
                    "text": "Cholesterol-reducing agents might improve unfavourable outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633351",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2150,
                    "offsetInEndSection": 2326,
                    "text": "We cannot draw any conclusions about the effectiveness and safety of lowering cholesterol in aneurysmal SAH because of insufficient reliable evidence from only one small trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633351",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 119,
                    "text": "Experimental evidence has indicated the benefit of simvastatin in the treatment of subarachnoid hemorrhage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23392270",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1293,
                    "offsetInEndSection": 1466,
                    "text": "There was an improvement in the functional outcome in the simvastatin group at 1, 3 or 6 months in the follow-up; however, this difference was not statistically significant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1648,
                    "text": " There was benefit of simvastatin in terms of reduction in clinical vasospasm, mortality or improved functional outcome, however, this was not statistically significant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 713,
                    "text": "Cerebral vasomotor reactivity, however, is significantly improved after long-term statin administration in most patients with severe small vessel disease, aneurysmal subarachnoid hemorrhage, or impaired baseline CA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Atorvastatin decreases computed tomography and S100-assessed brain ischemia after subarachnoid aneurysmal hemorrhage: a comparative study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1845,
                    "text": "In the overall population, cerebral vasospasm was significantly less common in the statin-treated group. Severity of vasospasm, as assessed on the most severe angiogram, was lowered with statin. Statins significantly reduced volume of ischemia in patients with vasospasm and an uncomplicated coiling procedure. S100B levels were significantly lower in statin-treated patients, and the decrease was greatest among high-grade patients (World Federation of Neurological Surgeons 3-5). No differences were found between statin-treated and untreated groups regarding rescue therapy intensity or 1-yr clinical outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1859,
                    "offsetInEndSection": 2321,
                    "text": "Atorvastatin reduces the incidence, the severity and the ischemic consequences of vasospasm as assessed on computed tomography. In high-grade World Federation of Neurological Surgeons patients, atorvastatin decreases serum levels of S100B, a biomarker of brain ischemia. Despite these positive effects on biomarkers, no improvement of outcome was seen in the overall population, although there was a tendency for a better clinical outcome in high-grade patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 281,
                    "text": "3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have been associated with improved clinical outcomes after ischemic stroke and subarachnoid hemorrhage, but with an increased risk of incidental spontaneous intracerebral hemorrhage (ICH).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21755120",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 536,
                    "text": "Statins are known to have pleiotropic vascular effects, some of which may interrupt the pathogenesis of DNDs. Based on promising preliminary reports, many clinicians routinely administer statins to prevent DNDs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1504,
                    "text": "However, observational studies have not revealed an association between statin-use and reduced DNDs or improved neurological outcomes. Results of RCTs have been inconsistent and limited by small sample size, but together suggest that statins may reduce DNDs, with no clear impact on mortality or neurological recovery.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1639,
                    "offsetInEndSection": 1797,
                    "text": "the role of statins in the management of patients with SAH remains unclear. Although promising, statins should not, at this time, be considered standard care.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 660,
                    "text": "In patients with SAH, they may decrease the incidence of symptomatic vasospasm, although the effects on overall outcome are less clear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20934152",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 202,
                    "text": "Statins treatment may have potential clinical impact in vascular disease beyond cholesterol lowering. Its benefits have been documented in cerebral ischaemia and in subarachnoid haemorrhage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19912325",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 24,
                    "offsetInEndSection": 257,
                    "text": "A recent meta-analysis investigating the efficacy of statin treatment in patients with aneurysmal subarachnoid hemorrhage reported a reduced incidence of vasospasm, delayed cerebral ischemia, and mortality in statin-treated patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19875741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1711,
                    "text": "The results of the present systematic review do not lend statistically significant support to the finding of a beneficial effect of statins in patients with aneurysmal subarachnoid hemorrhage as reported in a previous meta-analysis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19875741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 253,
                    "text": "Pre-treatment with cholesterol lowering drugs of the statin family may exert protective effects in patients with ischaemic stroke and subarachnoid haemorrhage but their effects are not clear in patients with intracerebral haemorrhage (ICH). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19614959",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "text": "Recently, two randomized controlled phase II studies showed that acute initiation of statin treatment directly after aneurysmal subarachnoid hemorrhage (SAH) decreases the incidence of radiologic vasospasm and clinical signs of delayed cerebral ischemia (DCI), and even reduces mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458605",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1218,
                    "offsetInEndSection": 1367,
                    "text": "We conclude that both the primary and secondary outcome results of this study do not support a beneficial effect of simvastatin in patients with SAH.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458605",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1051,
                    "offsetInEndSection": 1215,
                    "text": "Novel uses of their anti-inflammatory properties in sepsis and vasomotor properties in subarachnoid haemorrhage are being further investigated by randomised trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19439205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 970,
                    "text": "A trend towards a lower mortality within 14 days in patients receiving solely simvastatin and those receiving statin and magnesium as compared with the control group was found. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691455",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1546,
                    "text": "Initiation of statin therapy after aneurysmal SAH significantly reduces the incidence of vasospasm, delayed ischemic deficits, and mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18658040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1806,
                    "offsetInEndSection": 1986,
                    "text": "The addition of statins to standard care was not associated with any reduction in the development of vasospasm or improvement in outcomes after aneurysmal subarachnoid hemorrhage. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18382320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 24,
                    "offsetInEndSection": 184,
                    "text": "We have previously demonstrated that acute pravastatin therapy after aneurysmal subarachnoid hemorrhage ameliorates vasospasm-related delayed ischemic deficits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17413047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1617,
                    "text": " This trial demonstrates that acute statin treatment reduces traditional rescue therapy for vasospasm after aneurysmal subarachnoid hemorrhage. Improvement in early outcome has proved robust at 6 months, particularly in relation to physical and psychosocial (Short Form 36) outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17413047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 8,
                    "offsetInEndSection": 214,
                    "text": "The authors previously have demonstrated that acute treatment with pravastatin after aneurysmal subarachnoid hemorrhage (SAH) can ameliorate vasospasm-related delayed ischemic neurological deficits (DINDs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1715,
                    "offsetInEndSection": 1853,
                    "text": "The neuroprotective effects of acute treatment with pravastatin following aneurysmal SAH are associated with enhancement of autoregulation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16051891",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1861,
                    "text": "The use of simvastatin as prophylaxis against delayed cerebral ischemia after aneurysmal SAH is a safe and well-tolerated intervention. Its use attenuates serum markers associated with brain injury and decreases the incidence of radiographic vasospasm and delayed ischemic deficit.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16051891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1553,
                    "offsetInEndSection": 1709,
                    "text": "Acute treatment with pravastatin after aSAH is safe and ameliorates cerebral vasospasm, improves cerebral autoregulation, and reduces vasospasm-related DID.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16049199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1557,
                    "offsetInEndSection": 1911,
                    "text": " SAH statin users demonstrated significant improvement in 14-day functional outcome, a significantly lower incidence of DCI and cerebral infarctions of any type, as well as prevention of TCD highest mean velocity elevation. However, we did not find a significant statin impact on mortality or global outcome (Modified Rankin Scale) in this small sample. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15730572",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can NXY-059 be used for treatment of acute ischemic stroke patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17408618",
                "http://www.ncbi.nlm.nih.gov/pubmed/21651461",
                "http://www.ncbi.nlm.nih.gov/pubmed/11239186",
                "http://www.ncbi.nlm.nih.gov/pubmed/18369171",
                "http://www.ncbi.nlm.nih.gov/pubmed/17068304",
                "http://www.ncbi.nlm.nih.gov/pubmed/17975102",
                "http://www.ncbi.nlm.nih.gov/pubmed/19074479",
                "http://www.ncbi.nlm.nih.gov/pubmed/19631615",
                "http://www.ncbi.nlm.nih.gov/pubmed/18416999",
                "http://www.ncbi.nlm.nih.gov/pubmed/17420989",
                "http://www.ncbi.nlm.nih.gov/pubmed/23419732",
                "http://www.ncbi.nlm.nih.gov/pubmed/22709256",
                "http://www.ncbi.nlm.nih.gov/pubmed/16467546",
                "http://www.ncbi.nlm.nih.gov/pubmed/17478741",
                "http://www.ncbi.nlm.nih.gov/pubmed/17579658",
                "http://www.ncbi.nlm.nih.gov/pubmed/23109881",
                "http://www.ncbi.nlm.nih.gov/pubmed/17687131",
                "http://www.ncbi.nlm.nih.gov/pubmed/12848592",
                "http://www.ncbi.nlm.nih.gov/pubmed/17244778",
                "http://www.ncbi.nlm.nih.gov/pubmed/18673209",
                "http://www.ncbi.nlm.nih.gov/pubmed/19167593"
            ],
            "ideal_answer": [
                "No.  2,4-disulfonylphenyl PBN derivative, called NXY-059 in the stroke studies, was shown to be safe in humans and was taken all the way through clinical phase 3 trials and then was deemed to be ineffective."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "54d62faf3706e89528000003",
            "snippets": [
                {
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 704,
                    "text": "Even when the international recommendations for preclinical stroke research, the Stroke Academic Industry Roundtable (STAIR) criteria, were followed, we have still seen limited success in the clinic, examples being NXY-059 and haematopoietic growth factors which fulfilled nearly all the STAIR criteria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109881",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 791,
                    "offsetInEndSection": 1035,
                    "text": "This occurred during 1993-2006, when the 2,4-disulfonylphenyl PBN derivative, called NXY-059 in the stroke studies, was shown to be safe in humans and was taken all the way through clinical phase 3 trials and then was deemed to be ineffective. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419732",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 364,
                    "text": "The nitrone-based compound NXY-059, which is the first drug to reach clinical trials for the treatment of acute ischemic stroke, has provided promise for the development of more robust pharmacological agents. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22709256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 739,
                    "text": "OKN-007 is a proprietary compound that has had extensive commercial development (designated as NXY-059) for another indication, acute ischemic stroke, and after extensive clinical studies was shown to lack efficacy for this indication but was shown to be very safe for human use. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21651461",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 244,
                    "text": "NXY-059, a polar compound with limited transport across the blood-brain barrier, has demonstrated neuroprotection in several animal models of acute ischemic stroke but failed to confirm clinical benefit in the second phase III trial (SAINT-II).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631615",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 356,
                    "offsetInEndSection": 488,
                    "text": "NXY-059 is no longer in development following a lack of efficacy found in a Phase III trial in patients with acute ischemic stroke. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19167593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 385,
                    "text": "We analyzed the quality and adequacy of animal studies supporting the efficacy of NXY-059 and other neuroprotective agents that are currently being investigated in phase II/III trials",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 320,
                    "text": " In the aftermath of the failed stroke clinical trials with the nitrone spin trap/radical scavenger, NXY-059, a number of articles raised the question: are we doing the right thing? ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673209",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 852,
                    "text": " In 2006, the first positive trial of neuroprotection was published: the SAINT I (Stroke-Acute Ischemic NXY Treatment) study. In February 2008, the SAINT II study was published, indicating that NXY-059 was not effective for AIS treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18416999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1920,
                    "offsetInEndSection": 2010,
                    "text": "CONCLUSIONS: NXY-059 is ineffective for treatment of AIS within 6 hours of symptom onset. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18369171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "BACKGROUND AND PURPOSE: The SAINT I trial that showed a significant benefit of the neuroprotectant NXY-059 used a novel outcome for acute ischemic stroke trials: a shift toward good functional outcome on the 7-category modified Rankin scale (mRS).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17975102",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "BACKGROUND: The free-radical-trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke-Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ischemic stroke. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687131",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1773,
                    "offsetInEndSection": 1895,
                    "text": "CONCLUSIONS: NXY-059 is ineffective for the treatment of acute ischemic stroke within 6 hours after the onset of symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687131",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "The continued failure in approving new drugs for treatment of acute stroke has been recently set back by the failure of the NXY-059 (Stroke-Acute Ischemic NXY Treatment (SAINT) II) trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "The SAINT II Trial, a large randomized multicenter clinical trial of the putative neuroprotectant, NXY-059, failed to demonstrate a treatment benefit in acute ischemic stroke. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17478741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 844,
                    "text": "The positive results from the first Stroke-Acute-Ischaemic-NXY-Treatment (SAINT-I) trial of the free-radical spin-trap drug, NXY-059, which followed many of the STAIR guidelines, reinvigorated enthusiasm in neuroprotection, but the SAINT-II trial did not replicate the positive effect on the same primary prespecified outcome measure. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 613,
                    "text": "NXY-059, a free radical spin trap agent, was felt by many to have followed these criteria and it was recently shown to improve outcome in AIS patients in the SAINT I trial. However, the repeat, SAINT II trial was a neutral study, the results of which cast doubt on neuroprotection as a viable strategy for AIS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17408618",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "text": "NXY-059 is a novel free radical-trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. It is the first neuroprotectant to demonstrate a reduction in global disability in a phase III clinical trial, as measured by the modified Rankin Scale.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "BACKGROUND AND PURPOSE: NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17068304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1432,
                    "offsetInEndSection": 1527,
                    "text": "CONCLUSIONS: NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17068304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1701,
                    "offsetInEndSection": 2095,
                    "text": "CONCLUSIONS: The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467546",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "text": "BACKGROUND: The free-radical-trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke-Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687131",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 356,
                    "offsetInEndSection": 487,
                    "text": "NXY-059 is no longer in development following a lack of efficacy found in a Phase III trial in patients with acute ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19167593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 210,
                    "text": "The free-radical-trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke-Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ischemic stroke",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687131",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "text": "The continued failure in approving new drugs for treatment of acute stroke has been recently set back by the failure of the NXY-059 (Stroke-Acute Ischemic NXY Treatment (SAINT) II) trial",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579658",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are Notch mutations related to T-cell Acute Lymphoblastic Leukemia (T-ALL)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21302811",
                "http://www.ncbi.nlm.nih.gov/pubmed/24301524",
                "http://www.ncbi.nlm.nih.gov/pubmed/24252593",
                "http://www.ncbi.nlm.nih.gov/pubmed/18056171",
                "http://www.ncbi.nlm.nih.gov/pubmed/23033986",
                "http://www.ncbi.nlm.nih.gov/pubmed/23730497",
                "http://www.ncbi.nlm.nih.gov/pubmed/24401270",
                "http://www.ncbi.nlm.nih.gov/pubmed/24140475",
                "http://www.ncbi.nlm.nih.gov/pubmed/21463127",
                "http://www.ncbi.nlm.nih.gov/pubmed/20008221",
                "http://www.ncbi.nlm.nih.gov/pubmed/17575125",
                "http://www.ncbi.nlm.nih.gov/pubmed/20015880",
                "http://www.ncbi.nlm.nih.gov/pubmed/16707600",
                "http://www.ncbi.nlm.nih.gov/pubmed/24068942",
                "http://www.ncbi.nlm.nih.gov/pubmed/25493453",
                "http://www.ncbi.nlm.nih.gov/pubmed/18184405",
                "http://www.ncbi.nlm.nih.gov/pubmed/20967796",
                "http://www.ncbi.nlm.nih.gov/pubmed/21263446",
                "http://www.ncbi.nlm.nih.gov/pubmed/23022380"
            ],
            "ideal_answer": [
                "Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL). Activating mutations in NOTCH1, an essential regulator of T cell development, are frequently found in human T cell acute lymphoblastic leukemia (T-ALL). ",
                "Yes, Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL).T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is characterized by aberrant activation of NOTCH1 in over 60% of T-ALL cases."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:5603"
            ],
            "type": "yesno",
            "id": "5522fadb7b523f2123000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 467,
                    "text": "Notch receptors participate in a highly conserved signalling pathway that regulates normal development and tissue homeostasis in a context- and dose-dependent manner. Deregulated Notch signalling has been implicated in many diseases, but the clearest example of a pathogenic role is found in T-cell lymphoblastic leukaemia/lymphoma (T-LL), in which the majority of human and murine tumours have acquired mutations that lead to aberrant increases in Notch1 signalling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967796",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 351,
                    "text": "NOTCH proteins (NOTCH1, NOTCH2, NOTCH3 and NOTCH4) play crucial roles in embryonic development. Also, mounting evidence indicates that NOTCH contributes to the pathogenesis of hematopoietic and solid malignancies. Recent studies reported a high incidence of gain-of-function mutations of the NOTCH1 gene in T-cell acute lymphoblastic leukemias (ALL). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1126,
                    "offsetInEndSection": 1300,
                    "text": "Our data indicate that NOTCH1 is mutated in T-ALL, but not in other common human cancers, and that NOTCH2, NOTCH3 and NOTH4 genes are rarely mutated in common human cancers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 602,
                    "text": "The Notch signaling pathway plays a critical role in maintaining the balance between cell proliferation, differentiation and apoptosis, and is a highly conserved signaling pathway that regulates normal development in a context- and dose-dependent manner. Dysregulation of Notch signaling has been suggested to be key events in a variety of hematological malignancies. Notch1 signaling appears to be the central oncogenic trigger in T cell acute lymphoblastic leukemia (T-ALL), in which the majority of human malignancies have acquired mutations that lead to constitutive activation of Notch1 signaling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 521,
                    "text": "T-cell acute lymphoblastic leukemia (T-ALL) is characterized as a high-risk stratified disease associated with frequent relapse, chemotherapy resistance, and a poorer prognostic outlook than B-precursor ALL. Many of the challenges in treating T-ALL reflect the lack of prognostic cytogenetic or molecular abnormalities on which to base therapy, including targeted therapy. Notch1 activating mutations were identified in more than 50% of T-ALL cases and can be therapeutically targeted with \u03b3-secretase inhibitors (GSIs). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140475",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 296,
                    "text": "Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068942",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 364,
                    "text": "T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is characterized by aberrant activation of NOTCH1 in over 60% of T-ALL cases. The high prevalence of activating NOTCH1 mutations highlights the critical role of NOTCH signaling in the pathogenesis of this disease and has prompted the development of therapeutic approaches targeting the NOTCH signaling pathway. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Activating mutations in NOTCH1, an essential regulator of T cell development, are frequently found in human T cell acute lymphoblastic leukemia (T-ALL). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "NOTCH signaling pathway is essential in T-cell development and NOTCH1 mutations are frequently present in T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16707600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 342,
                    "text": "Mutations in NOTCH1/FBXW7 activate NOTCH signaling and are of prognostic significance in patients with T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 79,
                    "offsetInEndSection": 207,
                    "text": "Gain-of-function mutations in Notch-1 have been reported in more than 50% of human T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Notch signaling is of crucial importance in normal T-cell development and Notch 1 is frequently mutated in T-cell acute lymphoblastic leukemias (T-ALL), leading to aberrantly high Notch signaling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575125",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Activation of the Notch pathway occurs commonly in T acute lymphoblastic leukemia (T-ALL) because of mutations in Notch1 or Fbw7 and is involved in the regulation of cell proliferation and survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21263446",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "T-cell acute lymphoblastic leukemia (T-ALL) patients frequently display NOTCH1 activating mutations and Notch can transcriptionally down-regulate the tumor suppressor PTEN.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20015880",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "text": "The identification of activating mutations in NOTCH1 in over 50% of T-cell acute lymphoblastic leukemias (T-ALL) has generated major interest in the elucidation of the mechanisms of transformation downstream of oncogenic NOTCH and in the targeting of the NOTCH signaling pathway in this disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008221",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 263,
                    "text": "BACKGROUND: In T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), activating mutations of NOTCH1 are observed in more than 50% of cases, whereas the t(7;9)(q34;q34) involving NOTCH1 at 9q34 and TRB@ at 7q34 is an extremely rare but recurrent translocation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23033986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Activating mutations in NOTCH1 consitute the most prominent genetic abnormality in T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21463127",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that is frequently associated with activating mutations in NOTCH1 and dysregulation of MYC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24401270",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "The Notch signaling pathway has been recognized as a key factor for the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), because of the high incidence of activating mutations of Notch1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24301524",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "Notch signaling is of crucial importance in normal T-cell development and Notch 1 is frequently mutated in T-cell acute lymphoblastic leukemias (T-ALL), leading to aberrantly high Notch signaling",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575125",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "NOTCH signaling pathway is essential in T-cell development and NOTCH1 mutations are frequently present in T-cell acute lymphoblastic leukemia (T-ALL)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16707600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 207,
                    "text": "Gain-of-function mutations in Notch-1 have been reported in more than 50% of human T-cell acute lymphoblastic leukemia (T-ALL)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302811",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Achondroplasia associated with hearing loss?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3143244",
                "http://www.ncbi.nlm.nih.gov/pubmed/22628261",
                "http://www.ncbi.nlm.nih.gov/pubmed/9733026",
                "http://www.ncbi.nlm.nih.gov/pubmed/8456822",
                "http://www.ncbi.nlm.nih.gov/pubmed/22183904",
                "http://www.ncbi.nlm.nih.gov/pubmed/3240244",
                "http://www.ncbi.nlm.nih.gov/pubmed/8267016",
                "http://www.ncbi.nlm.nih.gov/pubmed/18328977"
            ],
            "ideal_answer": [
                "Yes, there is hearing deficit in achondroplasia"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000130",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006309",
                "http://www.disease-ontology.org/api/metadata/DOID:4480",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034381",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046089",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006315",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006313",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006311",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054062",
                "http://www.disease-ontology.org/api/metadata/DOID:10003",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007605"
            ],
            "type": "yesno",
            "id": "52b2efcb4003448f55000005",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 800,
                    "text": "A hearing screening program was performed to determine the prevalence of hearing loss and abnormal tympanometry in individuals with short-stature skeletal dysplasias attending a national meeting. Behavioral audiometry, otoacoustic emission testing, and tympanometry were used to assess hearing. Failed hearing screen was defined as hearing \u2265 35 dB at one or more frequencies or by \"fail\" on otoacoustic emissions. One hundred ten of 112 subjects completed the screening. 58 (51.8%) were children. Seventy-three (65.2%) had achondroplasia, 34 (30.4%) had one of 11 other diagnoses, and 5(4.4%) were undiagnosed. 25.8% of children failed hearing screening in one or both ears, while 46.3% of adults failed in one or both ears. 55.1% of adults and 25.0% of children with achondroplasia failed screening.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628261",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1520,
                    "text": "Forty-four children had achondroplasia, and 31 had normal hearing in both ears (71%); 8 failed hearing screening in 1 ear (18%), and 3 in both ears (7%). Tympanometry was performed in 45 children, with normal tympanograms found in 21 (47%), bilateral abnormal tympanograms in 15 (33%), and unilateral abnormal tympanograms in 9 (20%). Fourteen children with achondroplasia had normal tympanograms (42%); 11 had bilateral abnormal tympanograms (33%); and 8 had unilateral abnormal tympanograms (24%). For those children without functioning tympanostomy tubes, there was a 9.5 times greater odds of hearing loss if there was abnormal tympanometry (P\u00a0=\u00a0.03).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22183904",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 837,
                    "text": "Achondroplasia (MIM 100800) is the most common non-lethal skeletal dysplasia. Its incidence is between one in 10,000 and one in 30,000. The phenotype is characterized by rhizomelic disproportionate short stature, enlarged head, midface hypoplasia, short hands and lordotic lumbar spine, associated with normal cognitive development. This autosomal-dominant disorder is caused by a gain-of-function mutation in the gene encoding the type 3 receptor for fibroblast growth factor (FGFR3); in more than 95% of cases, the mutation is G380R. The diagnosis is suspected on physical examination and confirmed by different age-related radiological features. Anticipatory and management care by a multidisciplinary team will prevent and treat complications, including cervical cord compression, conductive hearing loss and thoracolumbar gibbosity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18328977",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 953,
                    "offsetInEndSection": 1213,
                    "text": "The report includes information on otitis media, ventilation tubes, hearing loss, tonsillectomy, speech problems, tibial bowing and osteotomy, ventricular shunting, apnoea, cervicomedullary decompression, and neurological signs attributable to spinal stenosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9733026",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1270,
                    "offsetInEndSection": 1483,
                    "text": "We conclude that verbal comprehension is significantly impaired in children with achondroplasia. This partial deficiency is probably related to frequent middle ear infections and resulting conductive hearing loss.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8267016",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 512,
                    "text": "In order to determine whether these morphologic changes are the cause of the hearing deficit in achondroplasia, audiometric studies and ENT evaluation were performed in eight of the nine patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456822",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1316,
                    "text": "Audiograms were obtained in six of the nine achondroplastic subjects (two adults and four children). There was evidence of mixed hearing loss in the four children, but only of sensorineural hearing loss in the adults. We believe that the persistent hearing loss in achondroplasia is not due to sequelae of otitis media as some authors have suggested. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3143244",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "The AA report a clinical and radiological study performed in 18 achondroplastic patients in order to achieve a nosological settlement of the otological impairments. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3240244",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can protein coding exons originate from ALU sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15328599",
                "http://www.ncbi.nlm.nih.gov/pubmed/21282640",
                "http://www.ncbi.nlm.nih.gov/pubmed/21188497",
                "http://www.ncbi.nlm.nih.gov/pubmed/20803091",
                "http://www.ncbi.nlm.nih.gov/pubmed/18332115",
                "http://www.ncbi.nlm.nih.gov/pubmed/20532223",
                "http://www.ncbi.nlm.nih.gov/pubmed/17594509",
                "http://www.ncbi.nlm.nih.gov/pubmed/19393186",
                "http://www.ncbi.nlm.nih.gov/pubmed/17204284",
                "http://www.ncbi.nlm.nih.gov/pubmed/23374342",
                "http://www.ncbi.nlm.nih.gov/pubmed/15099521",
                "http://www.ncbi.nlm.nih.gov/pubmed/18047649",
                "http://www.ncbi.nlm.nih.gov/pubmed/19324900",
                "http://www.ncbi.nlm.nih.gov/pubmed/15901843",
                "http://www.ncbi.nlm.nih.gov/pubmed/16027113",
                "http://www.ncbi.nlm.nih.gov/pubmed/23303787",
                "http://www.ncbi.nlm.nih.gov/pubmed/12764196"
            ],
            "ideal_answer": [
                "Yes. Intronic ALUs can evolve into exons by the activation of splice signals residing within the ALU sequence. While most ALU exons do not add or modify the coding capacity of the resulting transcript, examples have been identified of ALU exons becoming protein coding."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020087",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005091"
            ],
            "type": "yesno",
            "id": "51763a278ed59a060a000030",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "The Alu element has been a major source of new exons during primate evolution. Thousands of human genes contain spliced exons derived from Alu elements.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282640",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 671,
                    "text": "More than 25% of Alu exons analyzed by RNA-Seq have estimated transcript inclusion levels of at least 50% in the human cerebellum, indicating widespread establishment of Alu exons in human genes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282640",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1388,
                    "text": "his study presents genomic evidence that a major functional consequence of Alu exonization is the lineage-specific evolution of translational regulation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282640",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1222,
                    "offsetInEndSection": 1500,
                    "text": "Our data suggests that lineage-specific exonization events should be determined by the combination event of the formation of splicing sites and protection against site-specific mutation pressures. These evolutionary mechanisms could be major sources for primate diversification.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20803091",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Exonization of Alu elements creates primate-specific genomic diversity",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18332115",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 845,
                    "offsetInEndSection": 1158,
                    "text": "Our data show that, once acquired, some exonizations were lost again in some lineages. In general, Alu exonization occurred at various time points over the evolutionary history of primate lineages, and protein-coding potential was acquired either relatively soon after integration or millions of years thereafter.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15901843",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 355,
                    "text": "Once integrated, they have the potential to become exapted as functional modules, e.g., as protein-coding domains via alternative splicing. This particular process is also termed exonization and increases protein versatility",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15901843",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 288,
                    "text": "alternative \"Alu-exons\" also carry the potential to greatly enhance genetic diversity by increasing the transcriptome of primates chiefly via alternative splicing.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15328599",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 528,
                    "text": "ere, we report a 5' exon generated from one of the two alternative transcripts in human tumor necrosis factor receptor gene type 2 (p75TNFR) that contains an ancient Alu-SINE, which provides an alternative N-terminal protein-coding domain.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15328599",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is the PINES framework being used for the prediction of coding variants?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30359302"
            ],
            "ideal_answer": [
                "No. PINES (Phenotype-Informed Noncoding Element Scoring) predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype-dependent manner. PINES enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c58447f07647bbc4b000021",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "PINES: phenotype-informed tissue weighting improves prediction of pathogenic noncoding variants.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30359302",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 722,
                    "text": "Here, we introduce the computational framework PINES (Phenotype-Informed Noncoding Element Scoring), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype-dependent manner. PINES enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest. We illustrate that PINES identifies functional noncoding variation more accurately than methods that do not use phenotype-weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30359302",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 356,
                    "text": "Here, we introduce the computational framework PINES (Phenotype-Informed Noncoding Element Scoring), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype-dependent manner.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30359302",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 726,
                    "text": "We illustrate that PINES identifies functional noncoding variation more accurately than methods that do not use phenotype-weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30359302",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 357,
                    "offsetInEndSection": 498,
                    "text": "PINES enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30359302",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do selenoproteins and selenium play a role in prostate cancer prevention?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19074884",
                "http://www.ncbi.nlm.nih.gov/pubmed/15875088",
                "http://www.ncbi.nlm.nih.gov/pubmed/16690748",
                "http://www.ncbi.nlm.nih.gov/pubmed/19690186",
                "http://www.ncbi.nlm.nih.gov/pubmed/20852007",
                "http://www.ncbi.nlm.nih.gov/pubmed/20424130",
                "http://www.ncbi.nlm.nih.gov/pubmed/19299660",
                "http://www.ncbi.nlm.nih.gov/pubmed/23133653",
                "http://www.ncbi.nlm.nih.gov/pubmed/22072582",
                "http://www.ncbi.nlm.nih.gov/pubmed/17160069"
            ],
            "ideal_answer": [
                "No, although initial epidemiological studies on humans and on animal and cell- based models indicated that selenoproteins may be protecting against prostate cancer, more research is needed to improve the understanding of selenium metabolism and requirements for optimal health."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051140",
                "http://www.disease-ontology.org/api/metadata/DOID:10283"
            ],
            "type": "yesno",
            "id": "515ed87c298dcd4e51000032",
            "snippets": [
                {
                    "offsetInBeginSection": 1115,
                    "offsetInEndSection": 1402,
                    "text": "The selenoprotein-deficient mice exhibited accelerated development of lesions associated with prostate cancer progression, implicating selenoproteins in cancer risk and development and raising the possibility that selenium prevents cancer by modulating the levels of these selenoproteins",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690748",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1293,
                    "offsetInEndSection": 1564,
                    "text": "Notably and in contrast to previous studies, RWPE-1 cells were significantly more sensitive to selenite than either of the prostate cancer cell lines. These results demonstrate that selenoproteins and selenium metabolism are regulated at multiple levels in prostate cells",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160069",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1783,
                    "offsetInEndSection": 2110,
                    "text": "In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074884",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1417,
                    "offsetInEndSection": 1566,
                    "text": "Our results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20852007",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1470,
                    "offsetInEndSection": 1767,
                    "text": "This study provides evidence that SEP15 genetic variation may influence PCa mortality. Additionally, the association of selenium with PCa mortality was modified by a variant, suggesting the possibility that some men with PCa may benefit more from selenium than others, depending on their genotype.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20424130",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1619,
                    "offsetInEndSection": 1752,
                    "text": "We conclude that decreased SEPP concentration in serum might represent an additional valuable marker for prostate cancer diagnostics.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690186",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 289,
                    "text": "The recently completed Selenium and Vitamin E Cancer Prevention Trial (SELECT) was one of the largest human cancer prevention trials ever undertaken. Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299660",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 928,
                    "text": "We studied Se levels in whole blood, plasma and prostate of 32 PC and 40 benign prostate hyperplasia (BPH) patients and in the control group composed of 39 healthy subjects. The selenoenzyme glutathione peroxidase (GSH-Px) was also measured in the patients' red cells, plasma and prostate tissue. Se concentration in whole blood and plasma in both groups of patients was lower as compared with controls, while in prostate gland it was significantly higher in PC than in BPH patients and controls. Red cell GSH-Px activity was the same in PC patients and controls but significantly lower in BPH patients.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15875088",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1352,
                    "offsetInEndSection": 1553,
                    "text": "Of particular interest was the positive correlation between tissue GPx activity and Gleason score, with this relationship achieving statistical significance among African-Americans (r\u2009=\u20090.67, P\u2009=\u20090.02)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22072582",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Does SARM1 deletion cause neurodegeneration?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26820848"
            ],
            "ideal_answer": [
                "Mouse strain with Sarm1 deletion (Sarm1-/-) is highly resistant to axon neurodegeneration."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5a9931cd1d1251d03b00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1509,
                    "text": "Finally, using neurons from two distinct mutant mouse strains whose axons are highly resistant to neurodegeneration (Wld(S) and Sarm1(-/-)), we found that the three different fibrils were secreted by axons after anterograde transport, in the absence of axonal lysis, indicating that trans-neuronal spread can occur in intact healthy neurons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26820848",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has protein citrullination been implicated in rheumatoid arthritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24498912",
                "http://www.ncbi.nlm.nih.gov/pubmed/25182207",
                "http://www.ncbi.nlm.nih.gov/pubmed/25475141",
                "http://www.ncbi.nlm.nih.gov/pubmed/24763532",
                "http://www.ncbi.nlm.nih.gov/pubmed/24724574",
                "http://www.ncbi.nlm.nih.gov/pubmed/25116951",
                "http://www.ncbi.nlm.nih.gov/pubmed/24823363",
                "http://www.ncbi.nlm.nih.gov/pubmed/25520183",
                "http://www.ncbi.nlm.nih.gov/pubmed/25515746",
                "http://www.ncbi.nlm.nih.gov/pubmed/24782594",
                "http://www.ncbi.nlm.nih.gov/pubmed/25355199",
                "http://www.ncbi.nlm.nih.gov/pubmed/24497204"
            ],
            "ideal_answer": [
                "Yes, protein citrullination been implicated in rheumatoid arthritis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:848",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001168",
                "http://www.biosemantics.org/jochem#4275495",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001172",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001171",
                "http://www.disease-ontology.org/api/metadata/DOID:7148",
                "http://www.biosemantics.org/jochem#4249918",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002956",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0019240"
            ],
            "type": "yesno",
            "id": "54d796f93706e8952800001e",
            "snippets": [
                {
                    "offsetInBeginSection": 30,
                    "offsetInEndSection": 193,
                    "text": ": Citrullination has become a hot topic within recent years due to its involvement in diseases such as rheumatoid arthritis (RA), multiple sclerosis and fibrosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25520183",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 933,
                    "text": "Current literature suggests that increased levels of citrullinated proteins are found in several if not all inflammatory diseases. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25520183",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 377,
                    "text": "Antibodies directed against citrullinated proteins and peptides (ACPAs) are the most specific serological markers available for diagnosing RA. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25515746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 306,
                    "text": "Citrullination of proteins is well described in rheumatoid arthritis (RA), and hypercitrullination of proteins may be related to inflammation in general. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475141",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 982,
                    "offsetInEndSection": 1180,
                    "text": "Some ACPA are remarkably effective as diagnostics in autoimmune disorders, most notably rheumatoid arthritis (RA). Several ACPA can be observed before other clinical RA manifestations are apparent. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25355199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the presence of rheumatoid factor (RF) and anti-citrullinated protein/peptide autoantibodies (ACPAs). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182207",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "text": "Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182207",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1248,
                    "offsetInEndSection": 1467,
                    "text": "The implications of citrullination affecting integrin binding in disease open up a new area of study and might have implications for the pathogenesis of inflammatory diseases like rheumatoid arthritis and periodontitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116951",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 777,
                    "text": "In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation, and oxidation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782594",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Citrullinated collagen II (CII) is a well-known autoantigen in rheumatoid arthritis (RA). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24823363",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 501,
                    "text": "Among the RA-associated autoantibodies, especially anti-citrullinated protein antibodies (ACPAs) have been studied intensively in the last decade.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763532",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Protein citrullination is a posttranslational modification that has attracted increased attention, especially for its involvement in rheumatoid arthritis (RA).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24724574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Identification of citrullinated cellular fibronectin in synovial fluid from patients with rheumatoid arthritis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24498912",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 206,
                    "text": "Cellular fibronectin (cFn) has been implicated in the pathogenesis of rheumatoid arthritis (RA), and we previously demonstrated the presence of citrullinated cFn in rheumatoid synovial tissues. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24498912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 313,
                    "text": ". In rheumatoid arthritis, PAD4 and protein citrullination are increased in inflamed joints, and anti-citrullinated protein antibodies (ACPAs) form against citrullinated antigens are formed. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24497204",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is palbociclib effective for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30151703",
                "http://www.ncbi.nlm.nih.gov/pubmed/29726787"
            ],
            "ideal_answer": [
                "No. In a clinical trial palbociclib monotherapy was not an effective treatment for recurrent glioblastoma."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e290a268b3851296d00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 1543,
                    "offsetInEndSection": 1810,
                    "text": "Although further research is needed, cyclin-dependent kinase 4/6 inhibitors represent intriguing developments in the treatment of various malignancies, including those with such poor prognoses as glioblastoma multiforme, mantle cell lymphoma, and metastatic melanoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29726787",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1441,
                    "offsetInEndSection": 1578,
                    "text": "CONCLUSION: In this trial, despite adequate tissue PK, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151703",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1584,
                    "text": "CONCLUSION\n\nIn this trial, despite adequate tissue PK, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151703",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1441,
                    "offsetInEndSection": 1577,
                    "text": "CONCLUSION In this trial, despite adequate tissue PK, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151703",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1584,
                    "text": "CONCLUSION\nIn this trial, despite adequate tissue PK, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151703",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can ferric carboxymaltose be used to treat anemia in inflammatory bowel disease patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21340038",
                "http://www.ncbi.nlm.nih.gov/pubmed/19787830",
                "http://www.ncbi.nlm.nih.gov/pubmed/20648930",
                "http://www.ncbi.nlm.nih.gov/pubmed/23078888",
                "http://www.ncbi.nlm.nih.gov/pubmed/23889159",
                "http://www.ncbi.nlm.nih.gov/pubmed/24114623",
                "http://www.ncbi.nlm.nih.gov/pubmed/21479141",
                "http://www.ncbi.nlm.nih.gov/pubmed/22023204",
                "http://www.ncbi.nlm.nih.gov/pubmed/18371137",
                "http://www.ncbi.nlm.nih.gov/pubmed/21699794",
                "http://www.ncbi.nlm.nih.gov/pubmed/23644823",
                "http://www.ncbi.nlm.nih.gov/pubmed/24081613",
                "http://www.ncbi.nlm.nih.gov/pubmed/22179489"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A13386134",
                    "o": "C522335"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2001867",
                    "o": "http://linkedlifedata.com/resource/umls/label/A13386134"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A13386134",
                    "o": "ferric carboxymaltose"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2001867",
                    "o": "http://linkedlifedata.com/resource/umls/label/A13386134"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A13386134",
                    "o": "MeSH"
                }
            ],
            "ideal_answer": [
                "Ferric carboxymaltose can be used to treat anemia in patients with inflammatory bowel disease, and prevents recurrence of anemia in these patients, compared with placebo. Treatment with ferric carboxymaltose is efficious, safe and well tolerated in iron-deficient IBD patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003093",
                "http://www.disease-ontology.org/api/metadata/DOID:2355",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005290",
                "http://www.disease-ontology.org/api/metadata/DOID:0050589",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015212",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009220"
            ],
            "type": "yesno",
            "id": "530cf4fe960c95ad0c00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 805,
                    "text": "Intravenous iron should be preferred where oral iron is poorly tolerated or where it has failed in moderate to severe anemia, and in combination with erythropoietin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114623",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 938,
                    "offsetInEndSection": 1069,
                    "text": "Ferric carboxymaltose is much more convenient, and has been shown to be more effective than iron sucrose in a large randomized tria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114623",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 84,
                    "text": "nemia and iron deficiency anemia are very common in inflammatory bowel disease (IBD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114623",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 941,
                    "text": "Ferric carboxymaltose was associated with cost savings of 30-44\u00a0% per patient per treatment cycle compared to iron sucrose. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24081613",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 385,
                    "text": "Iron deficiency is common in pregnancy, postpartum, inflammatory bowel disease, chronic kidney disease, chronic heart failure, heavy uterine bleeding, cancer and following surgery. We estimate the budget impact (BI) on the Swiss mandatory health insurance associated with substituting iron sucrose (standard) with ferric carboxymaltose (new treatment) using real-life data.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24081613",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1438,
                    "offsetInEndSection": 1583,
                    "text": "reating iron deficiency involves substantial costs to the Swiss MHI which may be reduced by substituting iron sucrose with ferric carboxymaltose.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24081613",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 347,
                    "text": "e aim of this study was to observe, in a non-interventional way, how Swedish gastroenterologists adhere to guidelines in IBD outpatients treated with intravenous ferric carboxymaltose (FCM), and the result of treatment",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23889159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1658,
                    "offsetInEndSection": 1766,
                    "text": "FCM lowers platelet counts and platelet activation in patients with IBD-associated secondary thrombocytosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644823",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 588,
                    "offsetInEndSection": 777,
                    "text": "We performed a randomized, single-blinded placebo-controlled trial testing the effect of ferric carboxymaltose (FCM) in patients with IBD with secondary thrombocytosis (platelets > 450 G/L)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644823",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 410,
                    "text": "e performed a randomized, placebo-controlled trial to determine if administration of ferric carboxymaltose (FCM) prevents anemia in patients with IBD and low levels of serum ferritin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078888",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1670,
                    "offsetInEndSection": 1749,
                    "text": "FCM prevents recurrence of anemia in patients with IBD, compared with placebo. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078888",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 403,
                    "text": " A subgroup was analyzed regarding efficacy and side effects of iron supplementation with ferric carboxymaltose.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1169,
                    "offsetInEndSection": 1332,
                    "text": "Iron deficiency and anemia are frequent in IBD patients. Treatment with ferric carboxymaltose is efficious, safe and well tolerated in iron-deficient IBD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 1001,
                    "text": " Intravenous iron avoids these concerns, especially with the development of ferric carboxymaltose, which allow up to 1000mg to be given rapidly.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023204",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "What is the optimal treatment for anemia in inflammatory bowel disease?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023204",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 441,
                    "text": "We compared the efficacy and safety of a novel fixed-dose ferric carboxymaltose regimen (FCM) with individually calculated iron sucrose (IS) doses in patients with inflammatory bowel disease (IBD) and IDA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1332,
                    "offsetInEndSection": 1447,
                    "text": "Study drugs were well tolerated and drug-related adverse events were in line with drug-specific clinical experience",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1542,
                    "offsetInEndSection": 1706,
                    "text": " The simpler FCM-based dosing regimen showed better efficacy and compliance, as well as a good safety profile, compared with the Ganzoni-calculated IS dose regimen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1450,
                    "offsetInEndSection": 1701,
                    "text": "Ferric carboxymaltose can be rapidly administered in doses of 15 mg/kg body weight, up to a ceiling dose of 1000 mg. A test dose is not required, and it can be used more widely across a spectrum of iron deficiency and iron deficiency anemia indication",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340038",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 970,
                    "text": " Intravenous iron offers a rapid means of iron repletion and is superior to oral iron in many circumstances, especially in the presence of anemia of chronic disease, where it appears to overcome the block to absorption of iron from the gastrointestinal tract and immobilization of stored iron. The clinical situations where high doses of iron are commonly required are reviewed. These include nondialysis-dependent chronic kidney disease, inflammatory bowel disease, obstetrics, menorrhagia, and anemia associated with cancer and its treatment. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340038",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 723,
                    "text": "Ferric carboxymaltose can be administered at 15 mg/kg body weight to a maximum dose of 1000 mg, whereas iron isomaltoside 1000 can be administered at 20 mg/kg body weight. The ability to give high doses of iron is important in the context of managing iron deficiency anemia in a number of clinical conditions where demands for iron are high (including chronic blood loss associated with inflammatory bowel disease, menorrhagia, and chronic kidney disease)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479141",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 456,
                    "text": "erric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CKD) and those undergoing hemodialysis (HD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1306,
                    "offsetInEndSection": 1404,
                    "text": "In patients with IBD or PPA, improvements in Hb levels were more rapid with FCM than with FeSulf. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2101,
                    "offsetInEndSection": 2263,
                    "text": "CM improved patient quality of life to an equivalent extent to oral FeSulf in patients with IBD or PPA, and to a greater extent than oral FeSulf in women with AUB",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 949,
                    "offsetInEndSection": 1205,
                    "text": "Four different products are principally used in clinical practice, which differ in their pharmacokinetic properties and safety profiles: iron gluconate and iron sucrose (lower single doses), and iron dextran and ferric carboxymaltose (higher single doses).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19787830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 104,
                    "text": "he prevalence of anemia across studies on patients with inflammatory bowel disease (IBD) is high (30%).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19787830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 158,
                    "text": " novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1544,
                    "text": "FeCarb is effective and safe in IBD-associated anemia. It is noninferior to FeSulf in terms of Hb change over 12 wk, and provides a fast Hb increase and a sufficient refill of iron stores.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1156,
                    "offsetInEndSection": 1342,
                    "text": "Treatment-related adverse events (AEs) occurred in 28.5% of the FeCarb and 22.2% of the FeSulf groups, with discontinuation of study medication due to AEs in 1.5% and 7.9%, respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 812,
                    "text": "The median Hb improved from 8.7 to 12.3 g/dL in the FeCarb group and from 9.1 to 12.1 g/dL in the FeSulf group, demonstrating noninferiority (P= 0.6967). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078888",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 458,
                    "text": "Ferric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CKD) and those undergoing hemodialysis (HD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 457,
                    "text": "Ferric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CKD) and those undergoing hemodialysis (HD)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
                "http://www.ncbi.nlm.nih.gov/pubmed/28861122",
                "http://www.ncbi.nlm.nih.gov/pubmed/26788129"
            ],
            "ideal_answer": [
                "No. Atalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e48b1ddd14c9f295d000012",
            "snippets": [
                {
                    "offsetInBeginSection": 2879,
                    "offsetInEndSection": 3108,
                    "text": "INTERPRETATION: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 700,
                    "text": "In this review, we summarize the pathophysiological mechanisms involved in the development of SPMS and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of MS, to exert beneficial effects in reducing disease progression unrelated to relapses in SPMS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2885,
                    "offsetInEndSection": 3114,
                    "text": "INTERPRETATION\n\nNatalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 867,
                    "text": "Natalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive MS , but it did demonstrate a benefit on a prespecified component of the 9-Hole Peg Test . ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28861122",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2885,
                    "offsetInEndSection": 3114,
                    "text": "INTERPRETATION\nNatalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 700,
                    "text": "In this review, we summarize the pathophysiological mechanisms involved in the development of SPMS and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of MS, to exert beneficial effects in reducing disease progression unrelated to relapses in SPMS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2851,
                    "offsetInEndSection": 3064,
                    "text": "Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29545067",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does resveratrol reduce cardiac remodeling?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22926332",
                "http://www.ncbi.nlm.nih.gov/pubmed/22473781",
                "http://www.ncbi.nlm.nih.gov/pubmed/20869962",
                "http://www.ncbi.nlm.nih.gov/pubmed/23274061",
                "http://www.ncbi.nlm.nih.gov/pubmed/18853243",
                "http://www.ncbi.nlm.nih.gov/pubmed/19370079",
                "http://www.ncbi.nlm.nih.gov/pubmed/18310510",
                "http://www.ncbi.nlm.nih.gov/pubmed/16198371",
                "http://www.ncbi.nlm.nih.gov/pubmed/18356487",
                "http://www.ncbi.nlm.nih.gov/pubmed/20874677",
                "http://www.ncbi.nlm.nih.gov/pubmed/20491649",
                "http://www.ncbi.nlm.nih.gov/pubmed/22050707",
                "http://www.ncbi.nlm.nih.gov/pubmed/12679191",
                "http://www.ncbi.nlm.nih.gov/pubmed/18639559",
                "http://www.ncbi.nlm.nih.gov/pubmed/20675566",
                "http://www.ncbi.nlm.nih.gov/pubmed/19460403",
                "http://www.ncbi.nlm.nih.gov/pubmed/19370081",
                "http://www.ncbi.nlm.nih.gov/pubmed/20429690",
                "http://www.ncbi.nlm.nih.gov/pubmed/21352470",
                "http://www.ncbi.nlm.nih.gov/pubmed/17488730",
                "http://www.ncbi.nlm.nih.gov/pubmed/20008278",
                "http://www.ncbi.nlm.nih.gov/pubmed/19942861",
                "http://www.ncbi.nlm.nih.gov/pubmed/19959541",
                "http://www.ncbi.nlm.nih.gov/pubmed/18562309",
                "http://www.ncbi.nlm.nih.gov/pubmed/21054406",
                "http://www.ncbi.nlm.nih.gov/pubmed/17875610",
                "http://www.ncbi.nlm.nih.gov/pubmed/22245452",
                "http://www.ncbi.nlm.nih.gov/pubmed/22768138",
                "http://www.ncbi.nlm.nih.gov/pubmed/15498824",
                "http://www.ncbi.nlm.nih.gov/pubmed/23784505",
                "http://www.ncbi.nlm.nih.gov/pubmed/24289075",
                "http://www.ncbi.nlm.nih.gov/pubmed/22229508",
                "http://www.ncbi.nlm.nih.gov/pubmed/20716127"
            ],
            "ideal_answer": [
                "Resveratrol attenuates left ventricular remodeling.\nResveratrol is a beneficial pharmacological tool that augments autophagy to bring about reverse remodeling in the postinfarction heart.\nResveratrol administration improved cardiac environment by reducing inflammatory state and decreased unfavorable ventricular remodeling of the diabetic heart, leading to a marked recovery of ventricular function.\nResveratrol can constitute an adjuvant therapeutic option in prevention of dilated cardiomyopathy.",
                "Most of the evidence shows that Resveratrol supresses cardiac remodeling."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4272358",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064752",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006331",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006332",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0003015",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002306"
            ],
            "type": "yesno",
            "id": "52e7bbf698d023950500001d",
            "snippets": [
                {
                    "offsetInBeginSection": 1199,
                    "offsetInEndSection": 1498,
                    "text": "In conclusion, resveratrol attenuated cardiac oxidative damage and left ventricular remodeling and enhanced the decreased expression of SIRT1 in hearts of old rats with emphysema and thus might be a therapeutic modality for cardiac injury complicated in chronic obstructive pulmonary disease (COPD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289075",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1547,
                    "offsetInEndSection": 1697,
                    "text": "In conclusion, resveratrol is a beneficial pharmacological tool that augments autophagy to bring about reverse remodeling in the postinfarction heart.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23274061",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1794,
                    "offsetInEndSection": 2214,
                    "text": "Resveratrol administration reduced atrial CSPC loss, succeeded in preserving the functional abilities of CSPCs and mature cardiac cells, improved cardiac environment by reducing inflammatory state and decreased unfavorable ventricular remodeling of the diabetic heart, leading to a marked recovery of ventricular function. These findings indicate that RSV can constitute an adjuvant therapeutic option in DCM prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768138",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can adult humans be induced to produce fetal hemoglobin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24222332",
                "http://www.ncbi.nlm.nih.gov/pubmed/10908330",
                "http://www.ncbi.nlm.nih.gov/pubmed/22460946",
                "http://www.ncbi.nlm.nih.gov/pubmed/17041717",
                "http://www.ncbi.nlm.nih.gov/pubmed/11144280",
                "http://www.ncbi.nlm.nih.gov/pubmed/16939628",
                "http://www.ncbi.nlm.nih.gov/pubmed/10575541",
                "http://www.ncbi.nlm.nih.gov/pubmed/7541126",
                "http://www.ncbi.nlm.nih.gov/pubmed/20201948",
                "http://www.ncbi.nlm.nih.gov/pubmed/17486495",
                "http://www.ncbi.nlm.nih.gov/pubmed/14594506",
                "http://www.ncbi.nlm.nih.gov/pubmed/18379999",
                "http://www.ncbi.nlm.nih.gov/pubmed/21415990",
                "http://www.ncbi.nlm.nih.gov/pubmed/16735596",
                "http://www.ncbi.nlm.nih.gov/pubmed/17456718",
                "http://www.ncbi.nlm.nih.gov/pubmed/20305142",
                "http://www.ncbi.nlm.nih.gov/pubmed/23997901",
                "http://www.ncbi.nlm.nih.gov/pubmed/11929793"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15585362",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2350438",
                    "o": "http://linkedlifedata.com/resource/umls/label/A15585362"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15585362",
                    "o": "G gamma-Globin"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2350438",
                    "o": "http://linkedlifedata.com/resource/umls/label/A15591265"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15591265",
                    "o": "G gamma Globin"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2350438",
                    "o": "http://linkedlifedata.com/resource/umls/label/A15585362"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A15591265",
                    "o": "MeSH"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/P68078",
                    "o": "http://purl.uniprot.org/citations/2420747"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/2420747",
                    "o": "Hemoglobin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/2420747",
                    "o": "http://purl.uniprot.org/pubmed/2420747"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68078",
                    "o": "http://linkedlifedata.com/resource/#_503638303738009"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68078",
                    "o": "http://linkedlifedata.com/resource/#_503638303738008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303738008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303738007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68078",
                    "o": "http://linkedlifedata.com/resource/#_503638303738007"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/2420747",
                    "o": "http://purl.uniprot.org/medline/86167516"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303738009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/P68079",
                    "o": "http://purl.uniprot.org/citations/511581"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68079",
                    "o": "http://linkedlifedata.com/resource/#_503638303739007"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/511581",
                    "o": "Hemoglobin"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303739008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68079",
                    "o": "http://linkedlifedata.com/resource/#_503638303739008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303739009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303739007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68079",
                    "o": "http://linkedlifedata.com/resource/#_503638303739009"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/511581",
                    "o": "http://purl.uniprot.org/medline/80071586"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/511581",
                    "o": "http://purl.uniprot.org/pubmed/511581"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/P02097",
                    "o": "http://purl.uniprot.org/citations/105752"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/105752",
                    "o": "http://purl.uniprot.org/medline/79124683"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P02097",
                    "o": "http://linkedlifedata.com/resource/#_503032303937007"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/105752",
                    "o": "Biochemistry"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P02097",
                    "o": "http://linkedlifedata.com/resource/#_503032303937009"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P02097",
                    "o": "http://linkedlifedata.com/resource/#_503032303937008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503032303937007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503032303937009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/105752",
                    "o": "http://purl.uniprot.org/pubmed/105752"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503032303937008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/P68077",
                    "o": "http://purl.uniprot.org/citations/6157408"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68077",
                    "o": "http://linkedlifedata.com/resource/#_503638303737008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303737009",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/6157408",
                    "o": "Biochemistry"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/6157408",
                    "o": "http://purl.uniprot.org/pubmed/6157408"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68077",
                    "o": "http://linkedlifedata.com/resource/#_503638303737009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303737008",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/6157408",
                    "o": "http://purl.uniprot.org/medline/81000303"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68077",
                    "o": "http://linkedlifedata.com/resource/#_50363830373700A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_50363830373700A",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P08225",
                    "o": "http://linkedlifedata.com/resource/#_50303832323500A"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P08225",
                    "o": "http://linkedlifedata.com/resource/#_503038323235007"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503038323235007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P08225",
                    "o": "http://linkedlifedata.com/resource/#_503038323235008"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P08225",
                    "o": "http://linkedlifedata.com/resource/#_503038323235009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503038323235009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503038323235008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50303832323500A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P56285",
                    "o": "http://linkedlifedata.com/resource/#_50353632383500A"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P56285",
                    "o": "http://linkedlifedata.com/resource/#_503536323835007"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P56285",
                    "o": "http://linkedlifedata.com/resource/#_503536323835008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503536323835008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503536323835009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P56285",
                    "o": "http://linkedlifedata.com/resource/#_503536323835009"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50353632383500A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503536323835007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68071",
                    "o": "http://linkedlifedata.com/resource/#_50363830373100A"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68071",
                    "o": "http://linkedlifedata.com/resource/#_503638303731009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303731009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303731007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830373100A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68071",
                    "o": "http://linkedlifedata.com/resource/#_503638303731008"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68071",
                    "o": "http://linkedlifedata.com/resource/#_503638303731007"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303731008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68078",
                    "o": "http://linkedlifedata.com/resource/#_50363830373800A"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830373800A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68079",
                    "o": "http://linkedlifedata.com/resource/#_50363830373900A"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830373900A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q27940",
                    "o": "http://linkedlifedata.com/resource/#_51323739343000A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513237393430009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513237393430008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q27940",
                    "o": "http://linkedlifedata.com/resource/#_513237393430007"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513237393430007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q27940",
                    "o": "http://linkedlifedata.com/resource/#_513237393430008"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51323739343000A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q27940",
                    "o": "http://linkedlifedata.com/resource/#_513237393430009"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH6",
                    "o": "http://linkedlifedata.com/resource/#_51343558483600B"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51343558483600B",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH6",
                    "o": "http://linkedlifedata.com/resource/#_513435584836008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584836008",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH6",
                    "o": "http://linkedlifedata.com/resource/#_513435584836009"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH6",
                    "o": "http://linkedlifedata.com/resource/#_51343558483600A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584836009",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51343558483600A",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH7",
                    "o": "http://linkedlifedata.com/resource/#_51343558483700B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584837009",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51343558483700B",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH7",
                    "o": "http://linkedlifedata.com/resource/#_51343558483700A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51343558483700A",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH7",
                    "o": "http://linkedlifedata.com/resource/#_513435584837008"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH7",
                    "o": "http://linkedlifedata.com/resource/#_513435584837009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584837008",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH8",
                    "o": "http://linkedlifedata.com/resource/#_51343558483800B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51343558483800A",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH8",
                    "o": "http://linkedlifedata.com/resource/#_51343558483800A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584838009",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584838008",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH8",
                    "o": "http://linkedlifedata.com/resource/#_513435584838008"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH8",
                    "o": "http://linkedlifedata.com/resource/#_513435584838009"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51343558483800B",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/O77655",
                    "o": "http://linkedlifedata.com/resource/#_4F373736353500B"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/O77655",
                    "o": "http://linkedlifedata.com/resource/#_4F3737363535008"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/O77655",
                    "o": "http://linkedlifedata.com/resource/#_4F3737363535009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_4F3737363535009",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_4F373736353500B",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_4F373736353500A",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/O77655",
                    "o": "http://linkedlifedata.com/resource/#_4F373736353500A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_4F3737363535008",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P02097",
                    "o": "http://linkedlifedata.com/resource/#_50303230393700A"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50303230393700A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P08224",
                    "o": "http://linkedlifedata.com/resource/#_50303832323400A"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50303832323400A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503038323234009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P08224",
                    "o": "http://linkedlifedata.com/resource/#_503038323234007"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503038323234008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P08224",
                    "o": "http://linkedlifedata.com/resource/#_503038323234008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503038323234007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P08224",
                    "o": "http://linkedlifedata.com/resource/#_503038323234009"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P18436",
                    "o": "http://linkedlifedata.com/resource/#_50313834333600A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503138343336009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503138343336007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P18436",
                    "o": "http://linkedlifedata.com/resource/#_503138343336007"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50313834333600A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503138343336008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P18436",
                    "o": "http://linkedlifedata.com/resource/#_503138343336008"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P18436",
                    "o": "http://linkedlifedata.com/resource/#_503138343336009"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P19760",
                    "o": "http://linkedlifedata.com/resource/#_50313937363000F"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_50313937363000C",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P19760",
                    "o": "http://linkedlifedata.com/resource/#_50313937363000C"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P19760",
                    "o": "http://linkedlifedata.com/resource/#_50313937363000D"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50313937363000F",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P19760",
                    "o": "http://linkedlifedata.com/resource/#_50313937363000B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_50313937363000B",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_50313937363000D",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68030",
                    "o": "http://linkedlifedata.com/resource/#_50363830333000A"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68030",
                    "o": "http://linkedlifedata.com/resource/#_503638303330008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303330008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830333000A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303330007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303330009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68030",
                    "o": "http://linkedlifedata.com/resource/#_503638303330007"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68030",
                    "o": "http://linkedlifedata.com/resource/#_503638303330009"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68031",
                    "o": "http://linkedlifedata.com/resource/#_50363830333100A"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303331007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303331009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68031",
                    "o": "http://linkedlifedata.com/resource/#_503638303331009"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68031",
                    "o": "http://linkedlifedata.com/resource/#_503638303331007"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68031",
                    "o": "http://linkedlifedata.com/resource/#_503638303331008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303331008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830333100A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68068",
                    "o": "http://linkedlifedata.com/resource/#_50363830363800C"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68068",
                    "o": "http://linkedlifedata.com/resource/#_50363830363800A"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830363800C",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68068",
                    "o": "http://linkedlifedata.com/resource/#_503638303638009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303638009",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_50363830363800A",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68068",
                    "o": "http://linkedlifedata.com/resource/#_50363830363800B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_50363830363800B",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68069",
                    "o": "http://linkedlifedata.com/resource/#_50363830363900A"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68069",
                    "o": "http://linkedlifedata.com/resource/#_503638303639008"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830363900A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68069",
                    "o": "http://linkedlifedata.com/resource/#_503638303639007"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68069",
                    "o": "http://linkedlifedata.com/resource/#_503638303639009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303639009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303639007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303639008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68070",
                    "o": "http://linkedlifedata.com/resource/#_50363830373000A"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68070",
                    "o": "http://linkedlifedata.com/resource/#_503638303730009"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303730007",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303730009",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830373000A",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P68070",
                    "o": "http://linkedlifedata.com/resource/#_503638303730007"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/P68070",
                    "o": "http://linkedlifedata.com/resource/#_503638303730008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503638303730008",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P68077",
                    "o": "http://linkedlifedata.com/resource/#_50363830373700B"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_50363830373700B",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH5",
                    "o": "http://linkedlifedata.com/resource/#_51343558483500B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584835009",
                    "o": "Gamma-globin"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51343558483500B",
                    "o": "HBG"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH5",
                    "o": "http://linkedlifedata.com/resource/#_513435584835009"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH5",
                    "o": "http://linkedlifedata.com/resource/#_51343558483500A"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH5",
                    "o": "http://linkedlifedata.com/resource/#_513435584835008"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51343558483500A",
                    "o": "Hemoglobin gamma chain"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513435584835008",
                    "o": "Hemoglobin subunit gamma"
                },
                {
                    "p": "http://purl.uniprot.org/core/mnemonic",
                    "s": "http://purl.uniprot.org/uniprot/Q45XH8",
                    "o": "HBG_LOXAF"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/P19760",
                    "o": "http://purl.uniprot.org/citations/1639402"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/1639402",
                    "o": "http://purl.uniprot.org/medline/92347874"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/1639402",
                    "o": "Genomics"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/1639402",
                    "o": "http://purl.uniprot.org/pubmed/1639402"
                }
            ],
            "ideal_answer": [
                "Fetal hemoglobin, or foetal haemoglobin,  is the main oxygen transport protein in the human fetus during the last seven months of development in the uterus and in the newborn until roughly 6 months old. Functionally, fetal hemoglobin differs most from adult hemoglobin in that it is able to bind oxygen with greater affinity than the adult form, giving the developing fetus better access to oxygen from the mother's bloodstream.\nUnusually high levels of fetal haemoglobin production can ameliorate sickle cell disease and \u03b2 thalassaemia. Although efforts directed at the pharmacological stimulation of fetal haemoglobin as an approach to managing these conditions have met with limited success, there is wide variation in individual responses. \nBased on results, adults humans could be induced to produce fetal hemoglobin."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4249367",
                "http://www.uniprot.org/uniprot/GLB_APLLI",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006454",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055545",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055544",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005344",
                "http://www.uniprot.org/uniprot/HBG_BRAAR",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002648",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005319",
                "http://www.biosemantics.org/jochem#4249310",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005914"
            ],
            "type": "yesno",
            "id": "531481ade3eabad021000016",
            "snippets": [
                {
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 318,
                    "text": " At the time of birth, HbF accounts for approximately 70% of the total Hb. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 390,
                    "offsetInEndSection": 521,
                    "text": " whereas in the trace amounts of HbF that is found in the adult it reverses to 40:60 because of a gamma- to beta-globin gene switch",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379999",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 986,
                    "text": "With the increased understanding and discovery of molecular regulators of haemoglobin switching, such as BCL11A, new avenues of research may lead ultimately to novel therapeutic, mechanism-based approaches to fetal haemoglobin reactivation in patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20201948",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1050,
                    "offsetInEndSection": 1192,
                    "text": "The data suggest that TGF-beta reactivates gamma-globin expression, combined with a sequential stimulation and suppression of erythropoiesis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14594506",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there graph kernel libraries available implemented in JAVA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028902"
            ],
            "ideal_answer": [
                "No. Measuring the similarity of graphs is a fundamental step in the analysis of graph-structured data, which is omnipresent in computational biology. Graph kernels have been proposed as a powerful and efficient approach to this problem of graph comparison. Graphkernels are the first R and Python graph kernel libraries including baseline kernels such as label histogram based kernels, classic graph kernels such as random walk based kernels, and the state-of-the-art Weisfeiler-Lehman graph kernel. The core of all graph kernels is implemented in C\u2009++ for efficiency. Using the kernel matrices computed by the package, one can perform tasks such as classification, regression and clustering on graph-structured samples."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c6d97497c78d69471000040",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "graphkernels: R and Python packages for graph comparison.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028902",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 744,
                    "text": "Measuring the similarity of graphs is a fundamental step in the analysis of graph-structured data, which is omnipresent in computational biology. Graph kernels have been proposed as a powerful and efficient approach to this problem of graph comparison. Here we provide graphkernels, the first R and Python graph kernel libraries including baseline kernels such as label histogram based kernels, classic graph kernels such as random walk based kernels, and the state-of-the-art Weisfeiler-Lehman graph kernel. The core of all graph kernels is implemented in C\u2009++ for efficiency. Using the kernel matrices computed by the package, we can easily perform tasks such as classification, regression and clustering on graph-structured samples.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028902",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}